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Abstract
Cardiac surgery is traditionally a heavy user of blood and blood prod-
ucts. Until recently, the benefits of transfusion have been largely
assumed and the risks relatively ignored. This has prompted us to
examine new ways of minimising patient exposure to donor red blood
cells (RBC’s). At the present time, most clinical guidelines for RBC
transfusion are based mainly upon haemoglobin concentration ([Hb]).
As [Hb] may be artificially depressed by the haemodiluting effect
of the heavy clear fluid load associated with cardiac surgery, trans-
fusing based upon [Hb] alone may overestimate the requirement for
RBC’s. Where such haemodilution is present, systemic oxygenation
may be maintained through a viscosity mediated patho-physiological
response. The work reported in this thesis attempts to explore the rel-
ative contribution of both red cell volume (RCV) and plasma volume
(PV) to the anaemia encountered following cardiac surgery while also
examining factors that may be associated with a low post-operative
RCV. In addition, we have explored on a theoretical basis what [Hb]
would represent a critical level of systemic oxygen delivery (DO2Crit).
Taken together, this has allowed us to develop an RCV based trans-
fusion guideline aimed at reducing the incidence of unnecessary (and
potentially counter-productive) RBC transfusion. As RBC’s may be
associated with pulmonary endothelial damage, we have also studied
the impact of the RCV guideline developed on post-operative acute
lung injury (ALI). Finally, in a separate study, the merits of a sim-
ple activated clotting time (ACT) based system of anti-coagulation
management for cardiopulmonary bypass (CPB) versus that of an
individualised heparin management system (HMS) are described.
Acronyms
[HCO3−] bicarbonate ion.
[HbCrit] critical haemoglobin concentration.
[Hb] haemoglobin concentration.
2,3-DPG 2,3-diphosphoglycerate.
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ACS acute coronary syndrome.
ACT activated clotting time.
ACTGrp activated clotting time management group.
AHTR acute haemolytic transfusion reaction.
ALI acute lung injury.
APTTr activated partial thromboplastin time ratio.
ASD atrial septal defect.
AT-III anti-thrombin III.
ATR acute transfusion reaction.
AVR aortic valve replacement.
BFI blood flow index.
BHConc blood heparin concentration.
BIA bio-electrical impedance analysis.
BSA body surface area.
BSE bovine spongiform encephalopathy.
BV blood volume.
CABG coronary artery bypass grafting.
CAD coronary artery disease.










CvO2 venous oxygen content.
CXR chest x-ray.
DAT direct antiglobulin testing.
DHTR delayed haemolytic transfusion reaction.
DIC disseminated intravascular coagulation.
DNR do not resuscitate.
DO2 oxygen delivery.
DO2Crit critical oxygen delivery.
DoH Department of Health.
DTR delayed transfusion reaction.
ECF extra-cellular fluid.
ECG electro-cardiogram.
FEV1 forced expiratory volume 1s.
FFM fat free mass.
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FNHTR febrile non-haemolytic transfusion reaction.
FVC forced vital capacity.
HbGrp haemoglobin threshold transfusion group.
Hct haematocrit.
HDR heparin dose responsiveness.
HIV human immunodeficiency virus.
HLA human leucocyte antigen.
HMS heparin management system.
HMSGrp heparin management system group.
HPT heparin protamine titration.
IABP intra-aortic balloon pump.
ICSH International Committee on Standardisation
in Haematology.
ICU intensive care unit.
ICURet return to the intensive care unit.
ISBT International Society for blood Transfusion.
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IU International Units.
LMS left main stem.
LREC Lothian Regional Ethics Committee.
MAP mean arterial pressure.
MHRA Medicines and Healthcare Regulatory Agency.
MI myocardial infarction.
MVR mitral valve repair/replacement.
NaF sodium fluorescein.
NBTS National Blood Transfusion Service.
NHS National Health Service.
NO nitric oxide.
NoRBCGrp no red blood cell transfusion group.
NYHA New York Heart Association.
PV al P value.
PaCO2 arterial partial pressure of carbon dioxide.
PaO2 arterial partial pressure of oxygen.
PDH pyruvate dehydrogenase.
PFT pulmonary function test.
PHConc plasma heparin concentration.
PIHD pre-operative isovolaemic haemodilution.
Plt platelet count.
ppb parts per billion.
PTP post-transfusion purpura.
PTr pro-thrombin time ratio.
PV plasma volume.
PVD peripheral vascular disease.
PVO2 mixed venous oxygen partial pressure.
PVR pulmonary vascular resistance.
QO2 oxygen extraction.
QO2Crit critical oxygen extraction.
QOL quality of life.
r correlation coefficient.
RBC red blood cell.
RBCGrp red blood cell transfusion group.
RCT randomised controlled trial.
x
RCV red cell volume.
RCVGrp red cell volume guideline transfusion group.
SABRE serious adverse blood reactions and events.
SaO2 arterial oxygen saturation.
SASM Scottish Audit of Surgical Mortality.
SBE standard base excess.
SD standard deviation.
SEM standard error of the mean.
SHOT serious hazards of transfusion.
SIGN Scottish Intercollegiate Guideline Network.
SJvO2 jugular venous oxygen saturation.
SNBTS Scottish National Blood Transfusion Service.
SvO2 mixed venous oxygen saturation.
TA-GVHD transfusion associated graft versus host dis-
ease.
TACO transfusion associated circulatory overload.
TAT thrombin anti-thrombin.
TBW total body water.
TRALI transfusion related acute lung injury.
TRIM transfusion related immunodilution.
UPPO units per patient operated.
UPPT units per patient transfused.
USP United States Pharmacopeia.
vCJD variant Creutzfeldt-Jakob disease.
VO2 oxygen consumption.
WBC white blood cell.
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The first half of the twentieth century saw the evolution of techniques in blood
preservation and banking that permitted the beginnings of today’s liberal trans-
fusion practice1. The benefits of transfusion have always been assumed, the risks
largely ignored until the association between transfusion and viral hepatitis be-
came more widely recognised in the late 1960’s2. Since, the list of complications
has grown including the recent recognition of transmission of variant Creutzfeldt-
Jakob disease (vCJD) by blood from persons who inter-developed vCJD3.
Cardiac surgery remains a heavy user of blood and blood products4. In part,
this may be explained by improvements in clinical care which have led to more
complex procedures being performed on an increasingly elderly population5.
Recently, attention has been drawn to the general intensive care unit (ICU)
with regard to the efficacy of red blood cell (RBC) transfusion. In this pop-
ulation, the only large and well conducted randomised controlled trial (RCT)
showed that a liberal RBC transfusion policy may be counter-productive6. Thus
a timely re-appraisal of the role of RBC transfusion in cardiac surgery is required.
In the following sections we consider;
• A brief history of the development and use of autologous blood (sections
1.2 and 1.3).
• The risks associated with blood transfusion (section 1.4).
• Factors that may be relevant in deciding whether or not to administer a
blood transfusion (section 1.5).
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1.2 The History and Development of Blood Trans-
fusion
1.2.1 Early Beginnings
RBC transfusion has given itself a reputation as a simple and life saving procedure
since the turn of the twentieth century7;8. The foundations of this technique were
laid by the ancient Greeks and Romans circa 430 years BC. The first description
of blood as an essential basic ingredient of man was given by Hippocrates in his
central doctrine ‘On the nature of man’. He suggested that the four foundation
blocks of man were blood, phlegm, yellow bile and black bile. It was considered
that any illness was attributable to an imbalance between these humors and that
attention to diet and environment would result in their restoration9–11.
Despite this early recognition of the role of blood, further advances were lim-
ited by an inadequate knowledge of human circulatory physiology and anatomy.
It was William Harvey who first described accurately the human circulation in
his work of 1628 entitled “Exercitatio anatomica de motu cordis et sanguines
in animalibus”. This was followed by the first experiments with animal-animal
transfusion in Oxford around 1666 by Richard Lower. The first animal-human
transfusion was carried out by Jean Denis of Paris in 1667. There followed a
pause prior to the first human-human transfusion9–12.
Obstetrician James Blundell of Guy’s and St Thomas’s Hospital in London
observed many cases of fatal post-partum haemorrhage. He demonstrated that
death from haemorrhage in dogs could be prevented by re-infusing shed blood.
This discovery was somewhat tempered by his finding that nearly all dogs died
when given human blood. However, the direct result was his recommendation that
humans should only be given human blood. This he carried out successfully with
the aid of self designed transfusion apparatus. The net result was that survival
following post-partum haemorrhage was greatly enhanced. This began the rapid
development of transfusion medicine some 2000 years after the Hippocrates first
described the humoral elements (figure 1.1)9–12.
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Figure (1.1) Painting of an early blood transfusion. Reproduced from the Cana-
dian library archives (http: // www. collectionscanada. ca ).
1.2.2 Blood Grouping
As mentioned above, it was recognised that differences in the inter-species com-
patibility of blood could lead to cell lysis and ultimately death. However, blood
variability within man remained undescribed until 1901. Karl Landsteiner based
his description on experiments with blood and serum interactions in several hu-
man subjects. He noted that certain combinations of blood and serum would
result in red cell clumping and postulated the existence of an immunological
mechanism. Initially, three blood groups were described (A, B and C) based on
his observations7;13. Decastello & Sturli further expanded on this work the fol-
lowing year and identified a fourth blood group (AB). It was also recognised that
the so called “agglutinins” present were not associated with disease. Several other
groups duplicated Landsteiner’s work and different nomenclature’s for grouping
systems were introduced. This was resolved in 1937 by the International Society
for blood Transfusion (ISBT) when today’s ABO nomenclature was adopted as
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the universal standard. The discovery of the major human blood group system
was paralleled by the development of methods that would allow the storage and
preservation of donated blood7;14.
1.2.3 Red Cell Storage
In order to provide adequate storage of RBCs a medium that both anti-coagulates
and preserves is required. Hammarstein in 1875 was the first to describe the
dramatic effects of the calcium salts on the speed of blood clotting. Griesbach
(1891) noted that the addition of ammonium citrate to blood would cause it to
remain in a fluid state. It was subsequently realised this related primarily to the
affinity of calcium for citric acid. Other anti-coagulants (oxalates, tartrates) had
been described, but citrate was the only one that did not cause precipitation of
calcium salts. Sabbatini effectively demonstrated this property in 1902 and went
on to describe how citrate reduced the concentration of ionised calcium below the
concentration required for blood clotting7;9;15.
The first transfusion of citrated blood in a human is accredited to Hustin in
1914. After first experimenting on animals he concluded that the addition of 0.2%
citrate could delay blood clotting for as long as thirty minutes. He also noted that
RBCs in citrate did not survive as well as those in saline. Thus, the citrate was in
part replaced by glucose prior to the first human administration. This realisation
was further investigated by Rous & Turner in 1916. They experimented with
several sugar solutions aimed at minimising RBC lysis on storage. Ultimately
it was concluded that the storage of three parts human blood with two parts
3.8% citrate and five parts of 5.4% glucose would result in the adequate storage
of RBCs for up to a month15;16. It was mistakenly thought at this time that
RBCs were impervious to sugars and that it was their colloidal properties that
produced the preservative effect. The discovery was made later of the role of
glucose in RBC anaerobic metabolism. As the so called Rous & Turner solution
required a degree of sedimentation in order to remove excess supernatant, further
refinements were made resulting in a more compact storage medium by the time
of the Second World War1;17.
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1.2.4 Blood Banking
The first recorded storage of blood in advance of clinical requirement was carried
out by Oswald Robertson in 1918 behind the front line in France18. Donors
selected were healthy young men with trivial wounds sustained on the field of
battle. The average storage time was 10-14 days prior to transfusion. Recipients
were those critically injured but thought to have a chance of survival if given a
transfusion. In total 22 transfusions were given to 20 individuals. 11 out of the
20 individuals transfused were fit enough to be transferred back for active duty
after recovering from their injuries. Furthermore, it was noted that the immediate
improvement observed was just as prevalent with blood stored for up to 3-4 weeks
as with that stored for shorter periods17. Robertson concluded that the principle
priority with his technique was to have sufficient stored blood to cope with any
sudden increase in demand. The basic principles of modern blood banking had
been established17;18.
The first actual blood donor service was established by Percy Oliver (1921)
in London. Oliver’s division of the Red Cross received an appeal from Kings
College Hospital for blood donors. Members dutifully gave blood and Oliver was
prompted to set up a list of family and friends who could be called at short
notice to donate blood. Donors gave their services free of charge although would
be re-reimbursed travel expenses. Although there was a slow uptake, word spread
and Oliver’s services were called upon 428 times in 19259;14. At this time many
doctors remained reluctant to use a citrated anti-coagulant storage solution and
much reliance was placed upon direct transfusion. In addition, many people died
from ABO incompatibility as typing techniques were unreliable. Despite this,
donor lists sprang up in major cities around the UK and the practice became
adopted worldwide7;9;19.
Frederico Duran-Jordan, a physician during the Spanish civil war, is credited
with the first modern system of blood banking. A mobile storage unit of group
O blood was held and transported wherever required (figure 1.2)14;20. Following
the war he fled to London where he helped establish a similar system. At that
time further conflict with Germany was imminent and the war office established
the army blood supply depot. This was again a mobile system that held blood
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Figure (1.2) Mobile blood bank during the Spanish civil war. Reproduced from
the Canadian library archives (http: // www. collectionscanada. ca ).
centrally and transported it forward wherever required. By the end of the second
world war war 1300 units of blood were supplied and used each day. Following
the success of this system, and the creation of the National Health Service (NHS),
both the National Blood Transfusion Service (NBTS) and Scottish National Blood
Transfusion Service (SNBTS) were established in 194617;19;21.
1.2.5 Where Did We Get a ‘Transfusion Threshold’?
The first mention of a haemoglobin concentration ([Hb]) based transfusion thresh-
old can be traced back to 1941. Lundy wrote, without providing reference to
any supporting evidence, with respect to anaemia “This condition, owing to the
lowered oxygen carrying capacity of the blood, interferes with the adequate trans-
portation of oxygen to the tissues. When the concentration of haemoglobin is less
than 8-10g per 100cc of whole blood it is wise to give a blood transfusion before
operation”22;23. All though this statement could be deemed unfounded on the
basis of scientific or clinical evidence available at the time, subsequent attempts
were made at its justification24. However, the mathematical demonstrations of
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poor oxygen kinetics, when [Hb] is reduced, that followed were extremely lim-
ited as no consideration was given to the effects of general anaesthesia on basal
metabolic rate nor the scope for haemodynamic compensation in terms of an
increase in cardiac output (CO). Furthermore, as this was prior to the advent
of hypothermic cardio-pulmonary bypass (CPB), no consideration was given to
temperature, a variable particularly applicable to cardiac surgery25.
Interestingly, although over half a century has passed since Lundy’s unsub-
stantiated statement, RBCs are still widely administered based upon the [Hb]
level originally proposed by Lundy as a prudent threshold for transfusing RBCs.
1.3 Current Blood Usage
Blood transfusion therapy has become an everyday component of medical man-
agement since its early development as outlined above. At present, precise UK
wide information on blood usage does not exist26;27.
A retrospective analysis conducted during 2000/2001 estimated a total of 2.8
million whole blood donations were collected in the UK. This accounted for a
total of 1.7 million transfusion events at a total cost of 898 million pounds in
real terms. RBCs accounted for 0.98 million transfusion events averaging 2.7u
per transfusion28. When compared to a previous study by the same group in
1994/1995, it was estimated transfusion costs had risen by 256%29. Attempts
have been made to establish exactly where all this blood is used.
A prospective study in the North of England recorded the destination of 9774u
of RBCs over two fourteen day periods in 1999 and 2000. Overall, 40.7% of
units were used by surgical departments, the commonest indications being total
hip replacement (4.6%) and coronary artery bypass grafting (CABG) (4.1%)26.
Within the Edinburgh cardiac surgery unit, RBC transfusion practice was studied
in 1997. A cohort of 74 elective patients were recorded over a 1 month period.
Overall, 85% of patients were given RBCs. Those transfused on average received
2.3u with a figure of 2.1u per patient operated upon30. The Safe And Good
Use of Blood Products in Surgery (SANGUIS) study recorded transfusion rates
between 17.1 - 100% for CABG procedures across European units in 1989-90. At
that time 93% of CABG procedures in Edinburgh were transfused31. It should be
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added however, that the transfusion strategy in Edinburgh is now considerably
more restrictive than the strategy employed in 1989-90.
1.4 The Risks and Monitoring of Transfusion
The potential risks and complications of any RBC transfusion are numerous and
the true incidence of adverse events and reactions is almost certainly only partially
documented. In the following sections we firstly describe the UK haemovigilance
schemes followed by the specific risks of transfusing RBCs. Finally, we examine
the impact of RBC transfusion on mortality and long term outcome.
1.4.1 Haemovigilance in the UK
The recognition that the monitoring of transfusion complications is essential for
developing risk management strategies has led to the development of haemovigi-
lance schemes in many countries32;33.Haemovigilance may be defined as ‘a set of
surveillance procedures covering the entire transfusion chain (fromthe donation of
blood and its components to the follow-up of recipients of transfusions), intended
to collect and assess information on unexpected or undesirable effects resulting
from the therapeutic use of labile blood products, and to prevent the occurrence
or recurrence of such incidents’34.
In the UK, haemovigilance of adverse events and reactions has been carried
out by the serious hazards of transfusion (SHOT) scheme. Since its implementa-
tion in 1996, this system has relied upon the voluntarily return of questionnaires
documenting adverse transfusion events and ‘near misses’35. Only recently has
the reporting of adverse events become compulsory. The recent EU ‘blood safety
directive’ introduced a legal requirement for the reporting of adverse events in
member states to a competent authority. This was subsequently enforced in the
UK by the Department of Healths (DoHs) ‘Better Blood’ initiative and the en-
actment of the UK ‘Blood Safety (and quality) Regulations 2005’. The Medicines
and Healthcare Regulatory Agency (MHRA) was appointed as the competent re-
porting authority with the serious adverse blood reactions and events (SABRE)
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online reporting system subsequently being put into place36. A summary and
description of reportable SHOT events is given in table (table 1.1)35.
1.4.2 Specific Complications of Transfusion
In the following sections we discuss the pathogenesis, diagnosis and management
of the principle specific complications of RBC transfusion. A summary table of
events reported to SHOT 1996 - 2004 is given in table 1.233;37.
1.4.2.1 Acute Transfusion Reactions
Acute transfusion reactions (ATRs) include;
• Febrile non-haemolytic transfusion reactions
• Acute haemolytic transfusion reactions
• Reaction to bacterially contaminated blood
• Allergic reaction or anaphylaxis
• Transfusion related acute lung injury
• Transfusion associated circulatory overload
Transfusion related acute lung injury (TRALI) and transfusion associated
circulatory overload (TACO) are discussed in more detail in sections 1.4.2.6 and
1.4.2.7 respectively.
Febrile Non-haemolytic Transfusion Reactions
Febrile non-haemolytic transfusion reactions (FNHTRs) are not reportable
to SHOT but are particularly frequent. Such reactions are characterised by
fever, nausea, dyspnoea and occasionally hypotension. Onset is usually during
or shortly after the RBC transfusion has taken place35;38;39. The primary mech-
anism for these reactions is thought to be the interaction between the recipient’s
cytotoxic antibodies and donor leucocytes, leading to the release of endogenous
pyrogens40. The incidence of these reactions has reduced by as much as 50%
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with universal leucodepletion. Preventative measures include the administration
of anti-histamines, anti-pyretics such as paracetamol or corticosteroids41;42.
Acute Haemolytic Transfusion Reaction
Acute haemolytic transfusion reactions (AHTRs) may occur in a number of
ways. One of the commonest causes is the transfusion of ABO incompatible
blood, usually as a consequence of human error42. Other causes of haemolysis in-
clude the chemical or mechanical destruction of RBCs. Lysis may result from the
use of hypotonic fluids, overheating or improper freezing of units and prolonged
storage. Mechanical destruction can occur by the use of pumps or small cannulae
for transfusion38. Symptoms can be severe, depending on the degree of haemol-
ysis, including hypotension, shock and renal failure. Diagnosis can be confirmed
with the presence of free plasma haemoglobin and haemoglobinuria. Treatment
is supportive with the maintenance of urine output by a diuretic where required.
Severe cases may require inotropic support and renal filtration38;39;42.
Reaction to Bacterially Contaminated Blood
Most cases of bacterial infection occur with platelet transfusion, primarily be-
cause the product is stored at room temperature rather than the 2-40C of RBCs.
Organisms commonly implicated include Staphylococcus, Yersinia, Enterobacter
and Pseudomonas43;44. Potential donors with risk factors for blood borne bacte-
rial infection are excluded from blood donation. However, this does not prevent
asymptomatic donors with a transient bacteremia from giving blood. No screen-
ing tests are currently available to detect contaminated units. Recently, platelet
samples in Scotland have started being withdrawn for culture although this is not
a common practice44. Typical presentation is with sepsis and circulatory shock
in a matter of minutes or hours after the completion of transfusion35;39;43. Blood
samples should be taken from the patient and the suspected unit for culture.
Treatment is with broad-spectrum antibiotic therapy and cardio-respiratory sup-
port where required43.
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Allergic Reaction or Anaphylaxis
Allergic reactions following transfusion are common but fortunately usually
mild. Typically symptoms are cutaneous with pruritis accompanied by both
erythematous and papular rashes. These reactions are usually IgE mediated
with symptoms due to histamine release. Treatment consists of interrupting
the transfusion and the administration of an anti-histamine. Providing fever
is not present the transfusion may be recommenced following this action. At
the other end of the clinical spectrum is severe, potentially lethal, anaphylaxis.
Patients may develop laryngeal oedema with hypotensive shock. Management
should be prompt with adrenaline, vasopressor agents and airway management
where required38;39;42;45. Leucodepletion does not prevent allergic or anaphylactic
reactions as they are thought to be triggered by soluble substances in donor
plasma46.
1.4.2.2 Delayed Transfusion Reactions
Delayed transfusion reactions (DTRs) include;
• Delayed haemolytic transfusion reaction
• Post-transfusion purpura
• Transfusion associated graft versus host disease
Delayed Haemolytic Transfusion Reaction
Delayed haemolytic transfusion reactions (DHTRs) describe haemolysis that
typically occurs between 4 - 10 days following the offending transfusion. Patients
have usually been pre-sensitised to a RBC antigen either by child birth or previ-
ous transfusion42. Clinical features include a gradually falling [Hb], jaundice and
occasionally haemoglobinuria or renal failure47. The diagnosis can be confirmed
by the use of direct antiglobulin testing (DAT). Usually, the responsible antibody
is present on initial screening but at levels below clinical detection. Rarely, the
patient may have no pre-transfusion antibody but develops one while the sen-
sitising RBCs are in the circulation. Risk is minimised in most centres by the
provision of antigen matched RBCs42. Treatment is rarely required aside from
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the careful monitoring of renal function39.
Post-transfusion Purpura
Post-transfusion purpura (PTP) is a rare bleeding disorder characterised by
an acute thrombocytopenia occurring 5-10 days following RBC transfusion. The
condition is often missed because of the delay between the offending transfusion
and the onset of symptoms39;48;49. The cause is thought to be platelet alloim-
munisation in pre-sensitised individuals such as multiparous females, although
the precise mechanism is still controversial. Diagnosis of PTP can be confirmed
by the presence of anti-platelet antibodies in the recipient49;50. The incidence of
PTP has fallen dramatically in this country since the introduction of universal
leucodepletion. Primarily, this is thought to relate to the removal of platelets
from RBCs as part of the above process41. Treatment consists of the adminis-
tration of high dose intra-venous immunoglobulin, with or without steroids39;48;49.
Transfusion Associated Graft Versus Host Disease
Transfusion associated graft versus host disease (TA-GVHD) is a rare compli-
cation of transfusion which is fatal in virtually all cases. The risk of TA-GVHD is
related to the number of T-lymphocytes transfused, the recipient’s immune sta-
tus and the relationship between donor and recipient human leucocyte antigen
(HLA) types51–53. Symptoms usually consist of rash, fever, abdominal pain, liver
dysfunction and bone marrow suppression some 2-30 days following transfusion39.
Death usually occurs due to infection. Treatment is essentially preventative with
blood products for at risk groups being irradiated. Immunosuppressive therapy
has been used for those who contract the condition albeit with limited results51;52.
Leucodepletion has again had a profound effect on the incidence of the disease41.
1.4.2.3 Transfusion Related Immunodilution
Any blood product administered may contain a large amount of foreign antigenic
material in both soluble and cell associated forms. Such alloantigenic matter may
result in a down regulation of the host immune response. Commonly, this series of
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events is referred to as transfusion related immunodilution (TRIM)54;55. In surgi-
cal patients, such a scenario is generally considered deleterious with an increase in
post-resection tumour re-occurrence and the incidence of septic complications55.
As white blood cells (WBCs) are thought to be the principle source of these
alloantigens, studies have attempted to identify the effects of leucoreduction on
infectious complications following cardiac surgery55. Although, as yet the results
of this research has been inconclusive the possibility of TRIM associated post-
operative infection remains a possibility and should be considered in any decision
to transfuse RBCs56;57.
1.4.2.4 Transfusion Transmitted Infection
Human immunodeficiency virus (HIV), hepatitis B, hepatitis C and human T
cell lymphoma virus are all transmissible by blood. Transfusion centres in the
United Kingdom screen every donation with tests for these viruses becoming ever
more sensitive58;59. Despite this, transmission can still occur in the early phase of
infection, before the antibody response has become detectable, where blood has
been donated in the so called ‘window period’60.
The majority of data collected on transfusion transmitted viral infections has
relied upon reported cases. This is unreliable in that many cases may remain
asymptomatic or have contracted the disease by a route other than transfusion61.
This issue was recently addressed by a survey of over five thousand patients receiv-
ing blood in the UK. Interestingly, no instances of transfusion related infection
were reported although several patients had evidence of pre-transfusion infection.
Where infection was hospital acquired other sources were identified61;62. Thus,
it is reasonable to assume that viral transmission is exceedingly rare although
theoretically possible.
1.4.2.5 Variant Creutzfeldt-Jakob Disease
The first description of vCJD in the UK occurred in 199663. By 2001, slightly
over one hundred cases had been reported although it is worth noting that the
incidence of new cases has continued to decline for several years64. The presumed
mechanism of transmission in the majority of cases is by the ingestion of beef from
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cattle infected with bovine spongiform encephalopathy (BSE)65. Although the
link with RBC transfusion has always been tenuous, this picture is now chang-
ing. Recently published data by the National Creutzfeldt-Jakob disease (CJD)
Surveillance Unit has identified 3 cases of probable transfusion transmission of
vCJD. To date, no evidence exists that the familial or sporadic strains of CJD
may be transmitted in a similar manner66. The classic histological lesion evi-
dent is the presence of amyloid neural plaques surrounded by spongiform change
(figure 1.3)67. Patients usually experience neuro-psychiatric symptoms progress-
ing to ataxia and cognitive impairment over a period of 7-38 months. The long
subclinical incubation period gives rise to concerns that large numbers of the
population may be harbouring the disease asymptomatically65;68.
At present, no specific screening test or treatment exists. As a result, strate-
gies have now been implemented with the aim of reducing the risk of transmission.
UK donor plasma has been excluded from fractionation while blood components
are leucodepleted. However, despite these measures, risk can not be discounted
and the possibility of transmission should be remembered by all those who pre-
scribe blood65;68;69.
1.4.2.6 Transfusion Related Acute Lung Injury
TRALI has been shown to be one of the leading causes of transfusion related
morbidity and mortality both in the UK and US. This is despite the likelihood
the condition is under reported70–72. The aetiology may be antibody mediated
(immune) or initiated by neutrophil priming substances (non-immune). Due to
the universal leucodepletion of RBCs the former is thought to be the most preva-
lent in the UK70;73;74. The incidence of immune TRALI has been placed at 1 in
625 of all patients transfused. The classical symptoms are those of acute hypoxia
and non-cardiogenic pulmonary oedema, usually developing within 1-2h of the
offending blood transfusion72;75.
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Figure (1.3) Histological section demonstrating variant Creutzfeldt-Jakob disease
(vCJD). Cerebral cortex demonstrates classic plaque structure with a glassy centre
surrounded by spongiform change. Reproduced from the National vCJD Surveil-
lance Unit, The University of Edinburgh (http: // www. cjd. ed. ac. uk ).
Figure (1.4) Plain radiograph of acute lung injury (ALI). Reproduced from
Medicine Net (http://www. medicinenet. com ).
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Table (1.3) Clinical diagnostic criteria for TRALI. TRALI = transfusion related
acute lung injury, ALI = acute lung injury, PCWP = pulmonary capillary wedge
pressure and CXR = chest x-ray.
1. The onset of symptoms or signs is during or within 6h after the
end of transfusion of one or more plasma-containing blood products
2. New onset ALI recognised by; i) Timing: Acute onset
ii) PCWP: ≤18 mmHg or no clinical evidence of left atrial
hypertension
iii) CXR: bilateral fluffy infiltrates
iv) Hypoxia: Ratio of PO2/FiO2 ≤300 mmHg regardless of positive
end-expiratory pressure, or Oxygen saturation of ≤90% on room air
As defined at the Toronto consensus conference convened by the
Heart, Lung and Blood Institute, April 2004.
Although the subject of much debate, at present the only diagnostic criteria
for TRALI are clinical (table 1.3)73;74;76. Findings such as mild pyrexia, hypoxia,
tachypnoea, hypotension, bilateral crepitations, bi-basal dullness and fluffy bi-
lateral infiltrates on plain chest x-ray (CXR) may equally be attributed to CPB
related acute lung injury (ALI) (figure 1.4)77. Furthermore, subtler forms of the
condition, not complying with the above diagnostic criteria, are almost certainly
overlooked. At the present time, management of TRALI is for that of ALI with
ventilatory support as required. The majority of patients recover within 96h with
little in the way of permanent sequelae71.
1.4.2.7 Transfusion Associated Circulatory Overload
TACO is a term coined to describe cardiogenic pulmonary oedema following the
transfusion of RBCs78;79. Although TACO is often confused with TRALI, the
causality of the pulmonary oedema may be used to distinguish between the two
conditions. The aetiology of TACO is hydrostatic while TRALI results from
pulmonary endothelial damage and the resultant increase in permeability. As a
result, an increase in atrial natriuretic peptide, attributable to atrial distension,
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can help distinguish between the two conditions80;81.
Although the exact incidence of TACO is unknown, it is likely an under recog-
nised condition. Estimates vary from 1 - 8% in elderly orthopaedic patients.
Invariably onset is precipitated by the rapid infusion of RBCs, often by as lit-
tle as 1unit79;82. Clinical characteristics are those of congestive cardiac failure
with hypoxia, tachypnoea and tachycardia usually evident within 1-2h of RBC
transfusion. The one differentiating feature that may be noted is an increase in
blood pressure. Treatment is again supportive with mechanical ventilation where
required and the administration of a diuretic preparation if deemed necessary. In
extreme cases venesection may be indicated79;82.
1.4.3 Red Cell Transfusion and Survival
Although the recognised complications of RBC transfusion are rare, what about
the longer term effects on patient survival? Two large retrospective analysis have
associated RBC transfusion with all cause mortality following cardiac surgery.
Engoren et al conducted an analysis of 1915 patients. They found that RBC
transfusion was an independent mortality risk factor associated with a risk ratio
of 1.7 at 5y83. Kuduvalli et al performed a larger analysis of 3024 patients. It
was demonstrated that the mortality risk ratio, again adjusted for co-morbidity,
was 1.88 at 1y84. In the short term, RBC transfusion has also been identified
as an independent risk factor for in hospital mortality85. Further studies have
examined the association between RBC transfusion and mortality based outcome
in patients with with acute coronary syndromes (ACSs).
Wu et al reported findings in a retrospective cohort of 78,974 ACS patients.
They documented a reduction in 30d mortality if patients transfused had an ad-
mission haematocrit (Hct) < 30% while no benefit was found with a Hct > 33%86.
However, two key criticisms can be leveled at this study. Firstly, patients with
do not resuscitate (DNR) orders were included in the analysis. This may have
influenced a transfusion practitioners decision to administer RBCs. Secondly,
patients in the lower Hct groups underwent fewer coronary interventions, almost
certainly influencing baseline mortality.
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Perhaps a more rigorous analysis was performed by Rao et al in a smaller
retrospective cohort of 24,112 patients. They found that hazard adjusted mor-
tality in ACS patients was in fact higher when the Hct was greater than 25%.
Indeed, at 30d those receiving a transfusion had a fourfold increase in mortal-
ity. This contradicts the assumption that transfusion should normalise risk in
anaemic patients87. In the absence of large prospective analysis it is difficult to
draw definitive conclusions from the studies above. However, both studies sug-
gest that an element of caution should be applied to any decision to transfuse in
this sub group of patients.
1.5 What Factors Should we Consider in Decid-
ing to Transfuse?
1.5.1 Oxygen Transport
The role of [Hb] in transporting oxygen was recognised as early as the 1920’s.
Essentially, each [Hb] molecule consists of two alpha and two beta subunits, each
containing a central iron based haem ring responsible for binding oxygen (figure
1.5). The vast majority of oxygen is transported in this manner, with only about
2% carried in solution under normal atmospheric conditions88;89.
The relationship by which [Hb] binds oxygen can be represented graphically
by the oxy-haemoglobin dissociation curve (figure 1.6). The curve represents
the percentage saturation of [Hb] at various partial pressures of oxygen. The
sigmoidal nature relates to the property of co-operative binding whereby the
affinity of [Hb] for oxygen increases with each subunit that has bound an oxygen
molecule. At high partial pressures, [Hb] is maximally saturated while at low
partial pressures [Hb] looses its affinity for oxygen. The P50 value is often used
to describe the curve and refers to the oxygen partial pressure at which [Hb]
is 50% saturated. The ability of this curve to move under certain conditions is
vital in the body’s response to anaemia. Factors that shift the curve to the right
include an increase in temperature, hydrogen iron concentration, carbon dioxide
and organic phosphates, principally 2,3-diphosphoglycerate (2,3-DPG)88. More
detail on oxygen transport is given in appendix B (page - 182).
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Figure (1.5) Graphic representation of a haemoglobin molecule. Reproduced from
The Biopolymer Group, Sheffield (http: // www. biopolymer. group. shef.
ac. uk. ).
1.5.1.1 Supply Dependency
Systemic oxygen consumption (VO2) is regarded as an estimate of aerobic metabolic
activity within the human body. When systemic oxygen delivery (DO2) is at nor-
mal, or supra-normal, levels, VO2 remains constant. However, when DO2 falls
below a critical point, VO2 may be supply limited (figure 1.7). This phenomenon
has been described as pathological supply dependency as tissue oxygen extrac-
tion is unable to increase in proportion to the fall in DO2. In such a scenario,
anaerobic metabolism ensues with the accumulation of lactic acid89;90. Although
such a model is appealingly logical, it is increasingly being questioned.
As many of the measured variables that determine VO2 are also used in the
calculation of DO2, mathematical coupling may exist. For example, as arterial
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Figure (1.6) Oxygen dissociation curve. Reproduced from Anaesthesia UK
(http: // www. frca. co. uk. ).
oxygen saturation (SaO2) is found in the calculation of both VO2 and DO2 a
mathematical link is present. This may indicate a correlation between the two
variables in the absence of a true physiological association. It is now thought
that this is the most likely explanation for their associated fall below a theoretical
critical point91;92. This hypothesis is strongly supported by the observation by
Myles et al that VO2 following CPB, when measured by expired gas analysis, has
no association with the value calculated by use of the reverse Fick principle93.
1.5.1.2 Critical Oxygen Delivery
Several attempts have been made to identify when oxygen delivery becomes criti-
cal (critical oxygen delivery (DO2Crit)). Below this critical point metabolism can
be considered to be predominantly anaerobic. Nelson et al used animal models to
plot VO2 against oxygen extraction (QO2). The DO2 below which VO2 fell with
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Figure (1.7) Diagrammatic representation of pathological oxygen supply depen-
dency.
no further increase in QO2 (critical oxygen extraction (QO2Crit)) was defined in
this study as DO2Crit. In the absence of sepsis, DO2Crit was measured at 6.8 and
7.4ml/min/kg94;95. Similar findings have been reported in human models.
Shibutani et al identified a DO2Crit of 330ml/min/m
2 (8.2ml/min/kg) in 58
cardiac surgery patients prior to CPB96. In a similar cohort, but following CPB,
Komatsu et al found a value of 300ml/min/m2 based upon measurements in
66 patients25. Perhaps the most rigorous study was performed by Ronco et al
on a cohort of 9 non-septic, critically ill, ICU patients. VO2, as measured by
indirect calorimetry, was plotted against DO2, as calculated by the Fick method,
QO2 and measurements of plasma lactate concentration. DO2Crit was found to
occur at a value of 4.5ml/min/kg97. All of the above studies were performed
on anaesthetised patients at normothermia. In order for these values to have
relevance in cardiac surgery, consideration has to be given to the marked effects
of temperature in reducing VO2 and DO2Crit
89;98.
DO2Crit can be plotted against actual values of DO2 to demonstrate the
presence, or otherwise, of an oxygen reserve. Such a study was performed by
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Ganushchak et al with a cohort of 15 peri-operative cardiac surgery patients.
The value for DO2Crit was taken as that suggested by Komatsu et al, at the up-
per end the figures quoted. They found actual DO2 approached DO2Crit at two
points: removal of the aortic cross clamp and extubation. However, at no point
was systemic oxygenation impaired89. As it is likely that DO2Crit is lower than
the value used in this study, credence can be given to the theory that a significant
oxygen reserve does exist in peri-operative cardiac surgery patients97.
1.5.1.3 Lactic Acidosis
Most patients undergoing cardiac surgery will develop post-operative metabolic
acidosis due to accumulation of lactate. This has been attributed to systemic
hypo-perfusion and tissue hypoxia99;100. As cellular metabolism converts pyru-
vate to lactate under conditions of anaerobic metabolism it has been assumed
that the magnitude of this metabolic acidosis represents the scale of the oxy-
gen debt accrued during CPB100. Newer evidence however, has demonstrated
that post-operative metabolic acidosis can occur under conditions of aerobic
metabolism89;101;102. Commonly used drugs such as insulin and those contain-
ing calcium and magnesium can all lead to the deactivation of pyruvate dehy-
drogenase (PDH) with a resultant accumulation of lactate. Other factors in-
clude washout from previously hypo-perfused tissues and reduced lactate clear-
ance89;101.
It has recently been proposed that lactic acidosis following CPB may be iatro-
genic99;103. Patients undergoing cardiac surgery receive a large amount of exoge-
nous fluid, particularly from the pump prime during CPB. The net effect of this
non-bicarbonate ion ([HCO3−]) containing fluid may be to dilute extra-cellular
[HCO3−], thus reducing the patients own buffering capacity104.
Traditionally, acid-base balance has been interpreted using the Henderson-
Hasselbach equation. However, Stewart has proposed an alternative approach
that uses fundamental laws of physical chemistry, including that of electro-neutrality,
to determine exactly what variables influence hydrogen ion concentration in com-
plex solutions. The principle components of Stewart’s hypothesis are the strong
ion difference , arterial partial pressure of carbon dioxide (PaCO2) and the total
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Figure (1.8) Red cell storage lesion as viewed by electron microscopy. Image A
demonstrates the typical spiculated appearance as compared to a normal red cell in
image B. Reproduced by permission of Dr Katsuji Nishi, Shigi University, Japan.
concentration of weak acids105. It has been demonstrated that the administra-
tion of fluids that have little or no strong ion difference, such as normal saline,
reduce the strong ion difference of the blood with the net effect of an increase in
the dissociation of hydrogen ions and a resultant metabolic acidosis106–108. Thus,
metabolic acidosis after heart surgery may often reflect changes induced by ad-
ministration of intra-vascular fluids that are of a low strong ion difference rather
than anaerobic metabolism and accumulation of lactic acid.
1.5.1.4 Red Cell Storage
RBC transfusion is administered on the premise that it will improve tissue oxy-
genation. However, the evidence to support this statement is limited. Much
debate exists in the literature as to the efficacy of stored RBCs in terms of oxy-
gen transportation. Red cell 2,3-DPG is critically depleted after 10 days, which
results in an increase in the affinity of the haemoglobin moiety for oxygen (figure
1.6). Morphological changes have also been noted that reduce RBC deformability
and question their ability to traverse the micro-capillary bed (figure 1.8)109;110.
There is a dearth of solid clinical data as to the effects of transfused RBCs on
oxygen transport. Results from animal studies are not necessarily applicable to
the human population while the methodology of the majority of human studies
can be questioned due to the mathematical errors introduced when calculating
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DO2 and VO2
91. However, a recent RCT conducted by Walsh et al randomised 22
non-bleeding anaemic ([Hb]< 9g/dl) ICU patients to receive either fresh (≤ 5d) or
stored (≥ 20d) RBCs. No difference was found in indices of gastric and systemic
oxygenation between the two groups. Also of interest was that no improvement
was observed in global indices of tissue oxygenation by either group111. Although
the [Hb] levels in this study could not be considered ‘critical’, it does raise the
question as to the efficacy of RBCs for the transfusion threshold employed ([Hb]
< 9g/dl).
1.5.2 What Effect Does Lowering Haemoglobin Have on
the Heart?
In healthy adults and animal models, extreme haemodilution is well tolerated
by the heart. Compensatory mechanisms include; a viscosity mediated reduc-
tion in systemic vascular resistance, marked tachycardia (in non-anaesthetised
individuals), an increase in stroke volume and coronary vasodilation112. These
mechanisms appear adequate in protecting healthy hearts at a [Hb] of 5g/dl.
Below this [Hb] oxygenation is impaired with sub-endocardial ischaemia and a
resultant reduction in myocardial function. In addition, it has also been suggested
that any electro-cardiogram (ECG) changes that do occur above a [Hb] of 5g/dl
in healthy individuals may be benign and entirely reversible113.
The above straightforward scenario, however, does not apply to individuals
presenting for cardiac surgery with a variety of cardiac pathologies that may limit
the patho-physiological response.
1.5.2.1 Coronary Artery Disease
Most patients presenting to a cardiac surgical unit will have coronary artery
disease (CAD). Opinion as to the significance of normovolaemic anaemia with
co-morbid CAD is divided although generally it has been documented that a safe
transfusion threshold lies between 9-11g/dl114.
Licker et al reported results from 44 patients scheduled to undergo CABG
surgery. Individuals were randomised to receive either routine management (n =
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22) or to undergo pre-operative blood donation and normovolaemic haemodilu-
tion to a Hct of 28% ([Hb] approximately 9g/dl) (n = 22). Although the echo-
cardiographic characteristics of the intervention group changed with an increase
in CO and pre-load through increased venous return, both myocardial systolic
and diastolic function was comparable between the two groups. Although this
study was of limited power for the outcome variables examined, it was of note no
member of the intervention cohort developed evidence of myocardial ischaemia
(> 1mm ECG ST segment change or left ventricular wall motion abnormality).
This was despite a significant reduction in systemic DO2
115. The same group, us-
ing an identical technique, have also suggested that normovolaemic hemodilution
pre-CPB has a protective effect against myocardial injury116.
Previously considered a contraindication to isovolaemic haemodilution, results
have also been reported in patients with left main stem (LMS) stenosis. Herre-
gods et al examined 71 patients with significant LMS disease (> 60% stenosis)
immediately prior to CABG. When compared to controls (n = 32), patients un-
dergoing donation and limited pre-operative haemodilution (n = 39) to a Hct of
34% ([Hb] approximately 11g/dl) exhibited no difference in significant (> 1mm)
ECG ST segment change117;118. As hemodilution was ‘limited’ in this instance to
provide only a small fall in Hct (6%) only limited conclusions can be drawn.
Several researchers have examined the impact of CAD on outcome follow-
ing non-cardiac surgical procedures. Carson et al retrospectively studied 1958
patients undergoing major surgical procedures who refused RBC transfusion as
a matter of religious choice. Those with cardiovascular disease and a low pre-
operative [Hb] were found to have a greater overall mortality119. A limitation of
this study is that only pre-operative [Hb] could be accurately considered due to
incomplete data. Nelson et al conducted a small prospective observational study
of 27 patients undergoing vascular surgery. They found that cardiac morbidity
increased when post-operative Hct fell below 28% ([Hb] approximately 9g/dl)120.
As the study methodology did not provide detailed documentation of the presence
or absence of CAD the significance of the observations is uncertain.
The above findings may have some relevance to the general ICU setting but
it is likely they are of limited applicability to cardiac surgery. Patients scheduled
for valve surgery alone are likely to have had the presence of angiographically
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significant CAD excluded prior to operation. Those due to undergo CABG will
in the majority of cases have their coronary vascular reserve normalised121.
1.5.2.2 Valvular Heart Disease
Experience with hemodilution and other cardiac pathologies is less well docu-
mented. Licker et al randomised 28 patients with severe aortic stenosis, sched-
uled for aortic valve replacement (AVR), to undergo either moderate normo-
volaemic haemodilution or routine management. In the study group, Hct was
lowered to 28% ([Hb] approximately 9g/dl) compared with 39% ([Hb] approxi-
mately 12.9g/dl)in the control group. No difference was noted in terms of arterial
blood lactate, ECG change or left ventricular wall motion abnormality. Haemo-
dynamic compensation occurred in the study group through a viscosity-mediated
reduction in systemic vascular resistance with a subsequent increase in pre-load,
stroke volume and trans-valvular flow rates. It was felt however, that this re-
sponse may be limited due to less efficient left ventricular stroke work122.
Spahn et al similarly observed the effects of limited haemodilution ([Hb] =
10.3g/dl) on 20 patients with mitral insufficiency scheduled for operation. The
same physiological response was observed with an increase in cardiac index (CI)
due to after-load reduction and pre-load increase. Patients with chronic atrial
fibrillation demonstrated a similar reserve to those in sinus rhythm123.
1.5.2.3 Poor Ventricular Function
The reduction in viscosity associated with normovolaemic anemia results in a
reduction in after-load with a resultant increase in stroke volume as outlined
above. Where myocardial contractility is poor the compensatory increase in
stroke volume is likely to be limited. Casutt et al studied several parameters in-
fluencing post-operative oxygen kinetics in 67 patients following cardiac surgery
and found that pre-operative ejection fraction (25-87%) was not associated with
post-operative DO2
124. Spahn et al reported similar findings in a cohort of 90
patients. It was concluded that the compensatory mechanisms associated with
hemodilution were independent of pre-operative ejection fraction over the range
of 26-83%125. It has been commented however, that such results should be treated
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with caution as few patients were found at the lower end of the ejection fraction
range126.
1.5.3 Should Haemoglobin Concentration be the Only Pa-
rameter we Consider?
It may appear to be stating the obvious that as [Hb] is a concentration it is
determined by two variables, red cell volume (RCV) and plasma volume (PV).
Therefore, the relative contribution of RCV and PV to the post-operative anaemia
encountered in cardiac surgery patients will dictate the decision to transfuse if
[Hb] is the sole parameter considered. It is often assumed that any fall in [Hb]
is directly associated with RCV loss, however this is not necessarily the case.
Transfusing based upon RCV loss, as opposed reduction in [Hb], will reduce the
incidence of potentially unnecessary transfusion if PV expansion is a significant
factor. Further improvements in such a strategy may be made if we can predict
transfusion requirement based upon an individuals risk of a low post-operative
RCV as opposed to a reduction in [Hb]. A final consideration is whether it is
really necessary to transfuse RBCs in the absence of signs that would otherwise
suggest an inadequate circulation?
1.5.3.1 The Contribution of Haemodilution to Post-operative Anaemia
Cardiac surgery, involving CPB, is associated with a heavy fluid load, both in
relation to the pump priming solution and the additional intra-venous fluid ad-
ministered127;128. If [Hb] is artificially lowered by an excessive fluid load, patients
may be transfused RBCs even though RCV is only modestly reduced. In order
to examine this issue, Fransen et al analysed a cohort of 20 peri-operative car-
diac surgery patients. They identified a rise in PV and blood volume (BV) to a
maximum of 202% and 159% respectively of the pre-operative values, 12h after
removal of the aortic cross clamp (ACC). In contrast, RCV reached a low point of
95% of the pre-operative value 4h after removal of the ACC, while by 24h it had
risen to 107%. Although such results need cautious interpretation as the method
of calculation of RCV loss is prone to error, they suggest that PV expansion
may be an important factor in influencing [Hb] and the decision to transfuse129.
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Only one study has examined peri-operative RCV change directly. In a cohort
of 30 gynaecological patients, Orth et al used sodium fluorescein (NaF) and flow
cytometry to conclude that Hct was a poor indicator of change in RCV130.
1.5.3.2 Predicting Transfusion Requirement
Attempts have been made to construct predictive models for RBC requirement
in cardiac surgery131–141. The principle aim behind these models has been the
identification of high transfusion risk patients for whom pre and peri-operative
strategies can be devised to minimise RBC exposure. Significant factors identified
include; age, female gender, body surface area (BSA), low pre-operative [Hb], non-
elective surgery, re-operation, prolonged CPB time and deep hypothermia134;137.
In all the studies cited, the decision to transfuse was based upon measured [Hb].
Such an act may be misleading as [Hb] alone may not accurately represent peri-
operative blood balance. Thus, the validity of such studies remains in question.
1.5.3.3 Indicators of an Inadequate Circulation
RBCs are often administered without due consideration to the circulatory status
of the patient. In the absence of hypovolaemia, several compensatory mechanisms
exist to maintain tissue oxygenation in anaemic patients (section 1.5.2). There-
fore, it would seem reasonable to suggest that RBCs should only be administered
when these mechanisms can no longer maintain tissue oxygenation. Madjdpour
et al have suggested several parameters that may be indicate when this criti-
cal point is reached, and that can therefore be used as a guide to transfusion
requirement142;143.
These parameters are: relative tachycardia, relative hypotension, a decrease
in VO2 greater than 10% from baseline, an QO2 greater then 50%, a mixed
venous oxygen saturation (SvO2) less than 50% and a mixed venous oxygen partial
pressure (PVO2) less than 32mmHg
142–144. Of the parameters listed, SvO2 may be
the most valuable as it is a single variable that accurately reflects the adequacy of
systemic perfusion145. Furthermore, as jugular venous oxygen saturation (SJvO2)
is consistently 5% greater than SvO2, due to the admixture of de-oxygenated
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coronary sinus blood, estimates of SvO2 may be obtained in the absence of a
pulmonary artery catheter146;147.
In chapter 2 (page - 34), the principle points of the above discussion are
incorporated into a programme of research aimed at reducing the incidence of
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2.1 Developing a Red Cell Volume Based Trans-
fusion Guideline
As discussed in section 1.5.3.1 (page - 31), the large fluid load associated with
cardiac surgery may, mainly by lowering [Hb] through haemodilution, play a
significant part in the decision to transfuse RBCs127;128. It is therefore the case
that RCV should be given greater attention in selecting thresholds or ‘triggers’ to
guide the decision to transfuse RBCs112;113. Developing and incorporating such a
strategy into everyday clinical practice is no easy task as little or no data exists
in the current literature.
In section 1.5.3.2 (page - 32), we mentioned considering patient and operative
variables that may be associated with RBC transfusion where a [Hb] threshold
is the only trigger for transfusing. Such associations have been explored in the
past with the aim of tailoring peri-operative management to minimise exposure to
allogenic RBCs134;137. In chapter 3 (page - 40), consideration is given to the role
of parameters that may influence both RCV and PV, and hence RBC transfusion,
through a large retrospective analysis.
This idea is developed in the subsequent two chapters. In chapter 4 (page - 53),
we examine variables associated with loss of RCV, and therefore more likely to
be representative of peri-operative RCV balance, in a simple observational study.
The second issue we consider is the relative contribution of haemodilution to
post-operative anaemia. If, as may be expected, RCV is relatively well preserved
in the presence of PV expansion, then allowing for this haemodilution before
administering RBCs will allow a more evidence based approach to transfusion129.
In chapter 5 (page - 66), we examine this hypothesis using the data set from the
study cohort employed in chapter 4 (page - 53).
Traditionally, measurement of RCV has involved the use of chromium labelled
RBCs. Unfortunately this approach can not be applied to the rapidly changing
peri-operative situation as it is not possible to make repeated measurements over
short time periods due to persistence of the isotopic label. Recently however,
Lauermann et al reported results with the use of NaF flow cytometry as an
alternative technique for RCV estimation. The principle advantage is that this
technique may be repeated after 1h and as such may be applied in the surgical
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setting130;148. As the methodology used in chapters 4 (page - 53) and 5 (page -
66) relies upon the use of swab weight/drain volume and its measured Hct for
calculating RCV loss it may be prone to a degree of measurement error. In chapter
6 (page - 77) we attempt to validate the technique proposed by Lauermann et al
in order to allow for a more accurate calculation of peri-operative RCV loss.
There are two further important questions if RCV is to be considered in
the transfusion decision making process. First, if it can be demonstrated that
haemodilution is a significant factor in the peri-operative depression of [Hb], then
as normal circulatory physiology is restored, does [Hb] recover127;128? The second
is to ensure that if lower [Hb]s are to be tolerated peri-operatively, patients are
not compromised in terms of critical requirement for oxygen89;97. Both these
questions are addressed in chapters 7 (page - 83) and 8 (page - 94) respectively.
2.2 Lung Injury Following Red Cell Transfusion
ALI is a common occurrence following cardiac surgery. Causative factors may
include; pre-operative airways disease, smoking, the CPB circuit, sepsis, RBC
transfusion and ventilatory barotrauma. In its minor manifestations patients
may experience mild breathlessness. Those less fortunate, approximately 2%,
may develop the more acute form leading to prolonged ventilation and in 50%
of cases death77;149. Lung injury occurs due to the complex interaction of pro-
inflammatory mediators including; cytokines, complement, neutrophils, mono-
cytes, activated endothelial cells and platelets. Neutrophils deposited in the lung
cause widespread parenchymal injury through the release of elastase and oxygen
free radicals150.
As mentioned in section 1.4.2.6 (page - 18), when considering ALI in relation
to RBC transfusion the term TRALI is usually applied. However, TRALI only
describes the acute form of the condition. Subtler forms of ALI may well occur
though they have not been described in relation to RBC transfusion74. This al-
most certainly relates to the difficulty in making a sub-clinical diagnosis of ALI.
In the past, various inflammatory mediators have been measured but these may
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not be specific for the degree of pulmonary endothelial damage151. In attempt-
ing to address this issue in relation to CPB mediated ALI several authors have
explored the role of exhaled nitric oxide (NO) analysis152–154.
The rationale behind this approach is that any reduction in peri-operative
exhaled NO is likely to be a direct reflection of the degree of pulmonary endothelial
damage as the source of NO production is lost152–154. Although NO is produced by
several other sources in the lung, such as the bronchial epithelium, it’s diffusibility
ensures that a reduction from any one source is detectable clinically153. It should
be remembered that reduction in NO within the pulmonary vasculature is thought
to be the causative mechanism for an increase in pulmonary vascular resistance
(PVR) in cases of ALI. This provides the basis for the therapeutic administration
of inhaled NO to these individuals155.
In chapter 10 (page - 122), we conduct a small pilot study aimed at exploring
the association between transfused RBCs and exhaled NO.
2.3 Improving Anti-coagulation Strategies for
Cardio-pulmonary Bypass
Patients undergoing cardiac surgery, with the use of CPB, will consume coag-
ulation factors to a varying extent. This is a potentially detrimental scenario
which, in its extreme form, may result in disseminated intravascular coagulation
(DIC) and complications such as bleeding, microvascular thrombosis and renal
failure156. To minimise this risk, numerous anti-coagulation monitoring strategies
have been devised to control heparin administration during cardiac surgery157–159.
At present, activated clotting time (ACT) is the most frequently used method
of assessing the adequacy of heparinisation. Advantages include its; simplicity,
cost and relative effectiveness158;160;161. However, it may give misleadingly high
prolongations of clotting time during conditions of haemodilution and hypother-
mia i.e. as encountered during CPB162–164. The resultant possibly inadequate
heparinisation, with exposure of blood to foreign surfaces, may lead to excessive
coagulation activation and clotting factor loss165. Some investigators have thus
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advocated the use of individualised heparin management systems (HMSs) (figure
11.1, page - 136)164;166–169.
HMS provides in vitro analysis of individual heparin dose responsiveness
(HDR) allowing patient specific administration of loading dose heparin prior to
CPB. Blood heparin concentration (BHConc) is monitored during CPB by a hep-
arin protamine titration (HPT) technique allowing early detection and correc-
tion of sub-therapeutic anti-coagulation. Following the discontinuation of CPB,
HPT is again used to provide an accurate protamine dose calculation. Resid-
ual circulating heparin following protamine administration can also be detected.
Proposed benefits include a reduction in coagulation activation, blood loss and
post-operative blood product requirement164;166–169. Despite this, HMSs have not
been widely used to replace ACT as the standard heparin monitoring and dosage
system. Reasons may include cost and the cumbersome testing process involved.
Previous research has demonstrated that the key difference between ACT and
HMS based anti-coagulation is that the latter receive a greater dose of heparin,
primarily during CPB166–168. Thus it appears reasonable to hypothesise that the
administration of supplemental heparin, independent of ACT, may confer similar
benefits to HMSs.
In chapter 11 (page - 132), we examine the relative merits of a modified ACT
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The first step in any programme of research is to understand the basis for the
current issue. In this case that equates to answering the question of why cardiac
surgery is a heavy user of RBCs4. A good basis on which to begin to attempt to
answer this question is the observation that most centres consider [Hb] alone when
deciding to administer RBC transfusions. Presumably, this is based upon the as-
sumption that [Hb] is an accurate indicator of peri-operative RCV balance22;23;25.
As discussed in section 1.5.3 (page 31), there is currently no justification for this
assumption in the peer reviewed literature. In order to accurately determine the
role of [Hb] in RBC transfusion we need first to consider that laboratory assays
measure [Hb] in a sample of patients whole blood. [Hb] may be affected by both
RCV and PV. When, as is usual, [Hb] is taken as the threshold or ‘trigger’ for
administering RBCs, it is the relative balance between these two parameters that
determines when an RBC transfusion is given129;130. Theoretically, a patient may
receive an RBC transfusion in response to a heavy fluid load, despite the loss
of little RCV. This scenario occurs in cardiac surgery in relation to the use of
CPB127;139.
This study was designed to establish what patient and procedural variables
are associated with RBC transfusion through a large retrospective analysis with
the intention of gaining a greater insight into the relative contribution of RCV
and PV to post-operative anaemia.
3.2 Aim
To retrospectively analyse what patient and operative variables are associated
with RBC transfusion.
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3.3 Materials and Methods
3.3.1 Patients
As this was a retrospective analysis ethical approval was not required. Data from
all adult (age ≥ 16y) cardiac surgery patients presenting for operation between
January 2003 and December 2006 was included in the analysis. No exclusion
criteria were used. In total, 2399 data sets were collated.
3.3.2 Study Variables
For the purposes of the analysis, the variables outlined below were collected to
form each patient data set (tables 3.1 and 3.2). Data was collected from internally
held audit records, the Scottish Audit of Surgical Mortality (SASM) and the
SNBTS collated better blood database. The variables collected were divided into
continuous and categorical parameters. A further division was then made into;
patient factors, pre-operative variables and procedural variables. All definitions
given in the tables of variables examined were obtained from the Scottish Cardiac
Audit Definitions Database. Where body surface area is mentioned, this was
calculated as recommended by Gehan and George170. RCV was determined by
the formulae recommended by the International Committee on Standardisation
in Haematology (ICSH) (equations A.2 and A.3)171.
3.3.3 Red Cell Transfusion




The primary dependant variable for all analysis was whether or not patients
were transfused RBCs. All continuous variables were first analysed by Q-Q plot.
This test compares the quantile’s (Q) of the sample data against those of the
standard normal distribution. Where normal distribution was evident the two
group Students t-test was used, provided the further assumptions were met i.e.
homogeneity of variance. Where the data was non normal, or the assumptions of
the t-test were not met, Mann-Whitney U test was used. Normally distributed
data was presented as mean (standard deviation (SD)) with non normal data as
median (standard error of the mean (SEM)). For the same dependant variable,
categorical data was examined by chi-squared test and expressed as number (%).
In addition to the above, Spearman rank correlation coefficient (r) were calculated
for the continuous variables with the number of units RBCs transfused. A P value
(PV al) ≤ 0.05 was considered statistically significant. SPSS version 13 was used
for all statistical analysis.
3.4 Results
Of the retrospective data sets collected 1363 (56.8%) of patients were transfused
RBCs versus 1036 (43.2%) who were not. On average, individuals received a
mean of 2.5u per patient operated while those that received a transfusion were
given a mean of 4.3u.
3.4.1 Study Variables vs. Red Cell Transfusion Status
Analysis of all continuous variables versus RBC transfusion status is presented in
table 3.3. Of those parameters examined only; weight, BSA, creatinine and Euro
score met the assumptions of the two group t-test. The remainder were examined














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table (3.3) Analysis of continuous variables. PV al = P value, BSA = body sur-
face area, RCV = red cell volume, CPB = cardio-pulmonary bypass and ACC =
aortic cross clamp. As the majority of the variables were non-normally distributed
data is presented as median (SEM) unless otherwise indicated.
Parameter Transfused Not Transfused PV al Missing
(n =1363, (n = 1036, (n)
56.8%) 43.2%)
Patient Variables
Age (y) 69.0 (0.26) 65.0 (0.33) <0.001 2
Height (m) 1.68 (0.003) 1.70 (0.003) <0.001 131
Weight (kg)* 76.8 (14.8) 83.2 (15.2) <0.001 95
BSA (m2)* 1.86 (0.21) 1.94 (0.20) <0.001 138
RCV (ml) 1885 (10.0) 2035 (10.9) <0.001 138
Pre-Op Variables
Creatinine (µmol/L) * 107 (44) 105 (55) 0.41 133
Haemoglobin (g/dl) 13.4 (0.05) 14.3 (0.05) <0.001 169
Euro Score* 4.6 (2.9) 3.5 (3.0) <0.001 632
Procedural Variables
CPB Time (min) 110 (1.6) 98 (1.7) <0.001 0
ACC Time (min) 69 (1.1) 62 (1.2) 0.001 0
* As this variable was normally distributed data is presented as mean (SD).
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Table (3.4) Analysis of categorical patient variables. PV al = P value, MI =
myocardial infarction, PVD = peripheral vascular disease, COAD = chronic ob-
structive airways disease and LV = left ventricle. All data is presented as n (%).
Parameter Transfused Not Transfused PV al Missing
(n =1363, (n = 1036, (n)
56.8%) 43.2%)
Gender
Male 912 (52.6%) 822 (47.4%) <0.001 4
Female 449 (67.9%) 212 (32.1%)
Prev MI
Yes 485 (55.0%) 397 (45.0%) <0.001 59
No 849 (58.2% 609 (41.8%)
PVD
Yes 268 (59.9%) 179 (40.1%) <0.001 2
No 1093 (56.0%) 857 (44.0%)
COAD
Yes 125 (60.4%) 82 (39.6%) <0.001 2
No 1236 (56.4%) 954 (43.6%)
Diabetes
Yes 260 (61.9%) 160 (38.1%) <0.001 2
No 1101 (55.7%) 876 (44.3%)
Poor LV
Yes 80 (67.2%) 39 (32.8%) 0.008 143
No 1195 (55.9%) 941 (44.1%)
Smoking
Non 455 (59.6%) 308 (40.4%) 0.09 299
Ex 720 (56.2%) 561 (43.8%)
Current 152 (50.8%) 147 (49.2%)
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Table (3.5) Analysis of categorical pre-operative variables. PV al = P value,
NYHA = New York heart association and IABP = intra-aortic balloon pump.
All data is presented as n (%).
Parameter Transfused Not Transfused PV al Missing
(n =1363, (n = 1036,
56.8%) 43.2%)
Surgical Priority
Elective 935 (54.3%) 786 (45.7%) <0.001 2
Expedite 386 (62.1%) 236 (37.9%)
Emergency 39 (73.6%) 14 (26.4%)
Angina Class
Class 1 138 (53.3%) 121 (46.7%) 0.31 589
Class 2 302 (52.8%) 270 (47.2%)
Class 3 329 (54.9%) 271 (45.1%)
Class 4 227 (59.9%) 152 (40.1%)
NYHA Class
Class 1 351 (54.5%) 293 (45.5%) 0.03 30
Class 2 380 (54.0%) 323 (46.0%)
Class 3 450 (57.7%) 330 (42.3%)
Class 4 166 (68.6%) 76 (31.4%)
Pre-Op IABP
Yes 51 (69.9%) 22 (30.1%) <0.001 1
No 1310 (56.4%) 1014 (43.6%)
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Table (3.6) Analysis of categorical operative variables. PV al = P value, CABG
= coronary artery bypass grafting, AVR = aortic valve replacement and MVR =
mitral valve repair/replacement. All data is presented as n (%).
Parameter Transfused Not Transfused PV al Missing
(n =1363, (n = 1036, (n)
56.8%) 43.2%)
Operation
CABG 841 (52.5%) 762 (47.5%) <0.001 1
AVR 188 (60.8%) 121 (39.2%)
MVR 91 (61.9%) 56 (38.1%)
CABG + AVR 152 (71.0%) 62.0 (29%)
CABG + MVR 48 (64.6%) 17 (35.4%)
AVR + MVR 15 (33.3%) 10 (66.7%)
Redo
Yes 66 (67.3%) 32 (32.7%) <0.001 2
No 1295 (56.3%) 1004 (43.7%)
Hardy
Score 1 818 (52.0%) 755 (48.0%) <0.001 2
Score 2 250 (60.7%) 162 (39.3%)
Score 3 22 (71.0%) 9 (29.0%)
Score 4 271 (71.1%) 110 (28.9%)
The principle findings were that; increasing age, small height/weight/BSA/RCV,
low pre-op [Hb], high Euro score and prolonged CPB/ACC time were all identi-
fied as risk factors for receiving an RBC transfusion (PV al ≤ 0.001). Creatinine
was the only non-significant continuous variable examined (PV al = 0.41).
Analysis of all categorical variables versus RBC transfusion status is presented
in tables 3.4, 3.5, 3.6 and 3.7. All parameters were examined by chi-square test.
For the patient variables, the presence of; female gender, previous myocardial
infarction (MI), peripheral vascular disease (PVD), chronic obstructive airways
disease (COAD), diabeties and poor left ventricle were found to be significant at
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Table (3.7) Analysis of categorical operative variables for CABG only. CABG
= coronary artery bypass grafting, PV al = P value and CPB = cardio-pulmonary
bypass . All data is presented as n (%).
Parameter Transfused Not Transfused PV al Missing
(n = 835, (n = 769, (n)
52.3%) 47.7%)
3 Vessel Disease
Yes 614 (52.2%) 562 (47.8%) 0.83 1
No 225 (52.6%) 203 (47.4%)
Left Main Stem
Yes 286 (51.2%) 272 (48.8%) 0.324 1
No 553 (52.9%) 493 (47.1%)
CPB Status
On Pump 73 (22.5%) 251 (77.5%) <0.001 1
Off Pump 766 (59.8%) 514 (40.2%)
the 5% level (PV al ≤ 0.008). No such association was found with smoking habit
(PV al = 0.09) (table 3.4).
Similar findings were posted for the pre-operative factors of; increasing sur-
gical priority and the presence of an intra-aortic balloon pump (IABP) (PV al
< 0.001). New York Heart Association (NYHA) class did reach statistical sig-
nificance although this was not as strong an association as the aforementioned
variables (PV al = 0.03). Angina class was found to be non-significant (PV al =
0.31) (tables 3.1 and 3.5).
When considering the operative procedure, those of a more complex and pro-
longed nature were likely to result in an outcome of RBC transfusion. Maximal
risk was found for combined CABG and AVR procedures with 72% transfused.
This is compared to a rate of 52.5% for straightforward CABG procedures (PV al
< 0.001). The further indicators of operative complexity examined (Hardy clas-
sification and redo status) were both also highly significant predictors of RBC
transfusion (PV al < 0.001) (tables 3.1 and 3.6).
50
3.4 Results
Table (3.8) Correlation coefficient (r) for continuous variables vs RBCs (u)
transfused. PV al = P value, CPB = cardio-pulmonary bypass and ACC = aortic
cross clamp.
Parameter Correlation Coefficient (r)* PV al
Age (y) 0.23 <0.001
Height (m) -0.15 <0.001
Weight (kg) -0.24 <0.001
Body Surface Area (m2) -0.24 <0.001
Red Cell Volume (ml) -0.23 <0.001
Creatinine (µmol/l) 0.06 0.04
Haemoglobin (g/dl) -0.31 <0.001
Euro Score 0.28 <0.001
CPB Time (min) 0.21 <0.001
ACC Time (min) 0.16 <0.001
* Given the non-linearity of the data analysed Spearman’s rank
correlation test was used.
Of the parameters that could only be analysed for CABG procedures, CPB
status (on or off pump) was the only significant variable(PV al < 0.001). The pres-
ence of LMS (PV al = 0.324) or 3 vessel disease (PV al = 0.83) was non-significant
at the 5% level (table 3.7).
3.4.2 Continuous Variables vs. Red Cell Units Transfused
The correlation of the continuous variables with the number of units RBC trans-
fused produced similar findings to those found with RBC transfusion status. In-
dividuals of advancing age with small height/weight/BSA/RCV and prolonged
CPB/ACC times were more likely to receive a greater number of RBCs (PV al <
0.001). The strongest correlation was identified with pre-operative [Hb] (r = -
0.31, PV al < 0.001). Of notable difference in this analysis was that creatinine did
reach statistical significance (PV al = 0.04) (table 3.8).
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3.5 Summary of Principle Findings
Off the continuous variables examined it was evident that; advancing age, small
body size and low pre-operative [Hb] were all significantly associated with RBC
transfusion status and the number of units RBCs transfused. This was also true
of the continuous variables of CPB and ACC time that were indicative of a pro-
longed operative time. Creatinine was associated with units RBC transfused
but not transfusion status. When considering the categorical patient parame-
ters, it was evident that those individuals with any pre-operative morbidity were
at greater risk of receiving RBCs. The exception to the rule was pre-operative
smoking status. Factors that were indicative of clinical urgency for operation
also carried a greater attendant risk for RBC transfusion. Similarly, this was also
found where the procedural complexity increased.
Please see section 12.1 (page - 152) for a full discussion of the above findings.
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Chapter 4
Factors Predicting Loss and Gain




[Hb] is currently considered the most useful investigation on which to base RBC
transfusion . Several studies have developed predictive models based upon [Hb]
for blood product requirement in the cardiac surgery patient131–141. The aim
has been to tailor peri-operative management in order to minimise transfusion
whilst increasing blood ordering efficiency . The core assumption made by many
of these authors is that [Hb] accurately reflects peri-operative blood balance and
change in RCV. However, the dilutional effects of the CPB circuit, along with the
additional fluid received post-operatively, may depress [Hb] irrespective of RCV
status129;130;139. Thus some doubt can be cast on the efficacy of such models.
This study was designed to establish what patient and procedural variables
are associated with loss of RCV as opposed to a reduction in [Hb]. In addition,
we also determined which of these variables are associated with RBC transfusion
when a [Hb] transfusion trigger was the sole parameter considered.
4.2 Aim
To determine what pre and intra-operative variables are associated with loss or
gain in RCV due to bleeding or RBC transfusion.
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Table (4.1) RBC transfusion protocol. RBC = red blood cell, Hb = haemoglobin
concentration, CPB = cardio-pulmonary bypass and ICU = intensive care unit.
Time Transfuse if Hb (g/dl) <*
During CPBn 6
< 4h Post ICU Transfer 8
> 4h Post ICU Transfer 9
* This system was adopted from Scottish Intercolle-
giate Guideline Network (SIGN) number 54 (http:
//www.sign.ac.uk)172.
4.3 Materials and Methods
4.3.1 Patients
Ethical approval was gained from Lothian Regional Ethics Committee (LREC).
All adult (age ≥ 16y) elective cardiac surgery patients presenting for operation
between August and October 2003 were considered for recruitment. Exclusion
criteria were; inability to provide informed consent, pre-operative anaemia ([Hb]
< 13g/dl for males and < 11g/dl for females), emergency surgery, redo surgery
and surgical re-exploration.
Figure (4.1) Bayer Healthcare Rapidlab 855 Arterial Blood Analyser.
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4.3.2 Patient Management
Anaesthesia was induced and maintained with a combination of; fentanyl, mi-
dazolam, propofol, enflurane and pancuronium. Prior to the commencement of
surgery standard monitoring was instituted (arterial pressure, central venous pres-
sure, electrocardiogram, urinary catheter and nasal temperature). Heparin was
given at a dose of 300 International Units (IU)/kg to provide anti-coagulation
for CPB. An ACT in excess of 480s was maintained in all cases with supple-
mental heparin administered where required as per anaesthetic preference. The
extracorporeal circuit consisted of a roller pump∗, flexible venous reservoir, vent
and cardiotomy suction†. The circuit was primed with 2l Hartmann’s solution,
50mmol bicarbonate, 150mmol mannitol and 8000IU of heparin for a total volume
of 2250ml. Once CPB had been established, and the ACC applied, cold blood
cardioplegia was delivered to achieve cardiac arrest. When the procedure had
been completed, patients were rewarmed fully to 370C and CPB discontinued.
Protamine sulphate was given at a dosage ratio of 1:1 of the initial heparin bolus
dose. Additional protamine was given where the ACT remained in excess of 140s.
All available ‘pump blood’ remaining within the CPB circuit was returned to the
patient at the end of CPB.
Thoracic drainage was achieved with a combination of pericardial, mediastinal
and pleural drains where required. All drains were placed on continual suction
maintained at 20cmH2O. Plain chest radiographs were examined post-operatively
to ensure the absence of a significant thoracic collection. Crystalloid was given
in the ICU at a rate of 0.5ml/kg/h with colloid administered (4.5% human albu-
min solution) where required for hypotension (mean arterial pressure (MAP) <
60mmHg) and/or poor urine output (< 0.5ml/kg/h).
4.3.3 Red Cell Transfusion
All RBC transfusions were given strictly as dictated by local protocol as deter-
mined by the principal investigator (table 4.1).
∗Stockert Instruments, Munich, Germany.
†Medtronic Inc, Minneapolis, USA.
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Figure (4.2) Ohaus Navigator Precision Balances.
4.3.4 Calculation of Red Cell Volume Loss and Gain
The following peri-operative time points were identified for the collection of study
data; preoperative, induction, incision, on-CPB, off-CPB, return to the intensive
care unit (ICURet) and 1,3,6,10,16 and 24h post return to the ICU. RCV loss
was calculated from; swab weight, drape weight and arterial Hct at the time
of collection and; thoracic effluent volume, non-returned CPB volume, blood
sample volume and the directly measured Hct. Whole blood Hct was measured
by an arterial blood analyser (figure 4.1)∗. Effluent Hct was calculated by the
centrifugation (6000rpm for 10m) of a 3ml sample† . It should be noted that
effluent was only sampled following thorough mixing to ensure a homogeneous
solution. All weights were recorded to 0.01gm by the use of precision balances
(figure 4.2)‡.
Although RBC units are not constant in their Hct or volume, each unit of
RBCs transfused was taken to represent an RCV gain of 168ml. This figure is
the average RCV for units provided by the SNBTS. The RCV content of returned
∗Rapidlab 855 Arterial Blood Analyser, Bayer HealthCare, Leverkusen, Germany.
†CEP 2000 Centrifuge, Capricorn Laboratory Equipment, Ringwood, UK.
‡Navigator N08110 Balances, Ohaus Corporation, Pine Brook, USA.
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pump blood was calculated from its measured volume and Hct.
4.3.5 Patient and Operative Variables
Previous studies have identified several factors that may affect RCV loss/gain
from induction of anaesthesia (defined for the reporting of results as t = 0) until
24h postoperatively and also from ICURet until the same time point
131–141. These
are; age, sex, height, weight, BSA, initial patient RCV, Hct at induction and anti-
platelet therapy taken within seven days prior to surgery. Additionally, operative
factors that may affect loss or gain of RCV from chest closure were identified as;
CPB time, ACC time, minimum temperature, max re-warm temperature, loss of
RCV from induction to closure and the volume of non-blood fluid administered for
the same time period. In the present study, the initial patient RCV was calculated
as described by the ICSH (equations A.2 and A.3)171. BSA was determined as
recommended by Gehan and George (equation A.1)170.
4.3.6 Statistical Analysis
All variables were presented as mean (SD). To examine the association between
the numerical variables outlined above and RCV loss, linear regression analysis
was used. Pearson’s rank correlation was performed for the RCV gain data. To
determine the significance of any association between RCV loss/gain the binary
parameters of sex and anti-platelet therapy a Wilcoxon’s signed ranks test was
used. A PV al ≤ 0.05 was considered statistically significant. SPSS version 13 was
used for all statistical analysis.
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Table (4.2) Patient and operative characteristics. BSA = body surface area, Hct
= haematocrit, CABG = coronary artery bypass grafting, AVR = aortic valve
replacement, MVR = mitral valve repair/replacement, CPB = cardio-pulmonary
bypass and ACC = aortic cross clamp. All data is presented as mean (SD).
Patient Variables (n = 29) Age (y) 65 (9.6)
Gender (m/f) 18/11
BSA (m2) 1.9 (0.3)
Pre-operative Hct (%) 40.7 (3.4)
Operative Variables (n = 29) CABG 23
AVR 3
MVR 1
CABG + MVR 1
AVR + MVR 1
CPB Time (min) 91 (32)
ACC Time (min) 53 (24)
Min Temp (0C) 31.7 (1.6)
Max Temp (0C) 37.2 (0.3)
4.4 Results
4.4.1 Demographic and Peri-operative Data
Thirty-two adult elective cardiac surgery patients were recruited to the study over
a three month period. Three patients were subsequently excluded due to surgical
re-exploration for bleeding. Of the twenty-nine patients with complete data, 23
underwent CABG, 3 a AVR, 1 a mitral valve repair/replacement (MVR), 1 a
CABG and MVR and 1 a AVR and MVR. The mean age was 65y (SD 9.6) with
a BSA of 1.9m2 (SD 0.3) and pre-operative Hct of 40.7% (SD 3.4). Eighteen of
the patients were male, eleven female. The mean CPB time was 91min (SD 32)
with the ACC applied for 53min (SD 24). The minimal temperature on cooling




Table (4.3) Red cell volume loss and clear fluid administration until t = 24h.
RCV = red cell volume and ICU = intensive care unit. All data is presented as
mean (SD).
RCV Loss (ml) Theatre 450 (126)
ICU 205 (113)
Total 655 (161)
Fluid Administration Theatre (ml) Colloid 266 (383)
Crystalloid* 5470 (1178)
Total 5736 (1231)
Fluid Administration t = 0 - 24h (ml) Colloid 2111 (912)
Crystalloid* 6699 (1350)
Total 8810 (2262)
* This figure includes the 2250ml extra-corporeal circuit prime.
From t = 0 - ICURet mean RCV loss was 450ml (SD 126) with a further 205ml
(SD 113) lost from t = ICURet- 24h. There was no significant difference noted in
terms of RCV loss between the four surgeons taking part in the study. Clear fluid
administration from t = 0 - 24h was 2111ml (SD 912) for colloid and 6699ml (SD
1350)∗ for crystalloid (table 4.3). Over the same time period, 79% (n = 23/29)
of patients were transfused a mean of 2.4u (SD 1.1) of RBCs with a further 6.9%
(n = 2/29) receiving 5u (SD 1.4) of fresh frozen plasma (FFP) and 13.3% (n =
4/29) given 1.3u (SD 0.5) of platelets (table 4.4).
4.4.2 Factors Affecting Red Cell Loss
4.4.2.1 Time = 0 - 24h
The variables of; age (r = 0.29, PV al = 0.12), height (r = 0.19, PV al = 0.32),
weight (r = 0.08, PV al = 0.68), BSA (r = 0.1, PV al = 0.6), initial patient RCV
(r = 0.22, PV al = 0.25) and induction Hct (r = 0.27, PV al = 0.16) showed no
significant association with RCV loss. Similarly, no significant difference was
∗This figure includes the 2250ml extra-corporeal circuit prime.
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Table (4.4) Red cell transfusion data until t = 24h. RBC = red blood cell, FFP
= fresh frozen plasma, Plt = platelets. All data is presented as mean (SD).
Units Per Patient
% of Patients Overall Transfused
RBC 79.3 1.9 (1.4) 2.4 (1.1)
FFP 6.9 0.4 (1.3) 5 (1.4)
Plt 13.8 0.2 (0.5) 1.3 (0.5)
observed with gender (m = 697ml SD 177, f = 587ml SD 107, PV al = 0.24) nor
those taking anti-platelet agents within seven days of operation and those who
had not (y/n, 681ml SD 131, 647ml SD 172, PV al = 0.37) (table 4.5).
4.4.2.2 Time = ICURet - 24h
The variables of; age (r = 0.21, PV al = 0.28), height (r = 0.08, PV al = 0.69),
weight (r = 0.28, PV al = 0.14), BSA (r = 0.27, PV al = 0.16), initial patient RCV
(r = 0.1, PV al = 0.62), induction Hct (r = 0.13, PV al = 0.52), CPB time (r = 0.13,
PV al = 0.52), ACC time (r = 0.12, PV al = 0.54), minimum CPB temperature (r
= 0.28, PV al = 0.15), max re-warm temperature (r = 0.24, PV al = 0.21), theatre
RCV loss (r = 0.09, PV al = 0.63) and fluid administered in theatre (r = 0.27, PV al
= 0.15) showed no significant association with RCV loss. Again, no significant
difference was observed with gender (m = 217ml SD 100, f = 186ml SD 136, PV al
= 0.33) nor those taking anti-platelet agents within seven days of operation and
those who had not (y/n, 226ml SD 123, 199ml SD 113, PV al = 0.75) (table 4.6).
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Table (4.5) Correlation co-efficient (r) for study variables with RCV loss from
t = 0 - 24h. RCV = red cell volume, PV al = P value, BSA = body surface area
and Hct = haematocrit.
Variable Correlation Co-efficient (r) PV al
Age (y) 0.29 0.12
Height (m) 0.19 0.32
Weight (kg) 0.08 0.68
BSA (m2) 0.10 0.60
Initial RCV (ml) 0.22 0.25
Induction Hct (%) 0.27 0.16
Table (4.6) Correlation co-efficient (r) for study variables with RCV loss from
t = ICURet - 24h. RCV = red cell volume, PV al = P value, BSA = body surface
area, Hct = haematocrit, CPB = cardio-pulmonary bypass, ACC = aortic cross
clamp and Op = operative.
Variable Correlation Co-efficient (r) PV al
Age (y) 0.21 0.28
Height (m) 0.08 0.69
Weight (kg) 0.28 0.14
BSA (m2) 0.27 0.16
Initial RCV (ml) 0.10 0.62
Induction Hct (%) 0.13 0.52
CPB Time (min) 0.13 0.52
ACC Time (min) 0.12 0.54
Min Temp (0C) 0.28 0.15
Max Temp (0C) 0.24 0.21
Op RCV Loss (ml) 0.09 0.63
Op Fluid (ml) 0.27 0.15
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4.4.3 Factors Affecting Red Cell Gain
4.4.3.1 Time = 0 - 24h
The variables of; age (r = 0.46, PV al = 0.01), height (r = -0.51, PV al = 0.005),
weight (r = -0.59, PV al = 0.001), BSA (r = -0.6, PV al = 0.001) induction Hct
(r = -0.54, PV al = 0.003), initial RCV (r = -0.6, PV al = 0.001) and gender (m
= 1.4u SD 1.4, f = 2.6u SD 0.9, PV al = 0.03) were significantly associated with
RCV gain. No such association was found with anti-platelet therapy (y/n, 1.8u
SD 1.3, 2.1u SD 1.4, PV al = 0.24) (table 4.7).
4.4.3.2 Time = ICURet - 24h
The variables of; age (r = 0.40, PV al = 0.03), weight (r = -0.45, PV al = 0.02),
BSA (r = -0.43, PV al = 0.02), induction Hct (r = -0.37, PV al = 0.05), and initial
RCV (r = -0.42, PV al = 0.05) were significantly associated with RCV gain. No
such association was found with height (r = -0.24, PV al = 0.22), gender (m =
1.4u SD 0.7, f = 2.0u SD 0.8, PV al = 0.07), and anti-platelet therapy (y/n, 1.6u
SD 1.0, 1.6u SD 1.3, PV al = 0.32). The operative variables of; CPB time (r =
-0.04, PV al = 0.84), ACC (r = 0.06, PV al = 0.77), minimum temperature (r =
-0.31, PV al = 0.10) maximum temperature (r = 0.15, PV al = 0.45), theatre RCV
loss (r = 0.22, PV al = 0.26) and theatre fluid administration (r = 0.19, PV al =
0.33) showed no significant association with RCV gain for this time period (table
4.8).
4.4.4 Association Between Red Cell Loss and Gain
No association was found between RCV gain and total RCV loss(ml) at t = 24h
(r = 0.33, PV al = 0.08). When RCV loss was expressed as percentage reduction
in the initial estimated patient RCV a significant association with RCV gain was
identified (r = 0.48, PV al = 0.009).
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Table (4.7) Correlation co-efficient (r) for study variables with RCV Gain from
t = 0 - 24h. RCV = red cell volume, PV al = P value, BSA = body surface area
and Hct = haematocrit.
Variable Correlation Co-efficient (r) PV al
Age (y) 0.46 0.01
Height (m) -0.51 0.005
Weight (kg) -0.59 0.001
BSA (m2) -0.60 0.001
Initial RCV (ml) -0.60 0.001
Induction Hct (%) -0.54 0.003
Table (4.8) Correlation co-efficient (r) for study variables with RCV gain from
t = ICURet - 24h. RCV = red cell volume, ICU = intensive care unit, PV al = P
value, BSA = body surface area, Hct = haematocrit, CPB = cardio-pulmonary
bypass, ACC = aortic cross clamp and Op = operative.
Variable Correlation Co-efficient (r) PV al
Age (y) 0.40 0.03
Height (m) -0.24 0.22
Weight (kg) -0.45 0.02
BSA (m2) -0.43 0.02
Initial RCV (ml) -0.42 0.05
Induction Hct (%) -0.37 0.05
CPB Time (min) -0.04 0.84
ACC (min) 0.06 0.77
Min Temp (0C) -0.31 0.10
Max Temp (0C) 0.15 0.45
Op RCV Loss (ml) 0.22 0.26
Op Fluid (ml) 0.19 0.33
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4.5 Summary of Principle Findings
For both study time periods, no significant association with RCV loss was identi-
fied for the variables of; age, sex, height, weight,BSA, induction Hct, initial RCV,
anti-platelet therapy, CPB time, ACC time, minimum and maximum tempera-
ture, theatre RCV loss and theatre clear fluid administration. When considering
RCV gain, the pre-operative variables of; age, sex, height, weight, BSA, induc-
tion Hct, initial RCV were strongly correlated from t = 0 - 24h. This remained
the case for t = ICURet- 24h with the exception of height. Anti-platelet therapy
showed no significant association for either time period. Similarly, the operative
variables of; CPB time, ACC time, minimum and maximum temperature, theatre
RCV loss and theatre clear fluid administration showed no significant correlation
with RCV gain. Finally, it was found that RCV gain was associated with RCV
loss only when expressed as percentage reduction in initial patient RCV.
Please see section 12.2 (page - 154) for a full discussion of the above findings.
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Chapter 5
Peri-operative Red Cell, Plasma




As discussed in the previous chapter 4 (page - 53, pre-operative RCV may be
an important factor in determining a patients requirement for RBC transfusion.
Those patient’s with a small RCV prior to operation have a lesser reserve to
cope with RCV loss137;173;174. The next important consideration is to quantify
the degree of haemodilution, primarily due to the extra-corporeal circuit, that
patients undergo127;128;139. Currently, [Hb] is often the sole parameter considered
when deciding whether to administer RBCs. This variable may be artificially
depressed by the aforementioned fluid loading, triggering transfusion despite the
loss of little RCV129. Therefore, considering estimates of pre-operative RCV
and haemodilution, instead of or as well as [Hb], in the decision making process
may identify those requiring RBCs while reducing the incidence of potentially
unnecessary transfusion in others.
This study was designed to record peri-operative change in RCV as opposed
to [Hb] or Hct. Estimates were also made of PV and BV from patient Hct.
5.2 Aim
To determine the relative contributions of RCV loss and haemodilution to the
post-operative anemia encountered following cardiac surgery.
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5.3.1 Patients
Please see section 4.3.1 (page - 55)∗.
5.3.2 Patient Management
Please see section 4.3.2 (page - 56)∗.
5.3.3 Red Cell Transfusion
Please see section 4.3.3 (page - 56).
5.3.4 Calculation of Red Cell Volume Loss and Gain
Please see section 4.3.4 (page - 57)∗.
5.3.5 Calculation of Red Cell, Plasma and Blood Volume
change
To estimate changes in patient RCV, the volume of RBCs lost or gained was
added or subtracted from an equation derived initial volume for each study time
point as outlined in section 4.3.4 (page - 57). This study used the formula for RCV
calculation as recommended by the ICSH (equations A.2 and A.3)171. BSA was
determined as recommended by Gehan and George (equation A.1)170. Both PV
and BV were derived from the calculated RCV and the measured Hct (equations
A.5 and A.4). Study time points were; induction (defined for the reporting of
results as t = 0), incision, on-CPB, off-CPB, ICURet and 1,3,6,10,16 and 24h
following ICURet.
∗The patient cohort for this study was as for Chapter 4 (page - 53) with 1 additional patient.




All variables were presented as mean (SD). A Student’s t-test was used to deter-
mine the significance of any difference in each of the variables between two time
points. A PV al ≤ 0.05 was considered statistically significant. SPSS version 13
was used for all statistical analysis.
5.4 Results
5.4.1 Demographic and Peri-operative Data
Thirty-three adult elective cardiac surgery patients were recruited to the study
over a three month period. Three patients were subsequently excluded due to
surgical re-exploration for bleeding. Of the thirty patients with complete data,
23 underwent CABG, 3 a AVR, 2 a MVR, 1 a CABG and MVR and 1 a AVR
and MVR. The mean age was 63y (SD 13.0) with a BSA of 1.9m2 (SD 0.3)
and pre-operative Hct of 40.6% (SD 3.3). Eighteen of the patients were male,
twelve female. During operation the mean CPB time was 90min (SD 31) with
the ACC applied for 54min (SD 25). The minimal temperature on cooling was
31.70C (SD 1.6) with a max re-warm temperature of 37.20C (SD 0.3). Clear fluid
administration from t = 0 - 24h was 2111ml (SD 897) for colloid and 6699ml (SD
1326)∗ for crystalloid (table 5.1).
∗This figure includes the 2250ml extra-corporeal circuit prime.
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Table (5.1) Patient and operative characteristics. BSA = body surface area, Hct
= haematocrit, CABG = coronary artery bypass grafting, AVR = aortic valve
replacement, MVR = mitral valve repair/replacement, CPB = cardio-pulmonary
bypass and ACC = aortic cross clamp. All data is presented as mean (SD).
Patient Variables (n = 30) Age (y) 63 (13)
Gender (m/f) 18/12
BSA (m2) 1.9 (0.3)
Pre-operative Hct (%) 40.6 (3.3)
Operative Variables (n = 30) CABG 23
AVR 3
MVR 2
CABG + MVR 1
AVR + MVR 1
CPB Time (min) 90 (31)
ACC Time (min) 54 (25)
Min Temp (0C) 31.7 (1.6)
Max Temp (0C) 37.2 (0.3)
5.4.2 Red Cell Volume Lost and Gained
The volume remaining in the extra-corporeal circuit accounted for the greatest
RCV loss (391ml SD 115). It should be noted however, that a large proportion of
this ‘pump blood’ was re-infused (195ml SD 90)∗. Only 4 patients were transfused
RBCs from t = 0 - ICURet. For this time period, the net RCV balance was a loss
of 213ml (SD 206) (table 5.2). From t = ICURet- 24h the RCV lost gradually
decreased giving a total of 200ml SD 116. The RCV gained for this period was
in excess of this figure (274ml SD 200) giving a net gain for the period of 75ml
(SD 198) (table 5.3). There was no significant difference noted in terms of RCV
loss between the four surgeons taking part in the study.
∗The full extra-corporeal circuit volume was considered lost at t = off-CPB as although
RCV was re-infused it was not part of the patients circulating BV at this time point.
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Table (5.2) Theatre RCV loss and gain. RCV = red cell volume, Ind = in-
duction, Inc = incision, ICU = intensive care unit return and CPB = cardio-
pulmonary bypass. All data is presented as mean (SD).
RCV Ind-Inc Inc-CPB CPB CPB-ICURet Total
Loss (ml) 1 105 391 145 447
(1) (61) (115) (98) (125)
Gain (ml) 0 0 39 195 234
(105) (90) (133)
Net (ml) -1 -105 -351 50 -213
(1) (61) (163) (142) (206)
Table (5.3) ICU RCV loss and gain, ICU = intensive care unit and RCV = red
cell volume. All data is presented as mean (SD).
RCV ICURet-1h 1-3h 3-6h 6-10h 10-16h 16-24h Total
Loss (ml) 43 46 33 33 24 22 200
(45) (35) (34) (30) (19) (33) (116)
Gain (ml) 28 56 56 78 56 0 274
(78) (92) (92) (106) (92) (200)
Net (ml) -15 11 23 46 32 -22 75
(83) (102) (91) (113) (92) (33) (198)
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Figure (5.1) RCV and PV for linear study time. Time = 0h equates to induction
of anaesthesia while 4h is mean time for ICU return. Hashed lines indicate period
of CPB. RCV = red cell volume, PV = plasma volume, ICU = intensive care
unit and CPB = cardio-pulmonary bypass.
5.4.3 Red Cell Volume Over Time
Calculated RCV (baseline plus or minus gains and losses) fell steadily from t =
0 - off-CPB (1931ml SD 479, 1474ml SD 391, PV al = 0.63). At t = ICURet a rise
was noted due to the re-infusion of pump blood (1524ml SD 412, PV al = 0.63).
With RBC transfusion this trend continued until t = 16h (1620ml SD 334, PV al
= 0.32) (figure 5.1, tables 5.4 and 5.5). A comparison of change in patient RCV
as compared to Hct is given in figure 5.2.
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Figure (5.2) RCV and Hct for linear study time. Time = 0h equates to induction
of anaesthesia while 4h is mean time for ICU return. Hashed lines indicate period
of CPB. RCV = red cell volume, Hct = haematocrit, ICU = intensive care unit
and CPB = cardio-pulmonary bypass.
5.4.4 Plasma Volume Over Time
Calculated PV rose from t = 0 - incision following the induction of general anaes-
thesia (2790ml SD 516, 3136ml SD 587, PV al = 0.02). A further large increase
was noted from t = on-CPB- off-CPB (3089 SD 683, 4101ml SD 873, PV al <
0.001). Thereafter a gradual fall occurred until until t = 3h (3915ml SD 1000,
PV al = 0.45) followed by a steady rise peaking at t = 16h (4380ml SD 951, PV al
= 0.07). At t = 24h a fall was noted (4077ml SD 858, PV al = 0.2) (figure 5.1,
tables 5.4 and 5.5).
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Table (5.4) Theatre RCV, PV and BV change. RCV = red cell volume, PV =
plasma volume, BV = blood volume, Ind = induction, Inc = incision, CPB =
cardio-pulmonary bypass and ICU = intensive care unit. All data is presented as
mean (SD).
Ind Inc On-CPB Off-CPB ICURet
RCV (ml) 1939 1930 1825 1474 1524
(471) (478) (471) (391) (412)
PV (ml) 2790 3136 3089 4101 4114
(516) (587) (683) (873) (103)
BV (ml) 4721 5076 4914 5575 5638
(949) (1003) (1074) (1139) (1281)
5.4.5 Blood Volume Over Time
BV changes were similar to those for PV with a sharp rise noted from t = on-
CPB- off-CPB (4914ml SD 1074, 5575ml SD 1139, PV al = 0.02). Again, a fall
occurred until t = 3h (5434ml SD 1224, PV al = 0.65) with a subsequent rise noted
at t = 16h (6000ml SD 1238) (tables 5.4 and 5.5).
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Table (5.5) ICU RCV, PV and BV Change. ICU = intensive care unit, RCV
= red cell volume, PV = plasma volume and BV = blood volume. All data is
presented as mean (SD).
1h 3h 6h 10h 16h 24h
RCV (ml) 1508 1519 1542 1588 1620 1598
(401) (380) (369) (347) (334) (338)
PV (ml) 3944 3915 4186 4348 4380 4077
(992) (1000) (925) (803) (952) (858)
BV (ml) 5452 5434 5728 5936 6000 5675
(1229) (1224) (1217) (1102) (1238) (1132)
Table (5.6) Ratios of pre-operative values for RCV, adjusted RCV, PV and BV.
RCV = red cell volume, RCVAdj = RCV minus transfused RBCs, PV = plasma
volume, BV = blood volume and ICU = intensive care unit. All data is presented
as mean (SD).
Ind - ICURet ICURet - 24h
RCV 0.79 (0.99) 0.84 (0.10)
RCVAdj 0.76 (0.07) 0.65 (0.25)
PV 1.48 (0.25) 1.47 (0.18)
BV 1.20 (0.17) 1.21 (0.11)
5.4.6 Ratios of Pre-operative Predicted Values for Red
Cell, Plasma and Blood Volume at Closure and 24h
The ratios of the pre-operative predicted values for PV and BV showed marked
increases both from t = 0 - ICURet (1.48 SD 0.25, 1.20 SD 0.17) and t = 0 -
24h (1.47 SD 0.18, 1.21 SD 0.11). The difference between the RCV ratio and the
value adjusted to exclude transfused RBCs was minimal at ICURet (0.79 SD 0.99,
0.76 SD 0.07) but more marked at 24h (0.84 SD 0.10, 0.65 SD 0.25) (table 5.6).
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In terms of RCV loss, the maximal figure obtained was at t = off-CPB. The
vast majority of this lost was attributable to the residual RCV remaining in the
extra-corporeal circuit. Prior to t = ICURet, approximately half of this RCV was
returned to the patient in the form of pump blood. From t = ICURet- 24h the
trend was for a net gain of RCV due to the transfusion of RBCs. Both PV and
BV had similar trends with two distinct peaks at t = off-CPB and 16h following
ICURet. Overall, at t = 24h the percentage rise in PV was greater than the per-
centage loss of RCV.
Please see section 12.3 (page - 156) for a full discussion of the above findings.
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Chapter 6
Evaluation of Sodium Fluorescein
Flow Cytometry in the





As mentioned, the results gained in chapters 4 (page - 53) and 5 (page - 66)
require to be treated with some caution due to the mechanical nature of the
methodology used. In the past, direct measurement of RCV has relied upon the
use of radioactive isotope labelled RBCs using elements such as such as Cr51 175.
These techniques have the disadvantage that they require the use of ionising
radiation and cannot be used over a short period. A method has been proposed
whereby RCV may be measured by the use of autologous NaF labelled RBCs.
The advantages of this technique are that it is non-toxic and repeat testing may
be carried out after one hour148;176.
This study was designed to assess NaF flow cytometry as an accurate repro-
ducible method of measuring peri-operative RCV change. It was intended to
perform this initial evaluation by the use of pre-operative isovolaemic haemod-
ilution (PIHD) where a known volume of RCV is removed from the patient130.
Unfortunately, the RBC-NaF complex was not sufficiently stable to allow us to
proceed. Hence, only the techniques of NaF flow cytometry and PIHD will be
described here along with the initial evaluation of NaF flow cytometry.
6.2 Aim
To assess the accuracy of NaF flow cytometry in the measurement of changes in
RCV by PIHD.
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6.3.1 Red Cell Volume Measurement by Sodium Fluores-
cein Flow Cytometry
The following summarises a version of the technique initially described by Lauer-
mann et al for measuring RCV by NaF flow cytometry130;148;176;
Initially, 20ml of the patient’s blood is collected in a heparinised sy-
ringe. The sample is then be spun at 1000g for 10min to separate
out the RBC column. The RBCs obtained are incubated with 24mg
of sodium fluorescein for five minutes and then washed twice with
calcium containing solution. The RBCs are re-suspended to 20ml
with Ringer’s lactate solution. The resultant injectate is placed on
ice prior to re-injection. Samples for analysis are taken at 4, 6 and
8min in duplicate, following re-injection. Samples aspirated are anal-
ysed on a Coulter FACS analyser with the fluorescent RBC population
measured dependent upon light scattering characteristics.
The results obtained can be used to calculate RCV as outlined in appendix A.6
(page - 181).
6.3.2 Assessment of Sodium Fluorescein Flow Cytometry
PIHD is currently being used as a method of reducing allogenic RBC transfusion
in cardiac surgery patients115;142. With this method a given volume of whole blood
is withdrawn from the patient and replaced with an identical volume of plasma
protein solution. Should transfusion be required then the patients own previously
donated blood is re-infused. This technique was selected to evaluate NaF flow
cytometry as the RCV within the PIHD bag can be directly measured130.
NaF RCV estimation was to be performed prior to, and following PIHD with
the change in RCV calculated (∆RCV). This could then be compared with the
known RCV content in the PIHD bag returned to the patient (equation A.7).
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6.3.3 Statistical Analysis
When deciding upon sample size, it was considered that agreement between the
two measurements was an estimation problem rather than a hypothesis testing
issue. The planned study size of 30 patients was expected to result in a standard
error of approximately 16ml for the 95% limits of agreement between the RCV
removed during PIHD and change in RCV estimated using NaF, assuming a
standard deviation for the difference between the methods of 50ml. A two group
t-test was to be performed to determine the statistical significance of any observed
difference between the two measurements. If the assumptions of the two group
t-test were not met then non-parametric analysis would have been employed. A
PV al ≤ 0.05 would be considered statistically significant. SPSS version 13 was
used for all statistical analysis.
Table (6.1) Reduction in NaF stained RBCs over time. NaF = sodium fluores-
cein and RBC = red blood cell.
Positive RBCs (%)
Time (min) Run 1 Run 2 Run 3 Run 4 Mean
0 12 15 13 18 14.5
5 11 13 11 15 12.5
10 10 10 8 12 10.0
20 8 7 6 8 7.3
30 6 5 4 5 5.0
60 3 2 1 4 2.5




Prior to commencing the study, as outlined above, 4 coulter FACS analyser∗ runs
were performed for calibration purposes and to determine the stability of the
RBC fluorescence. Following preparation of the RBC-NaF injectate, 250µl of the
solution was added to 2.5ml of whole blood. Following thorough mixing, 10µl
of the new suspension was then added to 500µl of ringers lactate solution. The
result was an RBC sample containing approximately 15% fluorescent cells. Scans
were then performed at; 0 (defined for the reporting of results as t = 0), 5, 10,
20, 30, 60 and 120min.
Figure (6.1) Decay in NaF RBC’s. NaF = sodium fluorescein and RBC = red
blood cell.
∗FACS Calibur, Becton Dickinson, San Jose, USA.
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The results obtained indicated a rapid decay in the % of NaF positive RBCs
(table 6.1). From an initial value of 14.5% at t = 0, this had exactly halved
by t = 20min (7.3%). By the final time point at t = 120min, the fluorescent
cell population had fallen to a mere 1%, possibly due to enzymatic degradation
of the stained RBCs amine groups. An error bar plot of the exponential decay
in fluorescence is given in figure 6.1. This demonstrated a strong non-linear
association between % fluorescent RBCs and time (r = 0.93, PV al <0.001). In
terms of practical application, these findings negated the clinical application of
this process given the required timescales for injectate preparation and repeat
measurement. A single measurement comparison with an equation derived RCV
was not performed as it was felt this would not give the desired degree of accuracy
achievable with more stable RBC labels.
6.5 Summary of Principle Findings
Prior to the evaluation of NaF flow cytometry, by PIHD, 4 FACS Calibur runs
were performed with a 15% solution of NaF stained RBCs. By t = 20min, the
fluorescence had exactly halved to a mean of 7.3%. By t = 120min the corre-
sponding figure was 1%. The timescales involved prevented the clinical evaluation
of this technique as intended.
Please see section 12.4 (page - 158) for a full discussion of the above findings.
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Chapter 7
The Effect of Gain in Total Body
Water on Haemoglobin




As demonstrated in chapter 5 (page - 66), cardiac surgery is associated with a
heavy fluid load, primarily due to the pump priming solution and the admin-
istration of intravenous fluids38;127;139. This may depress [Hb]129;177. As most
guidelines for RBC transfusion are based upon [Hb], this effect of haemodilution
may result in RBCs being given despite the loss of little RCV.
Following cardiac surgery on CPB, patients are routinely prescribed a diuretic
preparation in order to facilitate the shedding of excess total body water (TBW).
A rise in [Hb] is routinely observed as excess TBW is lost. Therefore, consider-
ation of patient fluid status, as well as [Hb], may reduce the incidence of RBC
transfusion. Currently, fluid loss is monitored by recording daily patient body
weight. As patients following cardiac surgery are in a highly catabolic state, this
process may not be accurate178.
This study was designed to examine the paired associations between; TBW
(as measured by bio-electrical impedance analysis (BIA)), body weight and [Hb]
following cardiac surgery.
7.2 Aim
To determine whether [Hb] will recover as excess TBW is shed post-operatively
in association with a reduction in body weight.
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7.3.1 Patients
Ethical approval was gained from LREC. All adult (age ≥ 16y) elective cardiac
surgery patients presenting for operation between October and December 2004
were considered for recruitment. Exclusion criteria were; inability to provide
informed consent, pre-operative anaemia ([Hb] < 13g/dl for males and < 11g/dl
for females), RBC transfusion after 24h post-operatively, emergency surgery and
redo surgery. In addition, patients with a pre-operative condition (thyroid or
adrenal disease), or drug treatment (diuretics, steroids), interfering with total
body fluid distribution were also excluded.
7.3.2 Patient Management
Please see section 4.3.2 (page - 56).
7.3.3 Diuretic Administration
On the first post-operative day all patients were prescribed a diuretic preparation
according to routine practice (co-amilofruse (5mg Amiloride/40mg Frusemide)).
When TBW had returned to its pre-operative state, as indicated by BIA mea-
surements, this was discontinued.
7.3.4 Red Cell Transfusion
A transfusion threshold of 6g/dl was used during CPB, changing to 8g/dl for
all off-CPB time points∗. Where a patient received a RBC transfusion after 24h
post-operatively they were excluded.
∗This transfusion strategy was more restrictive than standard departmental policy in order
to ensure maximal study completion.
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Figure (7.1) Bodystat Dualscan Bio-electrical Impedance Analyser.
7.3.5 Study Variables
Study data was collected pre-operatively, one day prior to surgery (defined for
the reporting of results as t = 0) and at days 1, 3, 5 and 10 (t = 1 - 10d)
post-operatively. TBW was measured by the use of BIA as outlined below. Sam-
ples were also taken for [Hb], with body weight recorded on the same precision
balances.
7.3.6 Bio-electrical Impedance Analysis
The conductive properties of tissues were first described in 1871. The 1970’s saw
the development of BIA, which today is widely used as a method of assessing nu-
tritional status and body water volumes. Impedance describes the resistive force
to electrical currents created by both cell membranes (reactance) and body water
(resistance). Thus, the impedance of any tissue is determined by the tissue fluid
content. Fat free mass (FFM) is highly hydrated and therefore a good conductor
(low impedance), while poorly hydrated adipose tissue is a good insulator (high
impedance). When low frequency signals (<50KHz) are applied, the current
cannot penetrate the cell membrane and the impedance measured is limited to
the extra-cellular fluid (ECF) compartment. High frequency signals (>50KHz),
can traverse the cellular membrane and thus the impedance is generated by the
TBW38;127;179.
For the purposes of this study, the current injecting and current sensing elec-
trodes of the Bodystat analyser were placed on the wrist and ankle respectively
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(figure 7.1)∗. Measurements were taken of the length2/impedance index (L2/I
index) using high frequency signals (>50KHz). The L2/I index measured under
these conditions has been shown to be well correlated with TBW179;180.
7.3.7 Statistical Analysis
All variables were presented as mean (SD). For the purposes of the analysis,
all data was adjusted to reflect the percentage change from the baseline pre-
operative value (t = 0). Student’s t-test was used to determine the significance
of the difference in the percentage change from t = 0 between two study time
points. The percentage change in each of the variables was recorded from t = 0 -
1d, 1 - 3d, 1 - 5d, 1 - 10d and 5 - 10d. Pearson’s rank correlation was performed
to determine the paired associations between TBW and body weight, TBW and
[Hb] and finally body weight and [Hb]. A PV al ≤ 0.05 was considered statistically
significant. SPSS version 13 was used for all statistical analysis.
7.4 Results
7.4.1 Demographic and Peri-operative Data
Forty-two patients adult elective cardiac surgery patients were recruited to the
study over a three month period. Twelve patients were subsequently excluded
due to transfusion after 24h (n = 4) or missed follow-up appointments (n = 8).
Of the thirty patients with complete data, 22 underwent CABG, 4 a AVR, 2 a
CABG and AVR and 2 a atrial septal defect (ASD) repair. The mean age was
59.1y (SD 12.8) with a BSA of 2.1m2 (SD 0.2) and pre-operative [Hb] of 14.2g/dl
(SD 1.1). Twenty-five of the patients were male, five female. During operation
the mean CPB time was 157min (SD 52.8) with the ACC applied for 99min (SD
41.8). The minimal temperature on cooling was 29.10C (SD 2.3) with a max
re-warm temperature of 37.10C (SD 0.2) (table 7.1).
∗Bodystat Dualscan, Bodystat Ltd, Isle of Man, UK.
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Table (7.1) Patient and operative characteristics. BSA = body surface area, Hb
= haemoglobin, CABG = coronary artery bypass grafting, AVR = aortic valve
replacement, ASD = atrial septal defect, CPB = cardio-pulmonary bypass and
ACC = aortic cross clamp. All data is presented as mean (SD).
Patient Variables (n = 30) Age (y) 59.1 (12.8)
Gender (m/f) 25/5
BSA (m2) 2.1 (0.2)
Pre-operative Hb (g/dl) 14.2 (1.1)
Operative Variables (n = 30) CABG 22
AVR 4
CABG + AVR 2
ASD 2
CPB Time (min) 157 (52.8)
ACC Time (min) 99 (41.8)
Min Temp (0C) 29.1 (2.3)
Max Temp (0C) 37.1 (0.2)
Table (7.2) Peri-operative clear fluid and RBC transfusion. RBC = red blood
cell. All data is presented as mean (SD).
Intra-operative Crystalloid (ml) 2768 (1123)
Colloid (ml) 227 (410)
Total Clear Fluids (ml)* 2996 (1160)
Intensive Care Unit Crystalloid (ml) 1699 (681)
Colloid (ml) 1600 (669)
Total Clear Fluids (ml) 3299 (1119)
Patients Transfused RBC’s (%) 27 (n = 8/30)
Mean RBC’s per Patients Transfused (u) 2 (1.0)
* This figure includes the 2250ml extra-corporeal circuit prime.
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Table (7.3) Chest drain loss following operation. All data is presented as mean
(SD).
Time Period Chest Drain Loss (ml)
0-6h 243 (115)
6-12h 175 (175)
Total at Removal 747 (444)
A total of 2996ml (SD 1160)∗ of clear fluid (crystalloid and colloid) was admin-
istered during theatre management. The corresponding figure for the period of
ICU management until t = 1d was 3299ml (SD 1119). No patients were transfused
intra-operatively. During ICU management, 27% of patients were transfused a
mean of 2u of RBCs (table 7.2). The mean drain volume loss for the first 6h
following surgery was 243ml (SD 115). This fell to 175ml (SD 73) for the second
6h with a total at removal of 747ml (SD 444). The mean time until drain removal
was 20.4h (SD 7.1) (table 7.3).
7.4.2 Total Body Water, Body Weight and Haemoglobin
over Time
A sharp fall in TBW was noted between t = 1 - 3d (%∆12.1 SD 8.8, %∆6.5 SD
7.5, PV al < 0.001) with this being the overall trend from t = 1 - 10d (%∆12.1 SD
8.8, %∆1.0 SD 10.7, PV al < 0.001). At t = 10d, TBW approximated the baseline
pre-operative value (43.8l SD 9.0, 43.4l SD 7.8, PV al = 0.77). A similar pattern
was noted for body weight with a sharp fall between t = 1 - 3d (%∆4.7 SD 3.3,
%∆1.8 SD 2.5, PV al < 0.001) and a significant overall loss demonstrated from t
= 1 - 10d (%∆4.7 SD 3.3, %∆5.2 SD 3.8, PV al < 0.001). At t = 10d, the value
had fallen below that measured pre-operatively (87.3kg SD 14.5, 86.9kg SD 15)
although this was not significant (PV al = 0.31) (figures 7.2, 7.3 and table 7.4).
A steady recovery in [Hb] was from t = 1 - 10d (%∆-37.0 SD 6.4, %∆-27.6 SD
8.3, PV al < 0.001), the biggest rise occurring between t = 5 - 10d (%∆-32.2 SD
∗This figure includes the 2250ml extra-corporeal circuit prime.
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Figure (7.2) Percentage change in TBW and Hb. TBW = total body water and
Hb = haemoglobin concentration.
5.9, %∆-27.6 SD 8.3, PV al = 0.001). At t = 10d the value remained significantly
below that recorded pre-operatively (10.2g/dl SD 1.1, 14.2g/dl SD 1.2, PV al <
0.001) (figures 7.2, 7.3 and table 7.4).
7.4.3 The Association between Change in Total Body Wa-
ter, Body Weight and Haemoglobin Concentration
Strong association was identified between change in TBW & body weight at t =
0 - 1d (r = 0.51, PV al = 0.004). For the same period, no such association was
found between TBW & [Hb] (r = -0.21, PV al = 0.28) or body weight & [Hb] (r =
0.05, PV al = 0.79). At t = 1 - 5d, significant associations were identified between
TBW & body weight (r = 0.55, PV al = 0.002), TBW & [Hb] (r = -0.42, PV al =
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Figure (7.3) Percentage change in body weight and Hb. Hb = haemoglobin con-
centration.
0.02) and body weight & [Hb] (r = -0.37, PV al = 0.04). This was also the case
for TBW & body weight (r = 0.60, PV al < 0.001) and TBW & [Hb] (r = -0.36,
PV al = 0.048) at t = 1 - 3d, however the association between body weight & [Hb]
was non-significant for this time period (r = -0.33, PV al = 0.07) (table 7.5).
When considering t = 1 - 10d and t = 5 - 10d, TBW & body weight demon-
strated significant association for both periods (r = 0.43, PV al = 0.02 and r =
0.39, PV al = 0.04). Although there was significant association between TBW &
[Hb] at t = 1 - 10d (r = -0.55, PV al = 0.002), this was not found for the second
half of this time period at t = 5 - 10d (r = -0.14, PV al = 0.47). Between body
weight & [Hb] no association was found at t = 1 - 10d (r = -0.32, PV al = 0.09)
and t = 5 - 10d (r = -0.23, PV al = 0.23) (table 7.5).
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Table (7.4) TBW, body weight and Hb for study time points. TBW = total body
water, Hb = haemoglobin concentration and %∆ = percentage change from the
baseline pre-operative value. All data is presented as mean (SD).
TBW Body Weight Hb
l %∆ kg %∆ g/dl %∆
Pre-operative 43.4 87.3 14.2
(7.8) (14.5) (1.2)
Day 1 48.8 12.1 91.4 4.7 8.9 -37.0
(9.8) (8.8) (15.5) (3.3) (0.6) (6.4)
Day 3 46.3 6.5 88.9 1.8 9.2 -34.6
(8.9) (7.5) (14.7) (2.5) (0.8) (8.2)
Day 5 45.0 4.0 87.4 0.1 9.6 -32.2
(8.4) (9.6) (14.4) (2.8) (0.7) (5.9)
Day 10 43.8 1.0 86.9 -0.5 10.2 -27.6
(9.0) (10.7) (15.0) (2.6) (1.1) (8.3)
Table (7.5) Correlation co-efficient (r) for percentage change in study variables.
TBW = total body water, Wt = body weight, Hb = haemoglobin concentration
and PV al = P value.
TBW & Wt TBW & Hb Wt & Hb
R PV al R PV al R PV al
T = 0 - 1d 0.51 0.004 -0.21 0.28 0.05 0.79
T = 1 - 3d 0.60 <0.001 -0.36 0.05 -0.33 0.07
T = 1 - 5d 0.55 0.002 -0.42 0.02 -0.37 0.04
T = 1 - 10d 0.43 0.02 -0.55 0.002 -0.32 0.09
T = 5 - 10d 0.39 0.04 -0.14 0.47 -0.23 0.23
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7.5 Summary of Principle Findings
The findings of this study have demonstrated a sharp associated rise in TBW &
body weight between t = 0 - 1d. [Hb] fell for the same period, however this was
not associated with either variable. Following this time point (t = 1 - 10d), an
associated fall occurred between TBW & body weight. At t = 5d bodyweight
approximated its pre-operative value. This did not occur with TBW until t =
10d. [Hb] recovered in association with TBW until t = 5d. A similar association
was found with body weight and [Hb] for the same time period (t = 1 - 5d).









It has long been thought that patients undergoing cardiac surgery with the use
of CPB accrue an oxygen debt peri-operatively181;182. Most commonly, this is
believed to manifest itself as a post-operative metabolic acidosis181. One of the
key observations supporting the debt theory has been so called “pathological
supply dependency”where DO2 determines VO2 below a critical point (figure
1.7). Recently it has been recognised that this association is likely to represent
mathematical coupling as opposed to a true patho-physiological state92;93. It
has also been shown that the invariably encountered post-operative metabolic
acidosis may accumulate under conditions of aerobic metabolism99. For many
years, the oxygen debt theory has been used as a mainstay in the argument for
maintaining a higher peri-operative [Hb] by the transfusion RBCs25.
This study has been designed to use measurements of DO2 to determine if
patients approach an estimated DO2Crit at any point during their peri-operative
management.
8.2 Aim
To examine the relationship between actual measured oxygen delivery and the
corresponding estimated critical values peri-operatively.
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8.3.1 Patients
Ethical approval was gained from LREC. All adult (age ≥ 16y) elective cardiac
surgery patients presenting for operation between May and July 2005 were con-
sidered for recruitment. Exclusion criteria were; inability to provide informed
consent, renal insufficiency, diabetes mellitus, thyroid disease, severe hyperten-
sion, active endocarditis, heart failure and redo surgery.
8.3.2 Patient Management
Please see section 4.3.2 (page - 56).
8.3.3 Red Cell Transfusion
A transfusion threshold of 6g/dl was used during CPB, changing to 8g/dl for all
off-CPB time points.
8.3.4 Study Variables
This study was based upon measurements of DO2 at several time points peri-
operatively. Measured actual values were compared against estimated critical
values corrected for temperature (equations B.1 and B.3). The [Hb] reflecting
the estimated DO2Crit (critical haemoglobin concentration ([HbCrit]))(assuming
other parameters are constant) was also derived.
The following time points were identified for the collection of study data;
induction of anaesthesia (defined for the reporting of results as t = 0), 10min CPB,
30min CPB, 60min CPB, max re-warm, 5min post-protamine, ICURet, 1,5,10 and
18h post ICURet. At these intervals the following measurements/ samples were
taken; blood flow index (BFI)∗, arterial blood sample, mixed venous blood sample
∗The term BFI (blood flow/BSA) was chosen as it applies to both the CPB and cardiac
based circulation. It may be used interchangeably with CI (CO/BSA) for all non-CPB time
points
96
8.3 Materials and Methods
and core body temperature (nasal temperature probe). It should be noted that
BFI was constant during the period of CPB.
For all off-CPB time points, BFI was measured by the thermo-dilution tech-
nique using a Swann-Ganz catheter. During CPB, pump flow rate was divided
by BSA to give this value. Mixed venous blood was obtained from the distal port
of the Swann-Ganz catheter. Arterial blood was collected from the radial artery
catheter. All blood sample analysis was performed on a Rapidlab 855 analyser
(figure 4.1)∗.
When considering DO2Crit, perhaps the most rigorous study was performed
by Ronco et al on 9 non-septic, critically ill, intensive care patients. VO2, as
measured by indirect calorimetry, was plotted against DO2, as calculated by the
Fick method, QO2 and measurements of plasma lactate concentration (equations
B.5 and B.6). DO2Crit was found to occur at a value of 4.5ml/min/kg
97;183.
This, however, is not directly applicable to cardiac surgery patients who undergo
a degree of controlled hypothermia. A correction coefficient was thus used to
adjust the DO2Crit for temperature (equation B.4)
98.
To provide an estimate of the [Hb] that would reflect DO2Crit ([HbCrit]),
DO2Crit was substituted for actual DO2 (equations B.1 and B.3) and [HbCrit]
derived. In performing this calculation the assumption was made that all other
parameters would remain constant. As blood flow rate during CPB is relatively
fixed, this scenario is directly applicable. As it may be reasonably expected that
cardiac output would rise in response to such anaemia post-CPB, it is likely that
the value for [HbCrit] reflects the upper end of the critical range
184.
8.3.5 Statistical Analysis
All variables were presented as mean (SEM). A Mann-Whitney U test was used
to determine the significance of any difference between the actual and critical
values for both DO2 and [Hb]. Wilcoxon’s rank sum analysis was performed
to determine the significance of any difference for a single variable between two
study time points. A PV al ≤ 0.05 was considered statistically significant. SPSS
version 13 was used for all statistical analysis.
∗Bayer HealthCare, Leverkusen, Germany.
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Table (8.1) Patient and operative characteristics. BSA = body surface area,
CABG = coronary artery bypass grafting, AVR = aortic valve replacement, MVR
= mitral valve replacement, CPB = cardio-pulmonary bypass and ACC = aortic
cross clamp. All data is presented as mean (SEM) where appropriate.
Patient Variables (n = 15) Age (y) 66.9 (2.8)
Gender (m/f) 9/6
BSA (m2) 1.9 (0.1)
Operative Variables (n = 15) CABG 4
AVR 6
MVR 1
CABG + AVR 1
CABG + MVR 3
CPB Time (min) 113 (9.6)
ACC Time (min) 80 (7.6)
Min Temp (0C) 30.9 (0.1)
Max Temp (0C) 37.0 (0.5)
8.4 Results
8.4.1 Demographic and Peri-operative Data
Nineteen adult elective cardiac surgery patients were recruited to the study over
a three month period. Four patients were subsequently excluded due to due to
incomplete data recording. Of the fifteen patients with complete data, 4 under-
went CABG, 6 a AVR, 1 a MVR, 1 a CABG and AVR and 3 a CABG and MVR.
The mean age was 66.9y (SEM 2.8)with a BSA of 1.9m2 (SEM 0.1). Nine of
the patients were male, six female. During operation the mean CPB time was
113min (SEM 9.6) with the ACC applied for 80min (SEM 7.6). The minimal
temperature on cooling was 30.10C (SEM 0.1) with a max re-warm temperature
of 37.00C (SEM 0.5) (table 8.1).
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Table (8.2) Core body temperature and BFI. BFI = blood flow index, CPB =
cardio-pulmonary bypass and ICU = intensive care unit. All data is presented as
mean (SEM).
Study Time Point Core Temperature (0C) BFI (l/min/m2)
Induction 35.8 (0.2) 2.2 (0.13)
10min CPB 32.2 (0.6) 2.4 (0.05)
30min CPB 31.5 (0.4) 2.4 (0.04)
60min CPB 30.1 (0.8) 2.2 (0.63)
Max Re-warm 37.0 (0.1) 2.3 (0.36)
Post-protamine 36.0 (0.1) 2.7 (0.12)
ICURet 35.7 (0.1) 2.6 (0.14)
1h ICU 35.8 (0.2) 2.4(0.15)
5h ICU 37.1 (0.3) 2.9 (0.16)
10h ICU 37.8 (0.2) 3.1 (0.13)
18h ICU 37.3 (0.2) 3.2 (0.10)
8.4.2 Core Body Temperature and Blood Flow Index
From t = 0 - 10min CPB, systemic cooling significantly lowered core body tem-
perature (35.80C SEM 0.2, 32.20C SEM 0.6, PV al = 0.001). This was reversed
from t = 60min CPB- max re-warm (30.10C SEM 0.8, 37.00C SEM 0.1, PV al =
0.005), prior to a fall noted at t = ICURet (35.7
0C SEM 0.1, PV al = 0.001). The
highest core body temperature occurred at t = 10h ICU, having rising steadily
from t = ICURet (37.8
0C SEM 0.2, PV al = 0.001) (table 8.2).
BFI did not change significantly from t = 0 - 10min CPB (2.2l/min/m2 SEM
0.14, 2.4l/min/m2 SEM 0.05, PV al = 0.268). Only two significant changes did
occur. The first between t = max re-warm - post-protamine, corresponding with
the discontinuation of CPB (2.3l/min/m2 SEM 0.36, 2.7l/min/m2 SEM 0.12, PV al
= 0.03). A second steady rise occurred between t = 1h - 10h ICU (2.4l/min/m2
SEM 0.15, 3.2l/min/m2 SEM 0.10, PV al = 0.001) (table 8.2, figure 8.2).
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Table (8.3) Observed and critical values for DO2. DO2 = oxygen delivery, PV al
= P value, CPB = cardio-pulmonary bypass and ICU = intensive care unit. All
data is presented as mean (SEM).
Study Time Point DO2 (ml/min/m
2) DO2Crit (ml/min/m
2) PV al
Induction 388 (27) 165 (4.9) <0.001
10min CPB 271 (12) 116 (5.1) <0.001
30min CPB 276 (13) 111 (4.3) <0.001
60min CPB 325 (16) 117 (9.2) <0.001
Max Re-warm 269 (15) 181 (5.6) <0.001
Post-protamine 333 (19) 167 (3.6) <0.001
ICURet 340 (24) 164 (4.6) <0.001
1h ICU 321 (19) 165 (5.1) <0.001
5h ICU 338 (23) 185 (7.6) <0.001
10h ICU 377 (17) 196 (7.2) <0.001
18h ICU 386 (14) 188 (6.8) <0.001
8.4.3 Oxygen Delivery and Consumption
When considering observed DO2, a marked fall occurred between t = 0 - 10min
CPB corresponding with the start of CPB and systemic haemodilution (388ml/min/m2
SEM 27, 271ml/min/m2 SEM 12, PV al = 0.001). Thereafter, no significant change
was noted in DO2 until t = max re-warm - post-protamine where the heart re-
sumed circulatory responsibility (269ml/min/m2 SEM 15, 333ml/min/m2 SEM
19, PV al = 0.008). From t = ICURet- 1h ICU a short fall occurred (340ml/min/m
2
SEM 24, 321ml/min/m2 SEM 19, PV al = 0.16) prior to a linear rise up until the
final time point at t = 18h ICU (386ml/min/m2 SEM 14, PV al = 0.002) (figures
8.1, 8.2 and table 8.3).
As DO2Crit was determined by temperature (equation B.4), peri-operative
change mirrored that for core body temperature as described previously (section
8.4.2). At no study time point did observed DO2 significantly approach DO2Crit
(PV al < 0.001 at all times) (figure 8.1 and table 8.3).
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Figure (8.1) Observed and critical DO2 for linear study time. Time = 0h equates
to induction of anaesthesia while 4h is mean time for ICU return. Hashed lines




Figure (8.2) Observed DO2 and core body temperature for linear study time.
Time = 0h equates to induction of anaesthesia while 4h is mean time for ICU




Table (8.4) Peri-operative VO2. VO2 = oxygen consumption, CPB = cardio-
pulmonary bypass and ICU = intensive care unit. All data is presented as mean
(SEM).
Study Time Point VO2 Study Time Point VO2
(ml/min/m2) (ml/min/m2)
Induction 89 (6.6) ICURet 106 (4.8)
10min CPB 40 (3.9) 1h ICU 110 (4.0)
30min CPB 35 (4.3) 5h ICU 122 (7.3)
60min CPB 37 (3.1) 10h ICU 140 (7.4)
Max Re-warm 68 (4.2) 18h ICU 145 (7.7)
Post Protamine 86 (6.8)
Table (8.5) Observed and critical values for Hb. Hb = haemoglobin concentra-
tion, PV al = P value, CPB = cardio-pulmonary bypass and ICU = intensive care
unit. All data is presented as mean (SEM).
Study Time Point Hb (g/dl) HbCrit (g/dl) PV al
Induction 12.9 (0.5) 5.8 (0.4) <0.001
10min CPB 8.4 (0.4) 3.6 (0.2) <0.001
30min CPB 8.6 (0.4) 3.5 (0.1) <0.001
60min CPB 8.6 (0.5) 3.9 (0.2) <0.001
Max Re-warm 8.6 (0.5) 5.8 (0.3) <0.001
Post Protamine 9.2 (0.4) 4.7 (0.2) <0.001
ICURet 9.6 (0.5) 4.8 (0.3) <0.001
1h ICU 10.2 (0.5) 5.4 (0.4) <0.001
5h ICU 8.7 (0.5) 5.0 (0.3) <0.001
10h ICU 9.1 (0.4) 4.8 (0.2) <0.001
18h ICU 9.0 (0.3) 4.4 (0.2) <0.001
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Changes in VO2 were similar to that for DO2 with one exception. Again a fall
occurred between t = 0 - 10min CPB (89ml/min/m2 SEM 6.6, 40ml/min/m2 SEM
3.9, PV al = 0.001), thereafter remaining relatively constant during the period of
CPB. As opposed to DO2 however, VO2 began its rise following the initiation
of re-warming from t = 60min CPB- max re-warm (37ml/min/m2 SEM 3.1 -
68ml/min/m2 SEM 4.2, PV al = 0.009). A further increase was noted from t =
1h - 18h ICU (110ml/min/m2 SEM 4.0, 145ml/min/m2 SEM 7.7, PV al = 0.03)
before leveling off (table 8.4).
8.4.4 Observed and Critical Haemoglobin Concentration
Between t = 0 - 10min CPB, actual [Hb] fell sharply, coinciding with the dilu-
tional effect of commencing CPB (12.9g/dl SEM 0.5, 8.4g/dl SEM 0.4, PV al =
0.001)38;127;129;139;177. Little variation in [Hb] was noted during CPB. Thereafter,
a steady rise occurred from t = post-protamine - 1h ICU (9.2g/dl SEM 0.4 to
10.2g/dl SEM 0.5, PV al = 0.021) followed by a significant fall to t = 5h ICU
(8.7g/dl SEM 0.5, p = 0.004). After t = 5h ICU [Hb] remained relatively stable
(table 8.5).
[HbCrit] similarly fell between t = 0 - 10min CPB (5.8g/dl SEM 0.4, 3.6g/dl
SEM 0.2, PV al = 0.001), again remaining relatively constant during CPB. With
rise in core temperature and VO2 between t = 60min CPB- max re-warm, [HbCrit]
also rose (3.9g/dl SEM 0.2, 5.8g/dl SEM 0.3, PV al = 0.007). It was at this point
[HbCrit] reached its closest approximation to observed [Hb]. Post-operatively,
[HbCrit] fell steadily between t = 1 - 18h ICU (5.4g/dl SEM 0.4, 4.4g/dl SEM
0.2, PV al = 0.014). At no study time point did actual [Hb] significantly approach
[HbCrit] (PV al < 0.001 at all times) (table 8.5).
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Following the initiation of CPB the variables of; core body temperature, DO2,
DO2Crit, VO2, [Hb] and [HbCrit] all underwent a significant fall to a plateau and
rose with re-warming. BFI underwent little change during the transition from
cardiac to CPB based circulation. DO2 and [Hb] reached their closest approxi-
mation with the corresponding critical values at t = max re-warm. The cessation
of CPB, with restoration of the cardiac based circulation, brought about a rise
in BFI. During the post-operative period, core body temperature, BFI, DO2,
DO2Crit and [Hb] all fell initially followed by a linear rise towards the final study
time point at t = 18h ICU. [HbCrit] fell steadily post-operatively from t = 1 - 18h
ICU accompanied by a rise in VO2. At all time points a statistically significant
difference existed between observed DO2, observed [Hb] and their corresponding
critical values.
Please see section 8.5 (page - 105) for a full discussion of the above findings.
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Chapter 9
The Impact of a Red Cell
Volume Based Transfusion





As mentioned in chapters 4 (page - 53),5 (page - 66) and 7 (page - 83), cardiac
surgery, using CPB, is associated with profound haemodilution38;127;129;139;177.
Use of [Hb] as a ‘trigger’ for RBC transfusion means that RBCs may be trans-
fused despite the loss of little RCV129;177. The ultimate ambition in peri-operative
transfusion medicine would be a simple reproducible test to accurately measure
and replace RCV where required. Unfortunately, as mentioned in chapter 6 (page
- 77), this is not possible with our current level of knowledge148;176. Thus, any
attempt to base RBC transfusion on RCV can only be performed by an approxi-
mation derived from the patient and operative characteristics described previously
(chapter 4, page - 53).
This study was designed to analyse the impact of a simple RCV based trans-
fusion algorithm, derived from the aforementioned variables, on blood usage and
clinical outcome.
9.2 Aim
To determine if RBC transfusion based upon an estimate of patient RCV confers
benefit in terms of a reduction in blood usage and improved clinical outcome.
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9.4 Patients
Ethical approval was gained from LREC. All adult (age ≥ 16y) elective cardiac
surgery patients presenting for operation between June 2005 and May 2006 were
considered for recruitment. Pre-operative exclusion criteria were; the inability
to provide informed consent, emergency surgery, redo surgery, active endocardi-
tis and poor left ventricular function (ejection fraction < 30%). Any patient
sustaining an intra-operative MI was also excluded.
9.4.1 Patient Management
Please see section 4.3.2 (page - 4.3.2).
9.4.2 Red Cell Transfusion
Prior to surgery patients were randomised (non-blinded) to either the intervention
group (red cell volume guideline transfusion group (RCVGrp)) or control group
(haemoglobin threshold transfusion group (HbGrp))
∗. The former were transfused
based both upon [Hb] and an estimate of RCV derived from body weight while
HbGrp received blood products as per standard unit [Hb] based protocol (tables
4.1, 9.2 and 9.1). It should be noted that the algorithm provided for RCVGrp was
only used for the first 48h post-operatively as this corresponds with the phase
of maximum haemodilution177;185. Standard unit protocol was applied for the
period of operative management while clinical symptomatology and consultant
preference determined whether patients were transfused RBCs after 48h post-
operatively (table 4.1).
∗Randomisation was carried out by randomly generated list (www.randomization.com)
with order of recruitment determining the group allocated.
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Table (9.1) Intervention group RBC transfusion protocol for males. RBC = red
blood cell and Hb = haemoglobin concentration.




Table (9.2) Intervention group RBC transfusion protocol for females. RBC =
red blood cell and Hb = haemoglobin concentration.




9.4.3 The Derivation of an Red Cell Volume Based Trans-
fusion Guideline
As gender and weight were identified as major determinants of RCV in chapter 4
(page - 53), our previous data obtained in chapter 5 (page - 66) was divided into
male and female categories with three further weight based sub-divisions171;173;177.
The mean pre-operative RCV for each weight based subdivision, calculated as rec-
ommended by the ICSH, was multiplied by a threshold ratio allowing a theoretical
RCV transfusion threshold to be calculated171. Finally, a dilution factor for both
males and females, again from our previous work, was applied to give relevance to
post-operative [Hb] (tables 9.2 and 9.1)177. Further details of how this algorithm
was calculated can be found in appendix C (page - 185).
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Although restrictive transfusion protocols have demonstrated the safety of
[Hb] transfusion thresholds as low as 8g/dl in cardiac surgery patients, the pro-
tocol included several exclusion criteria to minimise risk114;
• Drain losses greater than 500ml in the first post-operative hour∗.
• Continuing losses greater than 250ml an hour for subsequent hours.
• Persistent or worsening metabolic acidosis (H+ ≥ 55 with standard base
excess (SBE) ≥ - 6).
• Mean arterial pressure consistently ≤ 60mmHg
• ECG ST segment change suggestive of myocardial ischaemia.
An example of the algorithm provided for RCVGrp (male 78-97kg) is given in
figure 9.1.
9.4.4 Study Variables
9.4.4.1 Red Cell Transfusion
RBC transfusion was recorded in terms of; % patients transfused, average number
of units per patient transfused (UPPT) and average number of units per patient
operated (UPPO). Data was collected for both the initial 48h post-operatively,
as governed by the RCV guideline in RCVGrp, and total hospital stay.
9.4.4.2 Clinical Outcomes
The following variables were recorded to assess clinical patient outcome; inotrope
requirement, ventilation time, cardiac arrythmia including atrial fibrillation, my-
ocardial infarction (troponin≥0.5 ng/ml), cerebro-vascular accident (CVA), chest
infection and/or wound infection as confirmed by positive culture, discharge [Hb],
maximum creatinine, ICU stay and overall length of hospital stay.
∗As per unit policy to allow for the drainage of thoracic washout.
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Figure (9.1) Example study algorithm.
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9.4.4.3 Quality of life
In order to provide a baseline and post-operative assessment (at 3 months) of pa-
tient quality of life (QOL) the Euro QOL EQ-5D questionnaire was selected. The
EQ-5D descriptive system consists of 5 dimensions of health (mobility, self-care,
usual activities, pain/discomfort, anxiety/depression). Each dimension comprises
three levels (no problems, some/moderate problems/extreme problems). An EQ-
5D health state is defined by combining 1 level from each of the 5 dimensions. A
further section (EQ-VAS) records patients self rated health status on a graduated
(0-100) visual analogue scale186;187.
9.4.5 Statistical Analysis
It was calculated from our previous research that a sample size of 86 patients
would have 80% power to detect a difference of 0.7u in UPPO for the initial
48h post-operatively177. All variables were presented as mean (SD) unless non-
normally distributed in which case median (SEM) is given. All linear outcome
variables in the two groups were compared using the two group t-test. If the
assumptions of the two group t-test were not met for any of these variables then
logarithmic transformations or non-parametric tests were used as appropriate.
Binary outcome variables were compared using Pearson’s Chi Square test. A




Table (9.3) Patient characteristics and lung function. RCV = red cell volume,
Hb = haemoglobin concentration, PV al = P value and BSA = body surface area.
All data is presented as mean (SD) unless otherwise indicated.
RCVGrp HbGrp PV al
(n = 43) (n = 43)
Patient Variables
Age (y) 64.6 (10.6) 65.5 (10.0) 0.69
Gender (m/f) 31/12 29/14 0.64
Height (m) 167 (7.5) 168 (10.2) 0.42
Weight (kg) 78.4 (13.8) 83.3 (15.3) 0.12
BSA (m2) 1.92 (0.19) 1.99 (0.23) 0.13
RCV (ml)* 1945 (50) 2183 (62) 0.14
Anti-platelet <7d (y/n) 19/24 22/21 0.52
Pre-op Creatinine (µmol/l) 99.5 (17.6) 98.4 (18.5) 0.77
Parsonnet Score 10.1 (7.3) 11.3 (6.9) 0.45
Euro Score 3.8 (2.7) 4.4 (2.5) 0.36
Lung Function
Smoking Status (Current/Ex/Non) 5/27/11 7/20/16 0.32
FEV1 (L/s) 2.6 (0.8) 2.6 (0.8) 0.80
FEV1 % Predicted 96.8 (17.8) 93.4 (15.8) 0.40
FVC (L) 3.4 (0.9) 3.3 (1.0) 0.61
FVC % Predicted 100.1 (12.4) 96.3 (13.6) 0.13
* As the assumptions of the two group t-test were not met for this




Table (9.4) Pre-operative haematology. RCV = red cell volume, Hb =
haemoglobin concentration, PV al = P value, Hct = haematocrit, PTr = pro-
thrombin time ratio, APTTr = activated partial thromboplastin time ratio and
Plt = platelet count. All data is presented as mean (SD).
RCVGrp HbGrp PV al
(n = 43) (n = 43)
Hb (g/dl) 13.6 (1.5) 13.7 (1.5) 0.75
Hct (%) 40.5 (4.0) 40.7 (3.8) 0.77
PTr 0.7 (0.1) 0.7 (0.1) 0.58
APTTr 0.9 (0.1) 0.9 (0.1) 0.91
Plt (x103/ml) 230 (68) 240 (61) 0.47
Fibrinogen (mg/dl) 3.2 (0.7) 3.3 (0.5) 0.25
9.5 Results
9.5.1 Demographic and Peri-operative Data
Ninety-seven adult elective cardiac surgery patients were recruited to the study
over an eleven month period. Overall, eleven patients were subsequently excluded.
Of these, in RCVGrp four were subject to protocol error, two bled excessively (as
defined in section 9.4.3), and one patient sustained an operative MI. Similarly, in
HbGrp two protocol errors were observed with excessive blood loss in one patient
and one operative MI.
Of the eighty-six patients completing the study, 46 underwent CABG (RCVGrp
= 27, HbGrp = 19), 20 a AVR (RCVGrp = 9, HbGrp = 11), 1 a MVR (RCVGrp =
1), 2 a AVR and MVR (HbGrp = 2), 15 a CABG and AVR (RCVGrp = 5, HbGrp =
10) and 2 a CABG and MVR (RCVGrp = 1, HbGrp = 1). No significant difference
was observed between the groups for operation performed (PV al = 0.28) or the
surgeon performing the operation (PV al = 0.07).
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Table (9.5) Operative characteristics. RCV = red cell volume, Hb = haemoglobin
concentration, PV al = P value, CPB = cardio-pulmonary bypass and ACC =
aortic cross clamp. All data is presented as mean (SD) unless otherwise indicated.
RCVGrp HbGrp PV al
(n = 43) (n = 43)
Heparin (IU/kg) 471 (90) 483 (82) 0.53
Protamine (mg/kg) 3.0 (0.8) 3.0 (1.3) 0.93
CPB Time (min) 107 (57) 108 (34) 0.88
ACC Time (min) 69 (35) 70 (27) 0.93
Min Temp (0C) 31.2 (1.7) 31.2 (1.9) 0.93
Max Temp (0C) 36.4 (0.8) 36.4 (0.6) 0.73
Dilution Factor* 0.04 (0.03) 0.02 (0.02) 0.57
Aprotinin (y/n) 32/11 26/17 0.17
* As the assumptions of the two group t-test were
not met for this variable non-parametric analysis
was used with data presented as median (SEM).
Pre-operative patient characteristics were comparable for both groups in terms
of; age (RCVGrp = 64.6y SD 10.6, HbGrp = 65.5y SD 10.0, PV al = 0.69), gender
(m/f, RCVGrp = 31/12, HbGrp =29/14, PV al = 0.64), BSA (RCVGrp = 1.92m
2
SD 0.19, HbGrp = 1.99m
2 SD 0.23, PV al = 0.13), RCV
∗ (median, RCVGrp =
1945ml SEM 50, HbGrp = 2183ml SEM 62, PV al = 0.14), anti-platelet therapy
within 7 days of operation (y/n, RCVGrp = 19/24, HbGrp = 22/21, PV al = 0.52),
creatinine (RCVGrp = 99.5µmol/l SD 17.6, HbGrp = 98.4µmol/l SD 18.5, PV al =
0.77) and Euro score (RCVGrp = 3.8 SD 2.7, HbGrp = 4.4 SD 2.5, PV al = 0.36).
A full summary of all the pre-operative patient characteristics examined is given
in table 9.3.
As ventilation time/chest infection were recorded outcome measures, smoking
status and pulmonary function tests were documented for all patients. Again
these were comparable pre-operatively between the two groups (table 9.3).
∗Calculated as recommended by the ICSH171
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No significant difference was noted pre-operatively for the haematological vari-
ables of; [Hb] (RCVGrp = 13.6g/dl SD 1.5, HbGrp = 13.7g/dl SD 1.5, PV al =
0.75), Hct (RCVGrp = 40.5% SD 4.0, HbGrp = 40.7% SD 3.8, PV al = 0.77), pro-
thrombin time ratio (PTr) (RCVGrp = 0.7 SD 0.1, HbGrp = 0.7 SD 0.1, PV al =
0.58), activated partial thromboplastin time ratio (APTTr) (RCVGrp = 0.9 SD
0.1, HbGrp = 0.9 SD 0.1, PV al = 0.91), Plt (RCVGrp = 230x10
3/ml SD 68, HbGrp
= 240x103/ml SD 61, PV al = 0.47) and fibrinogen (RCVGrp = 3.2mg/dl SD 0.7,
HbGrp = 3.3mg/dl SD 0.5, PV al = 0.25) (table 9.4)
Similarly, operative data was comparable for; heparin dose (RCVGrp = 471IU/kg
SD 90, HbGrp = 483IU/kg SD 82, PV al = 0.53), protamine dose (RCVGrp =
3.0mg/kg SD 0.8, HbGrp = 3.0mg/kg SD 1.3, PV al = 0.93), CPB time (RCVGrp
= 107min SD 57, HbGrp = 108min SD 34, PV al = 0.88), ACC time (RCVGrp =
69min SD 35, HbGrp = 70min SD 27, PV al = 0.93), minimum CPB temperature
(RCVGrp = 31.2
0C SD 1.7, HbGrp = 31.2
0C SD 1.9, PV al = 0.93), max re-warm
temperature (RCVGrp = 36.4
0C SD 0.8, HbGrp = 36.4
0C SD 0.6, PV al = 0.73),
dilution factor (CPB clear fluid volume/BV) (median, RCVGrp = 0.04 SD 0.03,
HbGrp = 0.02 SD 0.02, PV al = 0.57) and Aprotinin administration (y/n, RCVGrp
= 32/11, HbGrp = 26/17, PV al = 0.17) (table 9.5). Post-operative drain loss was
also comparable between the two groups (RCVGrp = 897ml SD 542, HbGrp =
881ml SD 446, PV al = 0.89).
9.5.2 Red Cell Transfusion
Overall, a significantly smaller percentage of RCVGrp patients were transfused
(RCVGrp = 32.6%, HbGrp = 53.5%, PV al = 0.05). For the first 48h following
ICURet, RCVGrp were transfused fewer RBCs in terms of UPPO (RCVGrp =
0.42u, HbGrp = 0.81, PV al = 0.04) but not UPPT (RCVGrp = 1.29u, HbGrp = 1.59,
PV al = 0.17). Similar findings were noted for total RBCs transfused with UPPO
(RCVGrp = 0.60u, HbGrp = 1.19, PV al = 0.03) and UPPT (RCVGrp = 1.86u,
HbGrp = 2.22, PV al = 0.38). Insufficient numbers of other blood components




For both groups, several of the outcome measures occurred to infrequently to
allow meaningful analysis. In RCVGrp, 1 patient developed a deep wound in-
fection. In HbGrp, 1 patient developed a deep wound infection, 2 required renal
replacement therapy and 1 suffered a CVA. No patients died or met any of the
post-operative exclusion criteria with the exception of drain loss.
Of those examined statistically, total hospital stay was greater in HbGrp (me-
dian, RCVGrp = 5.9d SEM 0.8, HbGrp = 6.8d SEM 2.2, PV al = 0.02) while RCVGrp
had a higher inotrope requirement (RCVGrp = 25, HbGrp = 15, PV al = 0.03). No
significant difference was identified for the remaining variables of; ventilation time
(median, RCVGrp = 15.3h SEM 1.9, HbGrp = 12.7h SEM 6.3, PV al = 0.14), ICU
stay (median, RCVGrp = 1.0d SEM 0.1, HbGrp = 1.0d SEM 0.4, PV al = 0.67), dis-
charge [Hb] (RCVGrp = 10.2g/dl SD 1.0, HbGrp = 10.2g/dl SD 1.1, PV al = 0.90),
maximum creatinine (RCVGrp = 103µmol/l SD 24, 116µmol/l SD 38, PV al =
0.07), arrythmia (RCVGrp = 10, HbGrp = 11, PV al = 0.80), pneumonia (RCVGrp
= 12, HbGrp = 11, PV al = 0.81) and superficial wound infection (RCVGrp = 2,
HbGrp = 3, PV al = 0.65) (table 9.6).
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Table (9.6) Outcome measures. RCV = red cell volume, Hb = haemoglobin
concentration, PV al = P value, ICU = intensive care unit and HDU = high
dependency unit. All data is presented as mean (SD) unless otherwise indicated.
RCVGrp HbGrp PV al
(n = 43) (n = 43)
Ventilation Time (h)* 15.3 (1.9) 12.7 (6.3) 0.14
ICU Stay (d) * 1.0 (0.1) 1.0 (0.4) 0.67
Hospital Stay (d) * 5.9 (0.8) 6.8 (2.2) 0.02
Discharge Hb (g/dl) 10.2 (1.0) 10.2 (1.1) 0.90
Max Creatinine (µmol/l) 103 (24) 116 (38) 0.07
Inotropes (n) 25 15 0.03
Arrythmia (n) 10 11 0.80
Pneumonia (n) 12 11 0.81
Superficial Wound Infection (n) 2 3 0.65
* As the assumptions of the two group t-test were not met for
this variable non-parametric analysis was used with data
presented as median (SEM).
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9.5.4 Quality of Life
As discussed in section 9.4.4.3, QOL was assessed both pre-operatively and at 3
months following surgery. Pre-operatively, of the EQ-5D descriptive parameters
no significant difference was noted in terms of % patients with any problems for;
mobility (RCVGrp = 44.2%, HbGrp = 62.8%, PV al = 0.08), self care (RCVGrp =
4.7%, HbGrp = 11.6%, PV al = 0.24), usual activity (RCVGrp = 55.8%, HbGrp =
67.4%, PV al = 0.27), pain (RCVGrp = 60.5%, HbGrp = 53.5%, PV al = 0.51) and
anxiety (RCVGrp = 32.6%, HbGrp = 41.9%, PV al = 0.37). Similarly, the EQ-VAS
measured health assessment score (0-100) was found to be comparable between
the two groups (RCVGrp = 61.2 SD 17.6, HbGrp = 60.4 SD 14.3, PV al = 0.83).
In RCVGrp, thirty-nine patients (n = 39/43) returned completed question-
naires while the corresponding figure in HbGrp was thirty-six (n = 36/43). Of
the EQ-5D questions studied at 3 months, no significant difference was noted in
terms of % patients with any problems for; mobility (RCVGrp = 30.7%, HbGrp =
22.2%, PV al = 0.44), self care (RCVGrp = 7.7%, HbGrp = 11.1%, PV al = 0.55),
usual activity (RCVGrp = 53.8%, HbGrp = 44.4%, PV al = 0.45), pain (RCVGrp
= 53.9%, HbGrp = 63.9%, PV al = 0.42) and anxiety (RCVGrp = 28.2%, HbGrp =
27.7%, PV al = 0.6). Similarly, the EQ-VAS measured health assessment score (0-
100) was found to be comparable between the two groups at 3 months (RCVGrp
= 74.3 SD 16.2, HbGrp = 77.3 SD 12.3, PV al = 0.36).
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Table (9.7) Pre-operative quality of life. RCV = red cell volume, Hb =
haemoglobin concentration and PV al = P value. All data is presented as % pa-
tients with any difficulty apart from health state which is represented as mean
0-100 self assessment score (SD).
RCVGrp HbGrp PV al
(n = 43) (n = 43)
Mobility 44.2 62.8 0.08
Self Care 4.7 11.6 0.24
Usual Activity 55.8 67.4 0.27
Pain 60.5 53.5 0.51
Anxiety 32.6 41.9 0.37
Health State 61.2 (17.6) 60.4 (14.3) 0.83
Table (9.8) Post-operative quality of life. RCV = red cell volume, Hb =
haemoglobin concentration and PV al = P value. All data is presented as % pa-
tients with any difficulty apart from health state which is represented as mean
0-100 self assessment score (SD).
RCVGrp HbGrp PV al
(n = 39/43) (n = 36/43)
Mobility 30.7 22.2 0.44
Self Care 7.7 11.1 0.55
Usual Activity 53.8 44.4 0.45
Pain 53.9 63.9 0.42
Anxiety 28.2 27.7 0.63
Health State 74.3 (16.2) 77.3 (12.6) 0.36
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9.6 Summary of Principle Findings
Demographic and peri-operative data was comparable for both groups. Patients
in HbGrp received significantly more RBCs in terms of % patients transfused and
UPPO, but not UPPT. Of the outcome measures examined; deep wound infection,
renal impairment and CVA were of insufficient occurrence to allow meaningful
comparison. Significant associations were found with HbGrp exhibiting a longer
period of hospital stay while a greater number of RCVGrp patients received in-
otropic therapy. The remaining statistically examined variables of; ventilation
time, ICU stay, discharge [Hb], maximum creatinine, arrythmia, pneumonia and
superficial wound infection were non-significant between the two groups. In addi-
tion, no significant difference was noted in response to any of the QOL questions
at 3 months.
Please see section 12.7 (page - 163) for a full discussion of the above findings.
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As discussed in section 2.2 (page - 36), varying degrees of ALI are common
following cardiac surgery77;149. Although RBC transfusion has been described
in relation to the more extreme forms of ALI as TRALI, the subtler forms of
the condition are less well documented and almost certainly under recognised74.
Diagnosis is often difficult as the various measurable inflammatory mediators may
be non-specific for the causative pulmonary endothelial injury. In relation to the
use of CPB, several authors have attempted to document the association between
exhaled NO analysis and ALI. Reportedly, this technique has the advantage that
any reduction in exhaled NO is directly proportional to the degree of pulmonary
endothelial damage152–154.
This study was designed to explore whether RBC transfusion could be asso-
ciated with subtler forms of ALI, as measured by exhaled NO analysis, following
cardiac surgery.
10.2 Aim
To determine the association between pulmonary endothelial injury and RBC
transfusion.
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10.3.1 Patients
Please see section 9.4 (108)∗.
10.3.2 Patient Management
Please see section 4.3.2 (page - 56).
10.3.3 Red Cell Transfusion
Prior to surgery patients were randomised to either the RCVGrp or the HbGrp.
The former were transfused as per the RCV guideline described in appendix C
(page - 185) while group HbGrp received blood products as per the standard unit
protocol previously described in section 4.3.3 (page - 56).
10.3.4 Study Variables
10.3.4.1 Nitric Oxide Analysis
In order to quantify the degree of peri-operative lung injury NO measurements
were taken. Previous research has demonstrated that reduction in NO is asso-
ciated with the severity of the pulmonary endothelial damage sustained152–154.
The adherence of activated neutrophils to pulmonary endothelium with resultant
endothelial damage is widely recognised as the key component of TRALI74.
∗The cohort for this study was taken from patients recruited during the latter three months
of the study described in Chapter 9 (page - 106). As such, this section is as previously described.
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Figure (10.1) Nioxmino nitric oxide analyser. Reproduced from Aerocrine Inc
(http: // www. aerocrine. com ).
Exhaled NO analysis was performed at the time of hospital admission, and
at 48h post-operatively. NO analysis was performed by the hand held nioxmino
device (figure 10.1)∗. Patients are asked to make a 10s exhalation through the
device at a pressure of 10 - 20cm H2O maintaining a fixed flow rate of 50ml/s. As
exhalation is against positive pressure, the effects of nasal nitrate contamination
are minimised by the apposition of the soft palate against the posterior pharyngeal
wall. Results are provided on a digital read out expressed as NO parts per billion
(ppb)152–154 †. The primary outcome variable considered was % change in NO
(∆NO %) between the two study time points. Although this technique has been
validated for use in asthmatics, this represents a
∗Aerocrine AB, Solna, Sweden.





All demographic and peri-operative data was recorded. In addition, pulmonary
function tests (PFTs) for forced expiratory volume 1s (FEV1) and forced vital
capacity (FVC) were performed prior to operation. Where documented, RCV
was calculated as recommended by the ICSH (equations A.2 and A.3)171. BSA
was determined as recommended by Gehan and George (equation A.1)170.
10.3.5 Statistical Analysis
As this was an exploratory study, using patients from an ongoing study cohort,
no formal power calculation was performed. All linear outcome variables in the
two groups were compared using the two group t-test. If the assumptions of the
two group t-test were not met for any of these variables then transformations of
these variables or non-parametric tests were used as appropriate. Binary out-
come variables were compared using Fisher’s exact test. A PV al of ≤ 0.05 was
considered statistically significant. SPSS version 13 was used for all statistical
analysis.
10.4 Results
Twenty-four adult elective cardiac surgery patients were recruited to the study
over a three month period. Eight patients were subsequently excluded due to
an inability to complete the exhaled NO breath test at 48h post-operatively. On
analysing the data, another difficulty was identified. Namely, that no signifi-
cant difference existed in RBC transfusion status between the two groups (y/n,
RCVGrp = 5/1, HbGrp = 4/5, PV al = 0.36). This prompted a re-appraisal of the
way the results were analysed. It was decided that although any results would be
limited, the best course of action was to analyse patients per transfusion status
(red blood cell transfusion group (RBCGrp) vs no red blood cell transfusion group
(NoRBCGrp)). In addition, all study variables were correlated (r) with ∆NO %.
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Figure (10.2) Boxplots for percentage change in NO vs transfusion status. NO
= nitric oxide.
10.4.1 Red Cell Transfusion Status
Of the sixteen patients completing the study, 10 underwent CABG (RBCGrp = 6,
NoRBCGrp = 4), 5 received a AVR (RBCGrp = 3, NoRBCGrp = 2) and 1 a CABG
and AVR (NoRBCGrp = 1). No significant difference was observed between the
groups for operation performed (PV al = 0.50) or the surgeon performing the
operation (PV al = 0.30).
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When considering the individual patient variables, no significant difference
was observed for; age (RBCGrp = 68y SEM 2.1, NoRBCGrp = 57y SEM 1.9, PV al
= 0.61), gender (m/f, RBCGrp = 7/2, NoRBCGrp = 7/0, PV al = 0.48), height
(RBCGrp = 171m SEM 2.9, NoRBCGrp = 179m SEM 2.0, PV al = 0.84), weight
(RBCGrp = 76.9kg SEM 4.1, NoRBCGrp = 102.2kg SEM 7.6, PV al = 0.25), BSA
(RBCGrp = 1.9m
2 SEM 0.1, NoRBCGrp = 2.3m
2 SEM 0.1, PV al = 0.30), initial
RCV (RBCGrp = 1961ml SEM 110, NoRBCGrp = 2550ml SEM 660, PV al = 0.68),
pre-operative [Hb] (RBCGrp = 12.9g/dl SEM 0.3, NoRBCGrp = 14.5g/dl SEM 0.5,
PV al = 0.06), euro score (RBCGrp = 4.7 SEM 0.7, NoRBCGrp = 2.0 SEM 0.5,
PV al = 0.61), smoking (e/c/n, RBCGrp = 5/0/4, NoRBCGrp = 2/1/4, PV al 0.36),
FEV1 (RBCGrp = 2.6l/s SEM 0.2, NoRBCGrp = 3.3l/s SEM 0.2, PV al 0.47) and
FVC (RBCGrp = 3.6l SEM 0.3, NoRBCGrp = 4.4l SEM 0.2, PV al = 0.68) 10.1.
Similarly, operative data was comparable for; CPB time (RBCGrp = 113min
SEM 13.8, NoRBCGrp = 108min SEM 11.2, PV al = 0.54), ACC time (RBCGrp =
68min SEM 12.9, NoRBCGrp = 68min SEM 10.6, PV al = 0.47), minimum CPB
temperature (RBCGrp = 31.7
0C SEM 0.8, NoRBCGrp = 31.1
0C SEM 0.9, PV al
= 0.30), max re-warm temperature (RBCGrp = 36.6
0C SEM 0.4, NoRBCGrp =
36.30C SEM 0.3, PV al = 0.61) and ventilation time (RBCGrp = 13.7h SEM 2.0,
NoRBCGrp = 7.7h SEM 2.2, PV al = 0.02) (table 10.1).
For the primary outcome variable of ∆NO %, RBC transfusion status was
not found to have statistically significant association (RBCGrp = 14.7% SEM 8.8,
NoRBCGrp = 13.5% SEM 10.4, PV al = 0.30) (figure 10.2).
10.4.2 Correlation Coefficient for Study Variables
The continuous patient variables of; age (r = 0.15, PV al = 0.59), height (r = 0.18,
PV al = 0.50), weight (r = -0.13, PV al = 0.63), BSA (r = -0.09, PV al = 0.75), initial
patient RCV (r = -0.06, PV al = 0.84), pre-operative [Hb] (r = -0.36, PV al = 0.17),
euro score (r = 0.06, PV al = 0.84), FEV1 (r = -0.13, PV al = 0.65) and FVC (r =
-0.05, PV al = 0.86) demonstrated no significant correlation with ∆NO%.
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Table (10.1) Study variables vs transfusion status. PV al = P value, BSA =
body surface area, RCV = red cell volume, Hb = haemoglobin, FEV1 = forced
expiratory volume 1s, FVC = forced vital capacity, CPB = cardio-pulmonary
bypass, ACC = aortic cross clamp and NO = nitric oxide. All data is presented
as mean (SEM).
Transfusion Status
Variable Yes (n = 9) No (n = 7) PV al
Age (y) 68 (2.1) 57 (1.9) 0.61
Gender (m/f) 7/2 7/0 0.48
Height (m) 171 (2.9) 179 (2.0) 0.84
Weight (kg) 76.9 (4.1) 102.2 (7.6) 0.25
BSA (m2) 1.9 (0.1) 2.3 (0.1) 0.30
Initial RCV (ml) 1961 (110) 2550 (660) 0.68
Pre-op Hb (g/dl) 12.9 (0.3) 14.5 (0.5) 0.06
Euro Score 4.7 (0.7) 2.0 (0.5) 0.61
Smoking (ex/current/non) 5/0/4 2/1/4 0.36
FEV1 (l/s) 2.6 (0.2) 3.3 (0.2) 0.47
FVC (l) 3.6 (0.3) 4.4 (0.2) 0.68
CPB Time (min) 113 (13.8) 108 (11.2) 0.54
ACC Time (min) 68 (12.9) 68 (10.6) 0.47
Min Temp (0C) 31.7 (0.8) 31.1 (0.9) 0.30
Max Temp (0C) 36.6 (0.4) 36.3 (0.3) 0.61
Ventilation Time (h) 13.7 (2.0) 7.7 (2.2) 0.02
NO Reduction (%) 14.7 (8.8) 13.5 (10.4) 0.30
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Findings were similar for the peri-operative parameters of; CPB time (r =
-0.22, PV al = 0.42), ACC time (r = -0.10, PV al = 0.73), minimum CPB temper-
ature (r = 0.15, PV al = 0.58), maximal rewarm temperature (r = 0.04, PV al =
0.87), ventilation time (r = -0.09, PV al = 0.75) and units RBCs transfused (r =
-0.22, PV al = 0.42).
Table (10.2) Correlation co-efficient (r) for study variables vs percentage NO
reduction. NO = nitric oxide, PV al = P value, BSA = body surface area, RCV =
red cell volume, Hb = haemoglobin, FEV1 = forced expiratory volume 1s, FVC =
forced vital capacity, CPB = cardio-pulmonary bypass, ACC = aortic cross clamp
and RBC = red blood cell.
Variable Correlation Co-efficient (r) PV al
Age (y) 0.15 0.59
Height (m) 0.18 0.50
Weight (kg) -0.13 0.63
BSA (m2) -0.09 0.75
Initial RCV (ml) -0.06 0.84
Pre-op Hb (g/dl) -0.36 0.17
Euro Score 0.06 0.84
FEV1 (l/s) -0.13 0.65
FVC (l) -0.05 0.86
CPB Time (min) -0.22 0.42
ACC Time (min) -0.10 0.73
Min Temp (0C) 0.15 0.58
Max Temp (0C) 0.04 0.87
Ventilation Time (h) -0.09 0.75
RBC’s (u) -0.22 0.42
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10.5 Summary of Principle Findings
Two principle difficulties were encountered during this study. Firstly, a large
proportion of patients were unable to complete the exhaled NO analysis at 48h
post-operatively (33%). Secondly, no significant difference in RBC transfusion
was observed between RCVGrp and HbGrp. Thus, the analysis was performed
based upon RBC transfusion status and the calculation of correlation coefficients,
limiting the value of the study.
When considering RBC transfusion status, all demographic and peri-operative
data was broadly comparable between the two groups. Within the constraints of
this small pilot study RBC transfusion status was not found to influence ∆NO
%. Calculated correlation coefficients were all similarly non-significant when the
various study parameters were examined versus ∆NO %.
Please see section 12.8 (page - 164) for a full discussion of the above findings.
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Chapter 11
A Comparison of Individualised
and Modified Activated Clotting






Currently, heparin is considered the pharmacological anti-coagulant agent of
choice for CPB. Usually, activated clotting time (ACT) is employed to assess
the adequacy of heparinisation by virtue of its simplicity, safety, cost and relative
effectiveness158;160;161. On the negative side however, ACT may be prolonged by
both haemodilution and hypothermia, both of which are invariably encountered
during CPB162–164. The resultant inadequate anti-coagulation, with exposure of
blood to both foreign and intrinsic surfaces, may lead to coagulation activation
and thrombin generation165. In order to avoid this potentially detrimental sce-
nario, the use of HMSs has been advocated164;166–169. The objective of this study
was to compare the effects of HMS∗ and modified ACT based anti-coagulation
strategies on; haemostatic activation, post-operative blood loss and blood prod-
uct requirement.
11.2 Aim
To evaluate the impact of both HMS and modified ACT based anti-coagulation
management on; coagulation, thrombin generation, fibrinolysis, anti-thrombin III
(AT-III), post-operative blood loss and blood product requirement.
∗Hepcon, Medtronic Inc, Minneapolis, USA.
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11.3.1 Patients
Ethical approval was gained from LREC. All adult (age ≥ 16y) elective cardiac
surgery patients presenting for operation between January and September 2004
were considered for recruitment. Exclusion criteria were; the inability to provide
informed consent, pre-operative anaemia ([Hb] < 13g/dl for males and < 11g/dl
for females), anti-platelet therapy taken within seven days prior to surgery, long
term warfarin therapy, pre-operative heparin, disordered coagulation, emergency
surgery, redo surgery and surgical re-exploration.
On the day of operation, patients recruited to the study were randomised to
receive either a standard dose of heparin (activated clotting time management
group (ACTGrp)) or an individualised dose based upon the HMS (heparin man-
agement system group (HMSGrp))
∗. In all instances the operating surgeon and
staff responsible for post-operative care were blinded as to the randomisation.
11.3.2 Patient Management
Anaesthesia was induced and maintained with a combination of; fentanyl, mi-
dazolam, propofol, enflurane and pancuronium. Prior to the commencement
of surgery standard monitoring was instituted (arterial pressure, central venous
pressure, ECG, urinary catheter and nasal temperature). Anti-coagulation for
CPB, and its reversal, was as per the allocated study group protocol, described
in detail below (section 11.3.5). The extra-corporeal circuit consisted of a roller
pump†, flexible venous reservoir, vent and cardiotomy suction‡. The circuit was
primed with 2l Hartmann’s solution, 50mmol bicarbonate, 150mmol mannitol and
8000IU of heparin for a total volume of 2250ml. When the individual procedure
had been completed, patients were fully rewarmed to 370C and CPB discontinued.
All residual pump blood was returned to the patient.
∗Randomisation was carried out by randomly generated list (www.randomization.com)
with order of recruitment determining the group allocated.
†Stockert Instruments, Munich, Germany.
‡Medtronic Inc, Minneapolis, USA.
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Table (11.1) Clotting factor administration protocol. Plt = platelet count, PTr
= pro-thrombin time ratio, APTTr = activated partial thromboplastin time ratio
and Fib = fibrinogen.
Abnormality Administer
Plt < 100,000ml Platelets
PTr > 1.6 Fresh Frozen Plasma
APTTr > 1.6 Fresh Frozen Plasma
Fib < 1g/L Fresh Frozen Plasma
Thoracic drainage was achieved with a combination of pericardial, mediasti-
nal and pleural drains where required. Crystalloid was given in the ICU at a
rate of 0.5ml/kg/h with colloid administered (4.5% human albumin solution)
where required for hypotension (MAP < 60mmHg) and/or poor urine output (<
0.5ml/kg/h).
11.3.3 Red Blood Cell Transfusion
Please see section 4.3.3 (page - 56).
11.3.4 Blood Component Administration
Blood components for both groups were administered as per local protocol (table
11.1). It should be noted factors were only given in the presence of significant
post-operative blood loss (≥ 500ml in the first post-operative hour and/or con-
tinuing losses ≥ 250ml for subsequent hours).
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Figure (11.1) Hepcon heparin management system (HMS).
11.3.5 Anti-coagulation Management
11.3.5.1 ACT Group
In ACTGrp, ACT was measured using a Celite/Kaolin/Glass activator
∗ to min-
imise Aprotinin effect, on a Hemochron 401 analyser†. A baseline ACT mea-
surement was performed on induction of anesthesia. An initial heparin bolus of
300IU/kg was given to the patient with a further 8000IU added to the extra-
corporeal circuit prime. During CPB, 4000IU of heparin was given for each litre
of crystalloid or unit of RBCs infused. ACTs were checked post initial heparin
bolus and at 10min and every 30min of CPB. Where the ACT was less than 480s
a dose-response algorithm, as devised by Bull et al, was used to calculate the
additional heparin dose required (equation D.1)157;160.
∗Max-ACT, Helena Labs, Sunderland, UK.
†International Technidyne Corp, Edison, USA.)
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At the termination of CPB, protamine sulphate was given at a ratio of 1:1 of
the, dose-response curve calculated, estimated residual circulating heparin volume
(equation D.2)157;160. Further boluses were given, similarly calculated, following
protamine administration and and on ICURet where the ACT remained above the
pre-operative target level∗.
11.3.5.2 HMS Group
In HMSGrp, HDR was performed by the HMS at the induction of anaesthesia.
Heparin was subsequently given at the dose calculated to achieve a target ACT
of greater than 480s, usually resulting in an empirical BHConc target of 4-5u/ml
†.
The dose of heparin contained within the pump priming solution was deducted
from the bolus dose given to the patient. During CPB, the BHConc was measured
at 10min and every 30min of CPB by HPT. Where BHConc fell below the desired
target level additional heparin was given at the dose calculated by the HMS
(figure 11.1).
Following the termination of CPB, HPT was again used to calculate the pro-
tamine dose (again at a ratio of 1:1) required to neutralise all residual circulating
heparin. This was repeated post-protamine and on ICURet with further pro-
tamine given as indicated †. Further detail on the principles behind the HMS can
be found in appendices D.2 and D.3 (page - 190)
∗No further protamine was given if ACT remained elevated beyond this point unless residual
heparin effect was identified on formal coagulation screen
†Although heparin dosage is expressed as IU, BHConc and plasma heparin concentration
(PHConc) is given in United States Pharmacopeia (USP) units (u). The correction factor for
IU is 0.88. This was done to ensure accurate comparison with similar studies.
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11.3.6 Study Variables
All blood samples, apart from the pre-operative screen, were collected from the
radial artery catheter inserted prior to the induction of anaesthesia. Samples
were collected at the following time points; induction of anaesthesia (defined for
the reporting of results as t = 0), 5min post-heparin, 10min of CPB, every 30min
of CPB, termination of CPB, 5min post-protamine and ICURet.
Several routine and laboratory markers of coagulation were selected for the
study analysis (table 11.2). Thrombin anti-thrombin (TAT) was selected to record
the degree of thrombin generation while D-Dimer levels were used to quantify
fibrinolysis∗. AT-III assay was used to give an indication of both coagulation
activation and heparin sensitivity†.
For both groups, PHConc was calculated from the, HPT measured, BHConc
(equation D.3). This method has been shown to be accurate when compared to
sensitive anti-Xa chromogenic substrate assays163.
11.3.7 Statistical Analysis
It was calculated from previous similar research that a sample size of 36 patients
would have 80% power to detect a difference of 19g/ml in thrombin generation
(TAT assay)169. All variables were presented as mean (SEM). A Student’s t-test
was performed to determine the statistical significance of any observed difference
between variables for consecutive time points and between the study groups.
Where the assumptions of the two group t-test were not met non-parametric
analysis was used. Binary variables were compared by use of Fishers exact test.
A PV al ≤ 0.05 was considered statistically significant. SPSS version 13 was used
for all statistical analysis.
∗Both by ELISA, Dade Behring, Milton Keynes, UK
†Chromogenic Assay, Quadrateck, Epsom, UK
138
11.3 Materials and Methods
Table (11.2) Study variables. ACTGrp = activated clotting time group, HMS =
heparin management system, ACT = activated clotting time, Hb = haemoglobin
concentration, Hct = haematocrit, Plt = platelet count, HDR = heparin dose
response PT = pro-thrombin time ratio, APTT = activated partial thromboplastin
time, Fib = fibrinogen, TAT = thrombin anti-thrombin, AT-III = anti-thrombin
III, HPT = heparin protamine titration and ICU = intensive care unit.
ACTGrp HMSGrp
Induction ACT, Hb, Hct, Plt HDR, ACT, Hb, Hct
PT, APTT, Fib Plt, PT, APTT, Fib
Post-heparin TAT, D-Dimer, AT-III TAT, D-Dimer, AT-III
Fib, ACT, HPT, Hb, Hct Fib, ACT, HPT, Hb, Hct
10min CPB ACT, HPT, Hb, Hct ACT, HPT, Hb, Hct
Every 30min CPB ACT, HPT, Hb, Hct ACT, HPT, Hb, Hct
Termination CPB TAT, D-Dimer, AT-III TAT, D-Dimer, AT-III
Fib, ACT, HPT, Hb, Hct Fib, ACT, HPT, Hb, Hct
Post-protamine HPT, ACT, Hb, Hct HPT, ACT, Hb, Hct
Plt, PT, APTT, Fib Plat, PT, APTT, Fib
Return ICU HPT, ACT, Hb, Hct HPT, ACT, Hb, Hct




11.4.1 Demographic and Peri-operative Data
Forty-one adult elective cardiac surgery patients were recruited to the study over
a nine month period. Two patients in ACTGrp (n = 2/20) and one in HMSGrp
(n = 1/21) were subsequently excluded due to re-operation for surgical bleeding.
Of the thirty-eight patients completing the study, 21 underwent CABG (ACTGrp
= 12, HMSGrp = 9), 15 a AVR (ACTGrp = 7, HMSGrp = 8) and 2 a ASD repair
(ACTGrp = 1, HMSGrp = 1). No significant difference was observed between
the groups for operation performed (PV al = 0.94) or the surgeon performing the
operation (PV al = 0.40).
Pre-operative characteristics were comparable for both groups in terms of;
age (ACTGrp = 60.4y SEM 2.8, HMSGrp = 64.8y SEM 2.3, PV al = 0.24), weight
(ACTGrp = 83.5kg SEM 4.6, HMSGrp = 81.8kg SEM 4.0, PV al = 0.78), gender
(m/f, ACTGrp = 13/5, HMSGrp = 17/3, PV al = 0.44 ), BV (ACTGrp = 5415ml
SEM 337, HMSGrp = 5363ml SEM 300, PV al = 0.91), Hct (ACTGrp 43.6% SEM
0.7, HMSGrp = 41.9% SEM 0.8, PV al = 0.12), PTr (ACTGrp = 1.0 SEM 0.02,
HMSGrp = 1.0 SEM 0.02, PV al = 0.51), APTTr (ACTGrp = 0.9 SEM 0.02, HMSGrp
= 0.9 SEM 0.02, PV al = 0.44) and plt (ACTGrp = 213x10
3/ml SEM 8.4, HMSGrp
= 235x103/ml SEM 18.0, PV al = 0.27) (table 11.3).
Similarly, operative data was comparable for; CPB time (ACTGrp = 90min
SEM 10.1, HMSGrp = 102min SEM 9.3, PV al = 0.43), ACC time (ACTGrp =
67min SEM 8.5, HMSGrp = 72min SEM 8.4, PV al = 0.65), minimum CPB tem-
perature (ACTGrp = 31.8
0C SEM 0.3, HMSGrp = 31.4
0C SEM 0.5, PV al = 0.52),
max re-warm temperature (ACTGrp = 37.1
0C SEM 0.04, HMSGrp = 37.1
0C SEM
0.06, PV al = 0.68), CPB clear fluid volume (crystalloid and colloid)(ACTGrp =
5187ml SEM 378, HMSGrp = 4969ml SEM 285, PV al = 0.68)
∗, dilution factor
(CPB clear fluid volume/BV) (ACTGrp = 1.1 SEM 0.2, HMSGrp = 1.0 SEM
0.1, PV al = 0.64) and Aprotinin administration(y/n, ACTGrp = 7/18, HMSGrp =
11/20, PV al = 0.61) (table 11.3).
∗This figure includes the 2250ml extra-corporeal circuit prime.
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Table (11.3) Patient and operative characteristics. ACT = activated clot-
ting time, HMS = heparin management system group, PV al = P value, Hb =
haemoglobin concentration, Hct = haematocrit, PTr = pro-thrombin time ratio,
APTTr = activated partial thromboplastin time ratio, Plt = platelet count, CPB
= cardio-pulmonary bypass and ACC = aortic cross clamp. All data is presented
as mean (SEM).
ACTGrp HMSGrp PV al
(n = 18) (n = 20)
Patient Variables
Age (y) 60.4 (2.8) 64.8 (2.3) 0.24
Gender (m/f) 13/5 17/3 0.44
Weight (kg) 83.5 (4.6) 81.8 (4.0) 0.78
Blood Volume (ml) 5415 (337) 5363 (300) 0.91
Pre-operative haematology
Hct (%) 43.6 (0.7) 41.9 (0.8) 0.12
PTr 1.0 (0.02) 1.0 (0.02) 0.51
APTTr 0.9 (0.02) 0.9 (0.02) 0.44
Plt (x103/ml) 213 (8.4) 235 (18.0) 0.25
CPB Data
CPB Time (min) 90 (10.1) 102 (9.3) 0.43
ACC Time (min) 67 (8.5) 72 (8.4) 0.65
Min Temp (0C) 31.8 (0.3) 31.4 (0.5) 0.52
Max Temp (0C) 37.1 (0.04) 37.1 (0.06) 0.68
CPB clear fluid volume (ml)* 5187 (378) 4969 (285) 0.68
Dilution Factor 1.1 (0.2) 1.0 (0.1) 0.64
Aprotinin (y/n) 7/18 11/20 0.61




Table (11.4) Heparin and protamine administration. ACT = activated clotting
time, HMS = heparin management system and PV al = P value. All data is
presented as mean (SEM).
Heparin (IU) Protamine (mg)
ACTGrp HMSGrp PV al ACTGrp HMSGrp PV al
(n = 18) (n = 20) (n = 18) (n = 20)
Initial Dose 25056 25164 0.96 253 233 0.43
(1370) (1808) (20) (14)
Additional Dosage 17038 26373 0.001 37 42 0.55
(1328) (2309) (4) (6)
Total Dose 42094 51537 0.04 290 274 0.56
(2167) (3715) (22) (14)
Total per kg 510 633 0.001 3.5 3.4 0.70
of Body Weight (15) (32) (0.2) (0.2)
11.4.2 Heparin and Protamine Administration
Although no statistically significant difference was observed in the initial heparin
dose administered for the two groups (ACTGrp = 25056IU SEM 1370, HMSGrp =
25164IU SEM 1808, PV al = 0.96), HMSGrp received a greater total dose (ACTGrp
= 42094IU SEM 2167, HMSGrp = 51537IU SEM 3715, PV al = 0.04). All patients
reached the target ACT of 480s in ACTGrp (n = 18/18) while two patients required
a further heparin bolus prior to CPB in HMSGrp (n = 2/20) (table 11.4).
The initial protamine dose administered was comparable between the two
groups (ACTGrp = 253mg SEM 20, HMSGrp = 233mg SEM 14, PV al = 0.43) with
complete reversal achieved in 12 patients (n = 12/18) in ACTGrp and 16 patients
(n = 16/20) in HMSGrp. Heparin rebound was identified in 5 patients (n = 5/18)
in ACTGrp and 4 patients (n = 4/20) in HMSGrp following ICURet (table 11.4).
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Figure (11.2) ACT and PHConc during CPB for ACTGrp. Time = 1.1h equates
to 5min post-heparin. Hashed lines indicate period of CPB. ACT = activated clot-
ting time, PHConc = plasma heparin concentration and CPB = cardio-pulmonary
bypass.
11.4.3 Activated Clotting Time and Plasma Heparin Con-
centration
ACT rose markedly in both groups from its baseline value at t = 0 (ACTGrp =
141s SEM 3.5, HMSGrp = 138s SEM 2.7, PV al = 0.46) following the administration
of the initial heparin bolus (ACTGrp = 616s SEM 21.1, HMSGrp = 621s SEM 33.0,
PV al = 0.89). At t = 10min CPB a further rise occurred (ACTGrp = 837s SEM
40.1, HMSGrp = 763s SEM 48.3, PV al = 0.25) prior to a gradual fall towards
the end of CPB. Although this fall was more marked in ACTGrp a statistically
significant difference did not exist (ACTGrp = 620s SEM 32.4, HMSGrp = 735s
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Figure (11.3) ACT and PHConc during CPB for HMSGrp. Time = 1.1h equates
to 5min post-heparin. Hashed lines indicate period of CPB. ACT = activated
clotting time, PHConc = plasma heparin concentration, CPB = cardio-pulmonary
bypass and HMS = heparin management system.
SEM 54.0, PV al = 0.07) (figures 11.2 and 11.3).
PHConc fell for both groups from t = 5min post-heparin (ACTGrp = 6.5u/ml
SEM 0.3, HMSGrp = 6.7u/ml SEM 0.3, PV al = 0.63) following the start of CPB
(ACTGrp = 4.8u/ml SEM 0.3, HMSGrp = 4.6u/ml SEM 0.3, PV al = 0.56). There-
after an overall rise was noted in HMSGrp with a fall in ACTGrp at t = end-CPB
(ACTGrp = 4.2u/ml SEM 0.3, HMSGrp = 5.4u/ml SEM 0.2). Although the dif-
ference between ACTGrp and HMSGrp was significant (PV al = 0.003) for this time
point, all other time points were non-significant (figures 11.2 and 11.3).
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No statistically significant difference in ACT existed at t = 5m post-protamine
(ACTGrp = 141s SEM 3.5, HMSGrp = 134s SEM 2.8, PV al = 0.10). This finding
was also similar for PHConc (ACTGrp = 0.3u/ml SEM 0.1, HMSGrp = 0.2u/ml
SEM 0.1, PV al = 0.50). At t = ICURet data was comparable between the groups
for both ACT (ACTGrp = 143s SEM 6.3, HMSGrp = 143s SEM 4.5, PV al = 0.97)
and PHConc (ACTGrp = 0.2u/ml SEM 0.1, HMSGrp = 0.2u/ml SEM 0.1, PV al =
0.73) (table 11.5).
11.4.4 Peri-operative Coagulation
No statistically significant difference existed at t = 0 between the two groups
for; Hct (ACTGrp = 41.2% SEM 1.0, HMSGrp = 40.1% SEM 1.0, PV al = 0.40),
PTr (ACTGrp = 1.0 SEM 0.01, HMSGrp = 1.0 SEM 0.02, PV al = 0.15), APTTr
(ACTGrp = 1.0 SEM 0.02, HMSGrp = 1.0 SEM 0.02, PV al = 0.30) and platelet
count (Plt) (ACTGrp = 196x10
3/ml SEM 9.0, HMSGrp = 201x10
3/ml SEM 18.5,
PV al = 0.81). This was also noted at t = 5m post-protamine for; Hct (ACTGrp
= 26.8% SEM 0.8, HMSGrp = 26.8% SEM 0.12, PV al = 0.99), APTTr (ACTGrp
= 1.7 SEM 0.08, HMSGrp = 1.5 SEM 0.08, PV al = 0.24) and platelet count
(ACTGrp = 92 x103/ml SEM 9.9, HMSGrp = 99 x103/ml SEM 7.7, PV al = 0.59).
However, a significant difference was noted for PTr at this time point (ACTGrp =
1.7 S SEM 0.04, HMSGrp = 1.5 SEM 0.06, PV al = 0.03). At t = ICURet, all the
variables of; Hct (ACTGrp = 28.1% SEM 1.0, HMSGrp = 26.8% SEM 1.3, PV al
= 0.43), PTr (ACTGrp = 1.3 SEM 0.05, HMSGrp = 1.2 SEM 0.03, PV al = 0.42),
APTTr (ACTGrp = 1.7 SEM 0.16, HMSGrp = 1.5 SEM 0.08, PV al = 0.34) and
Plt (ACTGrp = 107x10
3/ml SEM 9.8, HMSGrp = 118x10
3/ml SEM 10.3, PV al =























































































































































































































































































































































































































































































































































































































































































































































































Table (11.7) Haemostatic markers. ACT = activated clotting time, HMS =
heparin management system, PV al = P value, TAT = thrombin anti-thrombin
complex and AT-III = anti-thrombin III. All data is presented as mean (SEM).
ACTGrp HMSGrp PV al
Pre-CPB
TAT (mg/l) 12.5 (3.7) 12.0 (3.6) 0.94
D-Dimer (ng/ml) 956 (92) 1135 (162) 0.33
Fibrinogen (g/l) 2.8 (0.1) 3.4 (0.2) 0.04
AT-III (IU/ml) 0.84 (0.03) 0.88 (0.04) 0.50
End-CPB
TAT (mg/l) 16.3 (2.9) 22.3 (6.6) 0.39
D-Dimer (ng/l) 1318 (300) 1981 (982) 0.50
Fibrinogen (g/l) 1.8 (0.2) 1.6 (0.1) 0.33
AT-III (IU/ml) 0.50 (0.03) 0.51 (0.03) 0.91
11.4.5 Thrombin Generation, Fibrinolysis and Antithrom-
bin III
At t = 0, all the variables of; TAT (ACTGrp = 12.5mg/l SEM 3.7, HMSGrp
= 12.0mg/l SEM 3.6, PV al = 0.94), d-dimer (ACTGrp = 956ng/ml SEM 92,
HMSGrp = 1135ng/ml SEM 162, PV al = 0.33) and AT-III (ACTGrp = 0.84IU/ml
SEM 0.03, HMSGrp = 0.88IU/ml SEM 0.04, PV al = 0.50), with the exception of
fibrinogen (ACTGrp = = 2.8g/l SEM 0.1, HMSGrp = 3.4g/l SEM 0.2, PV al = 0.04),
were comparable. At t = end-CPB, no significant difference existed between the
variables of; TAT (ACTGrp = 16.3mg/l SEM 2.9, HMSGrp = 22.3mg/l SEM 6.6,
PV al = 0.39), d-dimer (ACTGrp = 1318ng/ml SEM 300, HMSGrp = 1981ng/ml
SEM 982, PV al = 0.5), fibrinogen (ACTGrp = 1.8g/l SEM 0.2, HMSGrp = 1.6g/l
SEM 0.1, PV al = 0.33) and AT-III (ACTGrp = 0.50IU/ml SEM 0.03, HMSGrp =
0.51IU/ml SEM 0.03, PV al = 0.91) (table 11.7).
148
11.5 Summary of Principle Findings
11.4.6 Post-operative Drain Loss and Blood Product Re-
quirement
For 12h drain loss no significant difference was noted between the groups (ACTGrp
= 442ml SEM 76, HMSGrp = 637ml SEM 93, PV al = 0.06). This was also mirrored
in the 24h RBC transfusion data (ACTGrp = 1.1u SEM 0.3, HMSGrp = 1.6u SEM
0.5, PV al = 0.47). An insufficient number of patients received clotting factors to
allow meaningful analysis.
11.5 Summary of Principle Findings
Demographic and peri-operative data was comparable for both groups. Similarly,
no difference was observed in initial patient heparin bolus between ACTGrp and
HMSGrp. HMSGrp did receive a significantly greater total dose as a result of the
additional heparin administration during CPB. No difference was observed in pro-
tamine administration in terms of, initial, additional and total dosage. Although
ACT did not differ between the two groups, PHConc was significantly higher in
HMSGrp at t = end-CPB. Haematological investigation revealed no difference in
Hct, APTTr and platelet count at induction, post-protamine and ICURet. Only
PTr demonstrated a significant difference at t = 5m post-protamine. No differ-
ence existed between, TAT, d-dimer and AT-III at t = end-CPB. As fibrinogen
was significantly lower in HMSGrp prior to CPB this parameter was not suitable
for valid comparison. Chest drain losses at 12h and 24h RBC transfusion total
post-operatively were again, not significantly different.
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12.1 Patient and Procedural Variables Associ-
ated with Red Cell Transfusion
Study Aim
• To retrospectively analyse what patient and operative variables are associated
with RBC transfusion.
Please see section 3.5 (page - 52) for a summary of the principle findings.
Advancing age has been established as a predictor of RBC transfusion require-
ment by many studies, a finding confirmed by our data131–141. Primarily this is
thought to relate to a reduction in renal function and therefore erythropoietin
secretion188. Another consideration with advancing age is the increasing friability
of soft tissues and the resultant predisposition to surgical blood loss174;189.
Age is not only related to pre-operative [Hb] but also body size. This study
identified strong associations between; gender, height, weight and BSA with RBC
transfusion. An interesting observation is that all the aforementioned variables
may be considered determinants of pre-operative RCV (equations A.2 and A.3171.
Several studies have identified these parameters as being predictors of RCV loss
and therefore transfusion requirement131–141. An alternative angle may be to con-
sider the ability to tolerate RCV loss. Those with a higher RCV pre-operatively
will not suffer the same percentage reduction in RCV for a given RCV loss than
those at the lower end of the spectrum.
When considering pre-operative morbidity, it was evident that those in poorer
physical condition (diabetes mellitus, poor left ventricular function, pre-operative
IABP, high pre-operative creatinine level, NYHA class and Euro score) were more
likely to receive an RBC transfusion190. Several study limitations may explain this
finding. As the timing of transfusion was not recorded, the RBCs administered
may have been given at any time during the patients hospital stay. It seems
likely that increasing co-morbidity will result in prolonged periods in the ICU,
with resultant delay in hospital discharge, raising the incidence of transfusion
events. It is also important to note that as this was a retrospective analysis,
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there was no control over adherence to local RBC transfusion protocol (table
4.1). Therefore, sicker patients may simply receive more RBCs in the belief that
it will improve outcome.
In addressing some of these co-morbid parameters individually, additional
hypothesis may be offered. Diabetes mellitus has previously been identified as
an important risk factor for RBC transfusion among those undergoing cardiac
surgery. Possible explanations include more advanced CAD at the time of pre-
sentation and the presence of diabetic complications, both of which may increase
transfusion risk for the reasons outlined above191. IABPs carry their own inherent
risks for blood product requirement. Mechanical destruction of platelets through
continued use and arterial trauma at the time of insertion may both predispose
to bleeding192;193. Smoking status has been identified as a transfusion risk factor
with non-smokers more likely to receive RBCs. One reason suggested has been
the protective effects of secondary polycythaemia in smokers194;195. This study
could not confirm these suggestions as no association with smoking status was
found. Creatinine was only found to be associated with the number of units RBC
transfused and not RBC transfusion status. Although it is hard to say if this
was a significant finding, high creatinine has been associated in the past with an
increase in peri-operative blood loss196.
Surgical priority, redo status and Hardy class were all associated with RBC
transfusion. Possible reasons may include prolonged CPB times and a greater
likelihood of post-operative complications138;139. Patients with long CPB times
are predisposed to an increase in coagulation activation and subsequently RCV
loss197. Another consideration may be the artificial depression of [Hb] by the
large clear fluid load invariably associated127–129. This is further borne out by
the finding that patients undergoing CABG on-pump are more likely to receive
RBCs198;199.
It is evident that the majority of the positive indicators for RBC transfusion
found in this study may be associated with peri-operative RCV loss. However,
other possible rationales for an associated increase in transfusion requirement with
these variables were apparent. Parameters associated with a small pre-operative
RCV may predict an individual’s ability to cope with RCV loss. Furthermore,
small RCV in the presence of CPB associated haemodilution may dictate that
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patients are transfused despite little actual RCV loss. In the following section
(12.2) we discuss the results of a study to challenge this hypothesis in which the
association of several key variables with RCV loss and gain was examined.
12.2 Factors Predicting Loss and Gain of Red
Cell Volume
Study Aim
• To determine what pre and intra-operative variables are associated with loss
or gain in RCV due to bleeding or RBC transfusion.
Please see section 4.5 (page - 65) for a summary of the principle findings.
Our results demonstrated that; age, sex, height, weight, BSA and initial Hct
are all associated with RBC transfusion but not with RCV loss. These variables
are all predictors of pre-operative RCV as outlined by the ICSH (equations A.2
and A.3)171. Thus it would appear that those patients with a low RCV are not
at greater risk of RCV loss but may be less able to cope with any loss that
does occur131;136. Adding further weight to this argument was the finding that
percentage reduction in initial RCV (but not absolute RCV loss) was associated
with RBC transfusion. It is also likely that these individuals are more prone to
the ‘dilutional anaemia’ encountered during cardiac surgery139;141. As described
in previous predictive models, our results suggest that the above variables are
all indicators of transfusion risk when that decision is solely based upon a [Hb]
threshold131–141. However, they do not predict the volume of RCV a patient is
likely to lose as has often been the assumption.
None of the operative variables studied of; CPB time, ACC time and the-
atre fluid administration had any association with post-operative RCV loss or
RBC gain. Studies have also identified these factors as predictors for transfusion
through a combination of small BSA, the dilutional effects of the CPB circuit
and the large volumes of exogenous fluid administered135–139;141. Although our
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results did not demonstrate any such association it is clear that individuals with
a small BSA are at a greater risk of receiving RBCs. Similarly, hypothermia has
been identified as a causative factor for transfusion requirement due to its effects
on haemostasis174. Although our study showed no association with RCV loss
the explanation may simply be that as our cohort consisted of elective patients
only there was little variability in minimum CPB temperature. Only a minimal
difference was observed in RCV loss between those taking anti-platelet therapy
within seven days of operation and those not.
The results from this study suggest that pre-operative RCV and haemodilu-
tion are key components in determining RBC transfusion when [Hb] is the sole
parameter considered. Currently, much debate exists over what should be con-
sidered a safe transfusion threshold in the general and cardiac ICU. A growing
body of evidence is beginning to suggest that lower [Hb] concentrations are well
tolerated thus confirming clinical experience with Jehovah’s witness patients over
many years6;114;137;200. Thus the development of an RCV transfusion guideline,
where lower [Hb]s are tolerated provided haemodilution is the predominant fac-
tor, may be the most effective way of rationalising the current liberal transfusion
practice in cardiac surgery.
In the following sections we go on to discuss several key questions, outlined
below, that will allow us to develop an RCV transfusion guideline;
• What is the relative contribution of haemodilution/ RCV loss to the post-
operative anaemia encountered in cardiac surgery (section 12.3)?
• Is it possible to accurately measure RCV, reproducibly and reliably (section
12.4)?
• Will [Hb] recover as excess body water is shed following surgery (section
12.5)?
• What is the lowest [Hb] consistent with maintaining the minimal require-
ment for oxygen delivery peri-operatively (section 12.6)?
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12.3 Peri-operative Red Cell, Plasma and Blood
Volume Change
Study Aim
• To determine the relative contributions of RCV loss and haemodilution to
the post-operative anemia encountered following cardiac surgery.
Please see section 5.5 (page - 76) for a summary of the principle findings.
The results obtained in this study strongly suggest that PV expansion is a sig-
nificant factor in triggering RBC transfusion if this decision is based upon [Hb]
alone. Three distinct peaks of PV expansion occurred at anaesthetic induction;
end of CPB and at 16h of ICU management. General anaesthesia is known to
cause a degree of systemic vasodilation resulting in PV expansion201;202. This is
further compounded by the systemic inflammatory response resulting from the
use of extra-corporeal circulation203;204. In order to maintain circulatory volume
during this phase large volumes of clear fluids are usually administered, resulting
in profound haemodilution139;205. During the initial hours of ICU stay patients
vasodilate further as they re-warm fully to normothermia, again resulting in more
clear fluid administration206. At its greatest, PV reached one and a half times its
pre-operative value.
When considering RCV, the greatest loss occurred during CPB due to residual
volume remaining within the extra-corporeal circuit. It should be noted that
approximately half of this was returned to the patient in the from of ‘pump
blood’. The most interesting observation, however, occurred during the initial
phase of ICU management. Paralleling the rise in PV described above, patients
were transfused RBCs to the extent of a net RCV gain, despite the loss of RCV in
the thoracic effluent. Although our departments transfusion protocol threshold
[Hb] rises from 8g/dl to 9g/dl at 4h post-operatively, this trend continued well
beyond this time point and can therefore not be explained by this change. Indeed
three patients had an estimated RCV at 24h in excess of the pre-operative value.
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The results of this study suggest that transfusing RBCs based upon [Hb] is
an inaccurate way of replacing RCV loss. This is primarily due to the artificial
depression of [Hb] through PV expansion139;201–206. In tandem with the results
previously discussed (section 12.2), three key points now appear evident;
1. RCV is relatively well preserved in patients undergoing cardiac surgery.
2. Pre-operative RCV is the principle determinant of ability to tolerate RCV
loss.
3. When transfusion is based upon [Hb] alone, PV expansion has a profound
effect on the decision to administer RBCs and may lead to over-transfusion.
Taken together, these findings provide the basis for the development of an
RCV based transfusion guideline as outlined in section 12.2.
Although we consider the above statements to be valid, it is important to
remember they are based upon mechanical estimations of blood loss. That is to
say, calculation of RCV loss is by swab weight, drain loss etc and the measured
Hct. Such techniques are prone to a certain amount of error and can often only be
considered ‘best guess’. Until recently, accurate repeatable RCV measurement
has not been possible due to the radioactive nature of the markers used. In
the following section (12.4) we discuss the evaluation of a new and repeatable
technique using NaF flow cytometry in the calculation of RCV130;148;176.
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12.4 Evaluation of Sodium Fluorescein Flow Cy-
tometry in the Determination of Red Cell
Volume
Study Aim
• To assess the accuracy of NaF flow cytometry in the measurement of changes
in RCV by PIHD.
Please see section 6.5 (page - 82) for a summary of the principle findings.
Accurate replacement of RCV is dependant upon a technique which allows its di-
rect measurement. Such an investigation should be; simple to perform, non time
consuming, non-toxic and above all repeatable within a short time frame. NaF
labelled RBCs offer the first opportunity for a repeatable test that can directly
quantify the degree of surgical RCV loss130;148;176. The results of the preliminary
investigation we performed indicated that the rate of decay in fluorescence of
the NaF-RBCs was to rapid to allow the meaningful clinical application of this
technique. Paradoxically, it is this very property that allows for the repeat ap-
plication of this process within a short time frame. The original application by
Lauermann involved injection and analysis of results within a short time frame
(< 20min). Despite this, the good association demonstrated with Cr51 labelled
RBCs is perhaps surprising given that our results documented a fluorescent RBC
half life of 20min148;176.
As a result of the above, the derivation of the RCV transfusion guideline,
described in this thesis (appendix C, page - 185), was based upon the mechanical
methodology described previously in chapters 4 (page - 53) and 5 (page - 66).
In section 14.2 (page - 174), we suggest a method of correcting the deficien-
cies outlined above to allow for the proper assessment of NaF flow cytometry in
detecting RCV change.
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12.5 The Effect of Gain in Total Body Water
on Haemoglobin Concentration and Body
Weight
Study Aim
• To determine whether [Hb] will recover as excess TBW is shed post-operatively
in association with a reduction in body weight.
Please see section 7.5 (page - 93) for a summary of the principle findings.
At all times, the transfusion threshold of 8g/dl post-operatively was rigidly ad-
hered to. All patients receiving RBCs after day 1 were excluded. This has effec-
tively created a level ‘playing field’ allowing us to compare TBW, body weight and
[Hb] in a meaningful way. The first observation of note was the recovery of [Hb]
in association with a reduction in TBW until day 5 but not between days 5 and
10. One possible explanation for this finding may lie within the results discussed
in section 12.3. It was observed that both BV and PV rose markedly, artifi-
cially depressing [Hb]129;173. The suggestion from this study may be that TBW
acts as a surrogate marker for PV. As PV, and therefore TBW, returns to its
pre-operative state the dilutional effect on [Hb] is lost. From the trend observed
in chapter 5 (page - 66) (a progressive fall beginning at 16h post-operatively),
and these results, it would seem reasonable to postulate that normal circulatory
physiology is restored around day 5. The rise in [Hb] beyond this point may be
explained by the recovery of haemopoietic bone marrow function207;208.
The finding that body weight fell in association with reduction in TBW and
[Hb] recovery, between days 1 and 5, suggests that simple monitoring of body
weight may act as a guide to an individual’s fluid status, and therefore scope for
[Hb] recovery. Indeed, this confirms what has been observed in clinical practice
for many years (and prompted this study). Although the study period between
days 1 and 3 was non-significant for body weight and [Hb], some strength of
association was identified.
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The final finding of note was that although body weight returned to near its
pre-operative value at day 5, TBW remained significantly elevated, presumably
as a consequence of the highly catabolic effects of cardiac surgery178. Thus, if
using body weight to assess an individual’s fluid status, a value lower than that
recorded pre-operatively should be sought.
As mentioned in the introductory chapter 1 (page - 2), it has previously been
assumed that higher [Hb]s are required in order to maintain adequate systemic
oxygenation peri-operatively. This suggests that lower [Hb]s are not tolerated.
The evidence we have gathered thus far contradicts this assumption. We have
demonstrated that post-operative anaemia may be considered largely dilutional
and so may partially correct over a short period as fluid is lost. Taken in tandem
with the results of haemodilution studies (section 1.5.3.1, page - 31), it appears
that this is an entirely patho-physiological state where a variety of compensatory
mechanisms act to maintain adequate systemic oxygenation up to an as yet unde-
fined critical point. Of the questions identified in section 12.2, only one remains
in order to complete the body of evidence required to develop an RCV based
transfusion guideline.
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12.6 Oxygen Delivery and Haemoglobin Con-
centration in Cardiac Surgery
Study Aim
• To examine the relationship between actual measured oxygen delivery and
the corresponding estimated critical values peri-operatively.
Please see section 8.5 (page - 105) for a summary of the principle findings.
The results obtained demonstrate that lowering core body temperature signif-
icantly reduces both DO2Crit and VO2. As patients are re-warmed towards nor-
mothermia both the aforementioned variables rise while DO2 remains relatively
fixed. Discontinuation of CPB, and restoration of the cardiac based circulation,
allows DO2 to rise by way of an increase in BFI. Consequently, at no time did
DO2 significantly approach DO2Crit. This suggests that anaerobic metabolism
is of minimal importance in post-operative lactate accumulation following CPB.
Calculated [HbCrit] suggested that values as low as 3.9g/dl during CPB (provided
CPB flow rates are increased on re-warming), and 5.4g/dl post-operatively could
theoretically be tolerated.
Oxygen debt accrual during CPB has long been used as the basis for any
argument pertaining to maintaining a higher peri-operative [Hb]. Principally this
states that pathological supply dependency of VO2 on DO2 below a critical point
results in anaerobic metabolism and lactate accumulation89. Current evidence
suggests that this may not be the case. The observed dependency in many cases
may simply be a manifestation of mathematical coupling whereby many of the of
the parameters used in the calculation of VO2 are also used for DO2
91;92. This
theory is strongly supported by the finding that VO2 measured by the reverse
Fick principle has no association with VO2 as measured by expired gas analysis
(section 1.5.1.1, page - 23)93.
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Consideration also has to be given to causative factors of lactate accumulation,
as described fully in section 1.5.1.3 (page - 26). Outwith anaerobic metabolism;
lactate washout from hypo-perfused tissues, a reduction in lactate clearance and
deactivation of PDH by insulin and calcium containing drugs may all play a
role89;101;102. More recently attention has turned to the large volumes of exoge-
nous fluid administered during CPB. The net result of such a large non-[HCO3−]
containing fluid load may be to reduce extra-cellular [HCO3−] and therefore an
individual’s buffering capacity. This may be exacerbated where fluids with little
or no strong ion difference are given e.g. normal saline. The net effect may be to
increase hydrogen ion dissociation with a resultant metabolic acidosis99;103;104.
Although this study was largely a theoretical mathematical construct based
upon real time patient observations, the recording of such large differences in
observed and calculated critical values suggests that current transfusion practice
is excessive if oxygen requirement is the sole parameter considered. In association
with the evidence discussed so far we can now hypothesise the following;
• The ability to tolerate RCV loss is determined by the pre-operative RCV
(section 12.2).
• Haemodilution is a significant factor in determining the transfusion of RBCs
when [Hb] is the sole parameter considered (section 12.3).
• Haemodilution is maximal at 16h post-operatively, resolving by day 5 (sec-
tion 12.5).
• A significant oxygen/glshb reserve exists peri-operatively (section 12.6).
The above provided the basis for the construction of the RCV based transfu-
sion guideline described in appendix C (page - 185).
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12.7 The Impact of a Red Cell Volume Based
Transfusion Guideline on Blood Usage and
Clinical Outcome
Study Aim
• To determine if RBC transfusion based upon an estimate of patient RCV
confers benefit in terms of a reduction in blood usage and improved clinical
outcome.
Please see section 9.6 (page - 121) for a summary of the principle findings.
The clinical application of the RCV based guideline, in a pilot clinical study,
resulted in a significant reduction in blood usage expressed as both % patients
transfused and UPPO. When considering the annual cardiac case load in our unit
of 850 patients per annum, the assumed saving in RBCs transfused would ap-
proximate 500u. This represents half the number of RBCs currently prescribed.
Also of importance was the finding that all outcome parameters, with the ex-
ception of hospital stay (reduced in RCVGrp), were comparable between the two
groups. However, it should be noted that this study was not powered to detect a
difference for any of these variables. Furthermore, as this study was non-blinded
an element of bias may have existed.
As more rational transfusion policies become more frequently implemented,
it seems certain that physiological factors, additional to [Hb], will be given in-
creasing consideration in deciding when to transfuse RBCs142;143. Unfortunately,
such a scenario can only apply to those individuals with a relatively stable blood
balance e.g. general ICU patients. Further consideration is required for those un-
dergoing an operative procedure who will inevitably loose RCV of varying degree.
The RCV guideline used in this study provided an estimate of an individual’s abil-
ity to tolerate RCV loss while giving greater relevance to post-operative [Hb]. The
results obtained demonstrate that the use of such an approach, while significantly
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reducing RBC transfusion, may have no significant bearing on patient outcome
albeit for the limited number of outcome variables examined.
In section 14.1 (page - 173), we propose a study that will more accurately
evaluate the role of an RCV guideline in post-operative outcome.
12.8 Lung Injury Following Red Cell Transfu-
sion
Study Aim
• To determine the association between pulmonary endothelial injury and
RBC transfusion.
Please see section 10.5 (page - 131) for a summary of the principle findings.
ALI is a major cause of morbidity following surgery utilising extra-corporeal cir-
culation70–72. Although RBC transfusion has been implicated in the severe forms
of this condition (TRALI), uncertainty exists as to its contribution in subtler
forms74. Primarily, this is attributable to the non-specificity of the inflammatory
markers usually studied151. In addressing this issue we have studied the role of
exhaled NO in quantifying the degree of pulmonary endothelial damage following
RBC transfusion152–154.
The results of our analysis were largely disappointing in relation to the data
gained. Only small numbers could be successfully studied due to the inability of
many patients to complete the exhaled NO analysis at 48h. As a result no signif-
icant difference in RBC transfusion was present between the two study groups.
The study cohort was therefore analysed as transfused versus non transfused
groups. A further analysis was performed to correlate % NO reduction with the
study variables for the full study cohort. Perhaps not surprisingly, no positive
associations were found.
In section 14.3 (page - 175), we use the lessons learned from the initial pilot
investigation to suggest a study that will properly address the study aim above.
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12.9 Improving Anti-coagulation Strategies for
Cardio-pulmonary Bypass
Study Aim
• To evaluate the impact of both HMS and modified ACT based anti-coagulation
management on; coagulation, thrombin generation, fibrinolysis, AT-III, post-
operative blood loss and blood product requirement.
Please see section 11.5 (page - 149) for a summary of the principle findings.
Thrombin generation during cardiac surgery may be triggered through several
interlinked mechanisms. As blood is continually exposed to the foreign surfaces
of the CPB circuit and subendothelial tissue within the chest cavity, factor XII
may trigger the intrinsic or contact pathway. The interaction of factor VIIa
and tissue factor similarly triggers the extrinsic pathway197. Causative factors
include a combination of; sub-endothelial contact, an increase in tissue factor
expression on mononuclear cell membranes or an increase in free plasma tissue
factor through surgical trauma209;210. A key component of the above is consid-
ered to be the re-circulation of pericardial blood when it is returned to the CPB
circuit209;211.
To prevent the above, heparin is currently considered the anti-coagulant of
choice for the purposes of CPB. Circulating free heparin has no direct anti-
coagulant effect. However, when bound to AT-III it promotes the inactivation of
thrombin, factor X and several serine proteases212. The dose of heparin required
to achieve the above desired effect during CPB is far higher than for other indica-
tions e.g. deep venous thrombosis. This may relate to the exposure of blood to the
foreign surface of the extra-corporeal circuit, promoting the formation of bound
thrombin in addition to the free variety. As the anti-coagulant heparin/AT-III
complex is a less potent inhibitor of bound thrombin, the requirement for heparin
is significantly increased165;213.
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In order to assess the adequacy of heparinisation for CPB, ACT remains
the most widely used clinical test158;160;168. As mentioned in chapter 11 (page
- 132), it has been shown that ACT does not correlate well with sensitive as-
says of PHConc during CPB. Possible explanations for this include the dilutional
effects of the CPB circuit and the use of systemic hypothermia162;163. Another
possible consideration is that as ACT is based upon contact activation (kaolin
and/or cellite), it is not truly reflective of CPB conditions where the majority of
thrombin generation is triggered by factor VIIa and tissue factor. The interaction
of the above mechanisms may lead to an ACT that significantly overstates the
PHConc, with sub-therapeutic anti-coagulation and thrombin generation
168. To
prevent this detrimental scenario, the use of HMSs has been championed in some
quarters164;166–169.
Prior to CPB, HMS provides in vitro analysis of individual HDR allowing
patient specific administration of loading dose heparin prior to CPB. A heparin
protamine titration technique is used during CPB to measure whole BHConc.
This allows the early detection and correction of sub-therapeutic anti-coagulation.
Previous research has highlighted the efficacy of this system both in preserving
coagulation and reducing post-operative blood loss164;166–169.
As our standard departmental policy is to administer heparin during CPB,
independent of ACT, we hypothesised that similar results to that of an HMS
may be achieved. This was indeed borne out in terms of; coagulation activation,
post-operative blood loss and blood product requirement although it should be
noted that the study was not powered to detect a true difference in the latter
two variables. Despite the heparin dose received being significantly higher for
HMSGrp, this did not appear to influence the concentration of TAT complex. The
answer may lie in comparison with other studies where the difference in heparin
dose was appreciably larger between the two groups164;166–169. When considering
protamine dosage, no significant difference was noted. The suggestion here was
that ACT at termination of CPB is semi-accurate. Further evidence for this was
noted in the observation that ACT fell on rewarming independent of PHConc.
In section 14.4 (page - 176), we suggest a study to investigate the role of
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13.1 Developing a Red Cell Volume Based Trans-
fusion Guideline
RBC transfusion is a potentially life saving procedure with some of its earliest
origins found on the battlefield11. From this acute trauma scenario we have ar-
rived at today’s liberal practice of transfusion based largely upon a [Hb] trigger.
Much of the justification for this high blood usage in cardiac surgery has been
based upon calculations of the oxygen kinetics required for a satisfactory out-
come. However, there is an increasing recognition that the critical level of oxygen
delivery required is way below that previously assumed while many of the afore-
mentioned calculations are based upon mathematically questionable methodol-
ogy91;92;97. Furthermore, no allowances have been made for the viscosity mediated
patho-physiological adaptive responses to normovolaemic anaemia112;113.
At present, the current literature does not provide a definitive answer to the
question of when we should transfuse cardiac surgery patients? However, follow-
ing recommendations by The American Society of Anesthesiologists in 1994, atti-
tudes towards multiple physiological transfusion triggers have gradually changed214.
Using such triggers in association with [Hb] is almost certainly of value in ICU
patients with a stable blood balance. As this thesis has documented however,
[Hb] alone is a poor indicator of peri-operative RCV where CPB is used. Thus a
more multifactorial approach is required.
The first consideration in any transfusion decision should be to exclude any
possibility of hypovolaemia144. Cardiac surgery patients may remain intravascu-
larly deplete yet with a significant increase in TBW through compartmental fluid
shifts (chapter 7, page - 83)129;185. Due consideration should be given to; rela-
tive hypotension (MAP < 60mmHg), poor urine output (< 0.5ml/kg/h), central
venous pressure and pulmonary capillary wedge pressure (where available)142;143.
Tachycardia, in the presence of optimal anaesthesia, has been cited as a key
indicator of hypovolaemia144. However, as many cardiac surgery patients will
have tachy or brady-arrythmias post-operatively this is likely to be an inaccurate
sign215. It is also important to remember that patients may be haemodiluted
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yet hypovolaemic due to expansion of the intra-vascular space216. Once normo-
volaemia has been established it would seem logical to adopt a two stage RBC
transfusion strategy dependent upon the degree of haemodilution.
Prior to 48h due consideration should be given to; indicators of initial pre-
operative RCV (and therefore the patients ability to tolerate RCV loss) (chapter
4, page - 53), the potential for excessive RCV loss, the relative contribution of
haemodilution (chapter 5, page - 66) and indicators of an inadequate circulation or
increase in oxygen requirement (chapter 8, page - 94)129;144;173;177;185. This would
suggest that patients with a large initial RCV, in the presence of an adequate
circulation and non-excessive RCV loss, should be transfused at a lower [Hb], as
any fall is likely to relate haemodilution. The opposite scenario applies to those
with a small initial RCV who should be transfused at a higher [Hb]. Again, any
indicators of an inadequate circulation (in the presence of normovolaemia), or
an increase in oxygen requirement, should act as a prompt to RBC transfusion
(table 13.1)144. During this phase, cerebro-vascular disease (CVD) is likely to be
a lesser consideration due to a viscosity mediated increase in cerebral blood flow
rates217. This scenario may also apply to CAD, although this is likely to be of
lesser importance still as patients will have had significant CAD excluded pre-
operatively or undergone myocardial re-vascularisation as previously described121.
Following 48h post-operatively, as the transient effects of hemodilution are
lost, physiological and clinical factors, including [Hb], are likely to be of increas-
ing importance in the decision to transfuse RBCs129;173;177;185. More emphasis
should also be placed upon the presence of CVD and/or incomplete myocardial
revascularisation.
In order to incorporate any such guidelines into everyday clinical practice, a
simple easy to use decision making process is required. In chapter 9 (page - 106),
we incorporated; patient weight (as an estimate of pre-operative RCV), [Hb],
drain loss and several basic physiological criteria into such an algorithm. The
results obtained demonstrate the efficacy of such a process in rationalising RBC
transfusion. Although we consider the results reported in this study, and the
proceeding chapters, to be valid a note of caution needs to be applied in several
areas. In several of the chapters, multiple testing of the same dataset may have
yielded positive results through chance. Furthermore, the algorithm in chapter 9
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(page - 106) was trialled by non-blinded RCT and was underpowered to detect
any true difference in clinical outcome. For this reason, further appropriately
blinded and powered research is required before any definitive conclusions can be
drawn as proposed in section 14.1 (page - 173).
13.2 Lung Injury Following Red Cell Transfu-
sion
ALI following cardiac surgery is known to occur for a multitude of reasons. Only
the most severe forms have been described in relation to RBC transfusion. Diffi-
culty has existed with the diagnosis of subtler forms of the condition in the past
as the various markers measured are non-specific for the degree of pulmonary en-
dothelial damage74;151. Exhaled NO analysis offers the possibility of addressing
this issue152–154. Although our results demonstrated no significant associations
this could reasonably be attributed to the limited nature of the study.
13.3 Improving Anti-coagulation Strategies for
Cardio-pulmonary Bypass
ACT based heparin management offers the advantage it is a simple, safe and
cost effective technique158;160;161. However, several concerns have been raised
over its accuracy during CPB. Conditions of hypothermia and haemodilution, as
encountered during CPB, may lead it to under estimate the requirement for hep-
arin162–164. This has led to the advocacy of HMSs by some investigators164;166–169.
Our results suggest that the use of ACT may confer similar benefits provided ad-
ditional heparin is given during CPB, independent of the measured ACT.
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13.3 Improving Anti-coagulation Strategies for Cardio-pulmonary
Bypass
Table (13.1) Suggested considerations for RBC transfusion from 0-48 post-
operatively. RBC = red blood cell, RCV = red cell volume, BSA = body sur-
face area, Hb = haemoglobin concentration, CPB = cardiopulmonary bypass and
SVO2 = mixed venous oxygen saturation.
Small initial RCV ↑ Age
Female Gender
↓ Height/ Weight / BSA
↓ Hb
Excessive RCV Loss Surgical Bleeding
Coagulopathy - ↑ CPB Time / Hypothermia
Haemodilution ↑ CPB Time
↑ Clear Fluid Volume
Inadequate Circulation / Poor Cardiac Functiona





a Ejection fraction < 30%.
b Mean arterial pressure 70-80% of baseline or 60mmHg. This may be
higher in patients with severe hypertension.
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14.1 Establishing the Impact of a Red Cell Vol-
ume Guideline on Morbidity and Mortality
As the study in chapter 9 (page - 106) was designed to detect a significant differ-
ence in RBC transfusion, it was underpowered to detect a significant difference
in the clinical outcome measures recorded. What was gained however, was the
knowledge that such a system may be feasible for wider clinical application. By
recruiting larger, appropriately powered and blinded numbers then the full impact
of an RCV based guideline on morbidity and mortality can be examined.
As discussed in section 1.4.3 (page - 21), no large prospective analysis cur-
rently exist examining the impact of a restrictive transfusion policy on survival
following cardiac surgery. Thus, calculating the patient numbers required for such
an analysis is difficult. If short term mortality (30d) is considered the primary
outcome measure then taking the UK average of approximately 2% for elective
cases may give a rough estimation of the required cohort size. A sample of 1798
would give 80% power to detect a 2% difference in 30d survival. Conducting
such a study would be a major undertaking requiring a collaborative approach
by a minimum of 5 centres. This would however, be the first large prospective
evaluation of the effects of RBC transfusion on survival following cardiac surgery.
Summary of recommendations for future study;
• 30d mortality as primary outcome measure.
• Sample size of 1798 patients (899 per limb).
• Collaborative approach with a minimum of 5 centres to ensure adequate
numbers.
• Funding secured to provide a research coordinator in each centre with cen-
tral administration and collation of results.
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14.2 Sodium Fluorescein Based Measurement of
Red Cell Volume
Although the results gained in chapter 6 (page - 77), indicated that the NaF-RBC
complex was not sufficiently stable for practical use, as described, there may still
be the possibility of correcting for this deficiency. Performing further in vitro
experimentation with the rate of decay of the RBC fluorescence may alow for the
mathematical correction of the results obtained.
In figure 6.1, the error bar decay plot is given for the mean value of the four
run samples analysed. Provided a gap of less than 60m exists between injectate
preparation, blood sample aspiration and subsequent analysis then mathematical
correction may allow for a reasonably accurate calculation of circulating RCV as
per equation A.6.
Practically this would involve the following;
1. Recording of the injectate preparation completion time as t = 0.
2. Adjusting the fluorescence of the injectate at the time of patient injection
as per the exponential decay curve (t = 1).
3. Adjusting the fluorescence of the analysed RBC’s, as per the exponential
decay curve, to correspond with the time of aspiration (t = 2).
Using such a methodology should allow the practical assessment as per the
PIHD technique outlined in section 6.3.2 (page - 79). The same sample size
calculation for the original proposed study could reasonably be applied (6.3.3,
page - 80).
Summary of recommendations for future study;
• Multiple in vitro run analysis to accurately document exponential fluores-
cence decay curve.
• Sample size of 30 patients as previously described.
• Adjustment of fluorescence as per time point.
• Evaluation of NaF flow cytometry by PIHD.
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14.3 The Association Between Lung Injury and
Red Cell Transfusion
Although the pilot investigation in chapter 10 (page - 122) produced little in
the way of tangible results, the results gained can be used to power a future
investigation. It is also evident that several study adaptations would be required
to improve the low completion rate and appropriately test post-operative lung
function.
On determining sample size for a future investigation, it was calculated that
a cohort of 168 patients would have 80% power to detect a difference of 10% in
exhaled NO between the two groups. To improve completion rate, changes to the
exhalation rate would be required. Approximately one third of patients in the
initial investigation were unable to complete the 10s exhalation prescribed. The
Nioxmino allows this to be reduced to 6s by use of a paediatric card. This was
not done with the pilot investigation as the different times do not compare like
with like.
A further weakness of the study construct in chapter 10 (page - 122) was
that no measurements of post-operative lung function were made. This could be
rectified by performing repeat PFT measurements at 48h post-operatively and
possibly at 5d/pre-discharge. Results could be further improved by the measure-
ment of carbon monoxide (CM) transfer factor218.
Summary of recommendations for future study;
• % Reduction in exhaled NO at 48h as primary outcome measure.
• Sample size of 168 patients (84 per limb).
• 6s exhalation for NO measurement prior to surgery and at 48h following
operation.
• PFTs recorded prior to surgery and at 48h and 5d post-operatively. To
include CM transfer factor.
175
14.4 Continuous Heparin Infusions for Cardio-pulmonary Bypass
14.4 Continuous Heparin Infusions for Cardio-
pulmonary Bypass
As discussed in section 12.9 (page - 165), the results obtained in chapter 11 (page
- 132) suggest that additional heparin administration during CPB is required for
coagulation system preservation. This can be achieved by the use of HMSs or by
the administration of heparin independent of ACT.
The ACT system employed in our study gave additional heparin as per CPB
crystalloid administration. As such a system is intermittent and unpredictable in
nature, PHConc is not maintained at a steady concentration. It may be expected
that maintaining a constant PHConc will result in even greater levels of coagulation
preservation.
This hypothesis may be examined by the use of continuous heparin infusions
during CPB. The relative efficacy of such a technique in maintaining PHConc
has been documented previously when compared to the use of an HMS219. One
approach to such an investigation would be the use of three study limbs with
varying techniques for additional heparin administration;
1. Heparin/protamine as per standard ACT based nomogram.
2. Heparin/protamine as per standard ACT based nomogram with continuous
heparin infusion.
3. Heparin/protamine as per standard ACT based nomogram with continuous
heparin infusion and additional dosage as per supplemental fluid.
On determining sample size for such a study, it was calculated that a cohort
of 84 patients would have 80% power to detect a difference of 10mg/l in TAT
between the three groups.
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Summary of recommendations for future study;
• Post-CPB change in serum TAT complex as primary outcome measure.
• Sample size of 84 patients (28 per limb).
• Heparin/protamine dosage as per standard ACT based nomogram with






Red Cell Volume Calculations
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The basis for all RCV calculations is BSA. In all instances the formula used was
that recommended by Gehan and George (equation A.1)170;
S = 0.0235xHt0.42246xWt0.51456 (A.1)
Where; S = body surface area (m2), Exp = exponential, Ht = height (cm) and
Wt = weight (kg)
The most robust formulae for the calculation of RCV have been provided by
the ICSH171. Seperate formulae have been provided for males (equation A.2) and
females (equation A.3);
RCV = (1486xS)− 825 (A.2)
RCV = (1.06xA) + (822 + S) (A.3)
Where; RCV = red cell volume (ml), A = age (y) and S = body surface area (m2).
Once RCV has been calculated both BV (equation A.4) and PV (equation A.5)
can be derived using patient Hct;
BV = 100xRCV/Hct (A.4)
PV = BV −RCV (A.5)
Where; BV = blood volume (ml), RCV = red cell volume (ml), Hct = haemat-
ocrit (%) and BV = blood volume (ml).
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When performing NaF flow cytometry, RCV can be calculated according to the
following equation A.6;
RCV = (RBCixVixHctven)/(RBCpxF ) (A.6)
Where; RCV = red cell volume (ml), RBCi = RBC count per ml of the in-
jectate, Vi = volume of the injectate (ml), Hctven = venous haematocrit (%),
RBCp = RBC count per ml of venous blood and F = fraction of fluorescent to
non-fluorescent RBC’s.
We chose PIHD to assess the above technique. The volume of RBCs removed in
the PIHD bag was to be calculated as follows (equation A.7);
RCV = (PIHDwtxHctbag)/SGwb (A.7)
Where; PIHDwt = weight of PIHD blood (g), Hctbag = Hct (%) of PIHD blood





Oxygen may be transported bound to [Hb] or contained in solution as represented
below (equation B.1). This formula to calculate the oxygen content of blood
applies to both the arterial (arterial oxygen content (CaO2)) and venous (venous
oxygen content (CvO2)) circulation.
ConO2 = (1.36x(SO2/100)xHb) + (PaO2xZO2) (B.1)
Where; ConO2 = the oxygen content of blood (ml/dl), 1.36 = ml of oxygen
bound per g of [Hb], SO2 = oxygen saturation (%), PO2 = oxygen partial pres-
sure (mmHg) and ZO2 = the solubility coefficient of oxygen in blood for a given
temperature (ml O2 per dl of plasma per mmHg).
Under normal environmental conditions the oxygen content in solution may be
considered negligible (<2%). As outlined above, it is calculated by the product
of the arterial partial pressure of oxygen (PaO2) and the solubility coefficient
for oxygen in blood (ZO2). The ZO2 may be calculated as follows (equation
B.2)98;220;
ZO2 = [(4xHb+ 346)xT + (130xHb+ 35, 000)]x0.0001/760 (B.2)
Where; ZO2 = solubility coefficient (ml O2 per dl of plasma per mmHg) and T
= temperature (0C).
DO2 (ml/min/m
2) is considered a product of the CaO2 and an individuals cardiac
CI (l/min/m2) at the time of sampling (equation B.3);
DO2 = 10xCaO2xCI (B.3)
Where DO2 = oxygen delivery (ml/min/m
2), CaO2 = arterial oxygen content
(ml/dl) and CI = cardiac index (l/min/m2).
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When considering estimates of DO2Crit, a correction factor is required to allow
for hypothermia (equation B.4);
Coef = exp[(0.08329xT+1.5234)/100] (B.4)
Where; Coef = correction coefficient, exp = exponential and T = temperature
(0C).
VO2 (ml/min/m
2) may be represented mathematically as the difference in CaO2
and CvO2 multiplied by the CI (equation B.5);
V O2 = (CaO2 − CvO2)xCIx10 (B.5)
Where; VO2 = systemic oxygen uptake, CaO2 = arterial oxygen content (ml/dl),
CvO2 = venous oxygen content (ml/dl) and CI = cardiac index (l/min/m
2).
QO2 (%) is the proportion of systemic oxygen delivered that is actually utilised
by the tissues (equation B.6);
QO2 = (V O2/DO2)x100 (B.6)
Where; QO2 = oxygen extraction (%), VO2 = oxygen consumption (ml/min/m
2)
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As described briefly in chapter 9 (page - 106), the data obtained in chapter 5 (page
- 66) was used to design the RCV based transfusion guideline. This process was
completed stepwise as follows (tables C.1 and C.2);
1. Data was divided into males (n = 18) and females (n = 12).
2. For each gender, the data was divided roughly into 3 weight ranges (≤ 77,
78 - 97, ≥ 98 for males. ≤ 54, 55 - 74, ≥ 75 for females).
3. For each gender and weight based subdivision the mean pre-operative RCV
was noted.
4. This was then multiplied by a theoretical threshold ratio, descending from
0.85 - 0.6, to give a RCV transfusion threshold. A variable threshold was
incorporated as an estimate of the ability to tolerate RCV loss (section 12.2,
page - 154).
5. Under normovolaemic conditions i.e. static pre-operative BV, the Hct this
RCV threshold would represent was derived (equation C.1);
HctTh = (RCVTh/BVPre−op)x100 (C.1)
Where; HctTh = threshold haematocrit (%), RCVTh = threshold red cell
volume and BVPre−op = pre-operative blood volume (ml).
6. For this value to have relevance post-operatively it was necessary to include
a blood volume expansion factor i.e. the ratio of pre-operative BV to post-
operative BV. A factor of 1.17 for males and 1.26 for females was used∗.
7. By substituting pre-operative BV with the post-operative value in the above
formula (equation C.1), a meaningful RBC transfusion threshold was ob-
tained (tables C.1) and C.2)†.
∗No significant association was found between weight and BV expansion. Hence, only gender
was used to discriminate when applying a BV expansion factor.
†The [Hb] threshold for the male 78 - 79kg subdivision was changed from 7.7g/dl to 7.8g/dl.
This was to ensure the linearity of the transfusion model.
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Table (C.1) RCV algorithm derivation for males. Where; Wt = weight, Ind =
induction, RCV = red cell volume, RCVTh = red cell volume threshold, NDil =
non-diluted, HctTh = haematocrit threshold and RBCTh = red blood cell threshold.
Wt Ind RCV RCVTh RCVTh NDil HctTh RBCTh
(kg) (ml) (Ratio) (ml) (%) Hct (%) Hb (g/dl)
≤ 77 1948 0.70 1363 29.4 25.1 8.4
78 - 97 2249 0.65 1462 27.3 23.3 7.7
≥ 98 2619 0.60 1571 25.2 21.5 7.2
Table (C.2) RCV algorithm derivation for females. Where; Wt = weight, Ind =
induction, RCV = red cell volume, RCVTh = red cell volume threshold, NDil =
non-diluted, HctTh = haematocrit threshold and RBCTh = red blood cell threshold.
Wt Ind RCV RCVTh RCVTh NDil HctTh RBCTh
(kg) (ml) (Ratio) (ml) (%) Hct (%) Hb (g/dl)
≤ 54 1238 0.85 1052 32.3 25.6 8.5
55 - 74 1417 0.80 1134 30.4 24.1 8.0





D.1 Activated Clotting Time
D.1 Activated Clotting Time
When calculating additional heparin and protamine dosage in chapter 11 (page
- 132) (ACTGrp) the following formulae as recommended by Bull et al were used
(equations D.1 and D.2)157;
HepDose = HepInitial/(ACTPostHep − ACTPreHep)x(480− ACTCurrent) (D.1)
Where; HepDose = heparin dose required (IU), HepInitial = initial heparin bo-
lus (IU), ACTPostHep = activated clotting time post intial heparin bolus (s),
ACTPreHep = activated clotting time prior to intial heparin bolus (s) and ACTCurrent =
current activated clotting time (s).
ProtDose = HepInitial/(ACTPostHep − ACTPreHep)x(ACTCurrent − ACTPreHep)
(D.2)
Where; ProtDose = protamine dose required (mg), HepInitial = initial heparin
bolus (IU), ACTPostHep = activated clotting time post intial heparin bolus (s),
ACTPreHep = activated clotting time prior to intial heparin bolus (s) and ACTCurrent =
current activated clotting time (s).
As measurements of BHConc only were obtained using the Hepcon HMS, the
following formula was used to calculate PHConc (equation D.3);
PHCon = (BHConx100)/(100−Hct) (D.3)
Where; PHCon = plasma heparin concentration (IU/ml), BHCon = blood heparin
concentration (IU/ml) and Hct = haematocrit (%).
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D.2 Heparin Dose Response
The HDR test is essentially based around ACT measurement with the addition of
monitoring the effects of varying heparin doses on clotting time. This provides an
in vitro estimation of an individuals sensitivity to heparin and can also be used
to calculate the heparin dose required to reach the desired target ACT. The HDR
cartridge contains six channels with an equal amount of kaolin reagent. Channels
1 and 2 contain USP porcine heparin to reach a sample heparin concentration of
2.5u/ml once the blood has been dispensed. Channels 3 and 4 similarly contain
heparin to reach a sample heparin concentration of 1.5u/ml while channels 5 and
6 do not contain heparin and are used to obtain a baseline ACT. The clotting time
results from each channel are used to calculate the slope response to heparin and
the resultant dose required for the desired ACT. The formulae that provide the
basis for these calculations are given below (equations D.4, D.5, D.6 and D.7)221.
Slope = 1/2(Slope1 + Slope2) (D.4)
Slope1 = C −B/I, Slope2 = B − A/H (D.5)
Slope is given in ACT prolongation in seconds (s) per unit (u) of heparin (USP)
per ml of BV∗. Where; A = average clotting time of channels 5 and 6 (s), B
= average clotting time of channels 3 and 4 (s), C = average clotting time of
channels 1 and 2 (s), H = 1.5u/ml (channels 3 and 4 channels 5 and 6) and I =
1.0u/ml (channels 1 and 2 channels 3 and 4).
∗All heparin concentrations described here are given in USP units (u). To convert to IU
(as used for dosage in chapter 11) a correction factor of 0.88 is required.
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Once the slope is known the target heparin concentration can be calculated as
follows (equation D.6);
Heparin(u/ml) = (T − A)/S (D.6)
Where; A = average clotting time of channels 5 and 6, T = ACT target time (s)
and S = slope (s/u/ml).
The final HDR equation allows the calculation of the required patient heparin
bolus (equation D.7);
PatientBolusDose(u) = [RHx(BV + PV )]− PH (D.7)
Where; RH = target heparin concentration (u/ml), BV = blood volume (ml),
PV = pump volume (ml) and PH = pump heparin (u).
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D.3 Heparin Protamine Titration
The HPT cartridges contain thromboplastin and protamine of varying concentra-
tion in each channel. The channel that most accurately neutralises the contained
heparin will clot first in the test. Where the measured heparin concentration
is below the target value the additional dose required is calculated as follows
(equation D.8)221;
HeparinRequired(u) = V x(RH −MH) (D.8)
Where; RH = target heparin concentration (u/ml), MH = measured heparin
(u/ml) and V = volume (patient, pump, or total) (ml).
A similar principle is used to calculate the protamine dose required to neutralise
all the circulating heparin at the termination of CPB (equation D.9);
ProtamineDose(u) = (MHxV )xP : H (D.9)
Where; MH = measured heparin (u/ml), V = volume (patient, pump, or
total) (ml) and P:H = protamine heparin ratio.
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